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Abstract 
Taxanes represent a very important class of anticancer agents available for clinical use 
since 1990s. Currently, two taxanes, paclitaxel and docetaxel, are included in multi drug 
regimens for the therapy of several solid tumours, such as ovary, breast, head and neck, 
prostate and non-small cell lung cancers. 
Taxanes act by inhibiting microtubule dynamics, thereby blocking cell cycle and 
activating cell death. Oespite the relevant contribution of taxanes in improving the 
overall survival and the quality of life of cancer patients, there are some limitations in 
the therapeutic use of these drugs that have driven research for new analogues having an 
enlarged antitumour activity profile, with more favourable chemical-physical properties 
and pharmacological profile in terms of selectivity and tolerability. Because of its 
molecular complexity, paclitaxel is an ideal candidate for systematic modification to 
develop an understanding of its structure-activity relationships. 
Among all the investigated structural changes, two of them - the C-ring opening and the 
introduction of a functional group in position 14 - led to the compounds studied in this 
thesis: ION 5390, ION 5614, ION 5738, ION 5839 and ION 6140. The opening of C-
ring led to C-seco paclitaxel analogues, ION 5390 and ION 5614, while ION 5738, ION 
5839 and ION 6140 have an introduction of a functional group in position 14. 
The main feature of C-seco taxanes is related to their antiangiogenic properties against a 
scanty cytotoxicity which renders these taxanes cytostatic compounds rather than 
cytotoxic ones. Whereas the main characteristic of 14-functionalized taxanes is to be 
poor substrates for P-gp system, showing as a consequence good oral bioavailability, 
distribution in central nervous system and activity on paclitaxel-resistant tumours. 
The aim of this project was to characterize the preclinical phannacokinetics of the 
aforementioned new taxane derivatives. 
To describe the pharmacokineticlmetabolic profile of these compounds, as first step, it 
was necessarY to develo., and validate the assays to determine the concentration of the 
3 
Abstract 
new derivatives in biological specimens. Consequently, the validated assays were 
applied to characterize the phannacokinetics and the bioavailability of the new 
derivatives in mice after oral and intravenous administration. The methods were based 
on high-performance liquid chromatography coupled with tandem mass spectrometry 
(LC-MSIMS) technique, because of its success in phannacokinetic studies with small 
molecules and due to its high sensitivity and specificity. 
IDN 5390 and IDN 5614 showed a very high metabolic clearance that limits their 
systemic disposition and renders advisable a careful characterization of their main 
metabolites in terms of in vitro biological activity and toxicity, in case of further clinical 
development. 
As regards the 14-functionalized derivatives, IDN 5738 and IDN 5839 showed an 
interesting phannacokinetic profile, nevertheless superimposable with that of ortataxel -
their parent compound under clinical evaluation - against a halved half-life and a 
comparable cytotoxic activity on two sensitive and resistant human breast tumour cell 
lines (LCC6/LCC6-MDR and MCF-7IMCF-7-R), rendering them little interesting for 
further development. 
The last studied analogue, IDN 6140, seemed to be the most interesting one due to its 
peculiar phannacokinetic properties: good bioavailability, very long half-life and high 
distribution both in normal and tumour brain tissue. It showed considerable reduction in 
tumour volume in CD 1 xenografted nude mice obtained inoculating orthotopica11y two 
human glioma cell lines, U-87 MG and GBM. These results suggest a potential efficacy 
of this compound for the therapy of central nervous system tumours and brain 
metastasis. 
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Introduction 
CHAPTER 1 
INTRODUCTION 
I ntroduct ion 
1.1. History and discovery of taxanes 
Paclitaxel (Taxol~ and docetaxel (Taxotere~ (figure 1, panel A and B, respectively) 
are the most important members of the taxane family. 
Figure 1. Chemical structure of paclitaxel (panel A) and docetaxel (panel B) 
Paclitaxel is a natural product first isolated from the bark of the Pacific Yew (Taxus 
brevi/olia) while docetaxel, a semi-synthetic taxane analogue derived from the 
European Yew (Taxus baccata), was identified in the 1980s. Paclitaxel can also be 
derived from the leaves of European Yew, which is a more renewable source than the 
bark of the Pacific Yew. This ended a point of conflict in the early 1990s: many 
environmentalists, including Al Gore, had opposed the harvesting of paclitaxel for 
cancer treatments. 
The yews (members of the genus Taxus of the family Taxaceae) are non-resmous 
evergreen gymnosperms that are widely distributed throughout the moderate zone of the 
northern hemisphere. They grow primarily in the understory of moist, forested habitats 
in cool, temperate to subtropical climates I. The growth form may be a tree or a shrub. 
Crowns of these shrubby forms may attain as much as 24 m in diameter 2. The main 
stem of the yew tree can become quite stout in proportion to its height. Often the large 
diameter is attained by multiple stems that have fused over time. 
Introduction 
English (or European) yew has reached great age (1000 years) and girth, especially 
those planted in country churchyards 3. 
Taxus plants were known and cultivated for centuries: in 1021, A vicenna, a persian 
doctor, introduced the medicinal use of Taxus baccata for phytotherapy in the "Canon of 
Medicine". He named this herbal drug as "Zarnab" and used it as a cardiac remedy. The 
leaves of Taxus baccata contain an alkaloid mixture (taxines). It was recently 
demonstrated that this drug possessed calcium channel blocking activity 4. The first 
report about anticancer activity dates back to the beginning of 1900's, when a British 
official, in the Indian subcontinent, noted that parts of Taxus baccata were used to treat 
cancer: in the Central Himalayas, the plant was used in fact to cure breast and ovary 
cancer. 
The research on the anticancer properties of the plants started in the late 1950s when the 
U.S. National Cancer Institute (NCI) initiated a program to screen 35000 plant species 
for anti-cancer activity. As part of this program the U.S. Forest Service collected bark 
from the Pacific yew, Taxus brevifolia, and shipped it to NCI. Extracts from the bark 
were found to have anti-tumor activity and, in 1971, the active ingredient was identified 
as paclitaxel 5. 
As narrated by Wall and Wani, the isolation procedure, finally adopted after several 
unsuccessful trials, was carried out by ethanol extraction followed by a concentration 
procedure. The obtained ethanolic residue was partitioned between water and 
chloroform. At the end, the choloroformic residue was countercurrent extracted many 
times using a Craig apparatus (designed to obtain multiple liquid-liquid extractions 
permitting the separation of substances with different distribution coefficients). In this 
manner, approximately 0.5 g of taxol were isolated, for the first time in 1964, starting 
with 12 kg of air-dried stem and bark. The yield was about 0.004% 6. All the various 
steps were monitored by an in vivo bioassay which involved the inhibition of the 
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Walker Carcinosarcoma solid tumor. The isolation hence was carried out laboriously. 
but - thanks to the mild countercurrent distribution methodology - with no losses by the 
treatment or no changes in the unknown chemical constitution of the eventual product 
occurred. Much simpler procedures have been subsequently developed. 
The name "taxol" was assigned before knowing the complete structure of the 
compound, but it was evident that it contained some hydroxyl groups, and the name 
sounded interesting. 
In 1979, Susan Horowitz identified the unique mechanism of action of paclitaxel and 
when the NCI screening program was closed in 1981, paclitaxel was the only compound 
left to be tested in humans 7. 
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1.2. Taxane mechanism of action 
Taxanes are microtubule-interfering agents. Microtubules are part of cytoskeleton -
within the cell's cytoplasm - and are involved in numerous cellular functions, including 
the maintenance of cell shape, intracellular transport, secretion and neurotransmission. 
Microtubules are made up of polymers of tubulin and tubulin molecules in their turn, 
are made up of a heterodimer consisting of u- and ~-tubulin subunits. There are at least 
6 u- and ~-tubulin isotypes, differing in their intracellular localization. The tubulin 
subunits are arranged head to tail as are the molecules when they join together to form 
protofilaments. Each microtubule consists of 12 or 13 proto filaments aligned in paraJlel 
with the same polarity. 
Microtubules are highly dynamic and unstable structures that are constantly 
incorporating free dimers and releasing dimers into the soluble tubuJin pool (figure 2). 
tubulin molecule --
... ~ 
with bound GTP "'lo- . ... ~ .. ~ ~ , - ... . 
'---#~ fI'~ 
~ . .. .. 
GTP tubulin molecules 1 
add to end of microtubule 
addition proceeds fasterl 
than GTP hydrolysis 
fI'~ 1..-1 -------' 
GTPcap 
1 protofilaments containing GOP tubulin are unstable and peel away from the microtubule wall 
l
GPO tubulin is released 
to the cytosol 
tubulin molecule 
with bound GOP 
Figure 2. Microtubule ends in growing and shrinking states (from web sourcel 
Actually, they have a plus (+) end where there tends to be rapid tubulin a' cmbly and a 
minu (-) end with low as embly or even di a embly 8. The minu ' end i oilen 
anchored at the microtubule-organi ing centres with the plu ' end fi"ce in the cytoplasm. 
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Both ends having the ability to switch spontaneously from a growing to a shortening 
state, dependent on a cycle of GTP hydrolysis and exchange. GTP and magnesium are 
required for assembly. The combination of growth, shrinkage and rapid transitions 
between the two states of micro tubules is known as "dynamic instability". 
Concentration of ci+ is another factor that influences the degree of tubulin 
polymerization promoting the inhibition of assembly 9. The modulation of the dynamics 
at the end of the microtubules is carried out by the microtubule associated proteins. 
Taxanes bind to the p-tubulin subunit of the tubulin heterodimer (figure 3), accelerate 
the polymerization of tubulin and stabilize the resultant microtubules inhibiting their 
depolymerization. 
Figure 3. Molecular structure of a tubulin dimer. 
The a-tubulin subunit is on top, indicating a 
microtubule polarity with the (-) end towards 
the top of the page. The two GTP subunits 
are drawn as space filling models, and the 
paclitaxel molecule is attached to the p-
tubulin subunit and drawn as a ball and stick 
modellfrom web source] 
This inhibition results in the arrest of the cell division cycle which triggers the cell-
d I d· . f 11 10, 11 signaling casca e, ea lng to apoptoslS 0 cancer ce S . 
Docetaxel and paclitaxel share a mutual binding site on the p-tubulin subunit and 
docetaxel has a higher affinity for this site resulting in more potent tubulin as embly 
promoter and tubulin tabilizer than paclitaxel 12. 
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1.3. Role of taxanes in cancer therapy 
Both paclitaxel and docetaxel are indicated as preferred agents for recurrent and 
metastatic breast cancer by The National Comprehensive Cancer Network (NCCN) 
clinical practice guidelines for breast cancer 13. They are also widely used in the 
treatment of ovarian carcinomas and are being adopted as standard therapies for lung, 
digestive and prostate cancers. Other solid tumours that these drugs have been effective 
in treating include carcinomas of the head and neck and bladder. 
Though preclinical and toxicology studies of paclitaxel were well characterized in the 
late 1970s, it was not tested on humans till the mid-1980s and the results of the phase I 
trial were reported in 1987 14. The reasons for this delay in the clinical development of 
paclitaxel must be sought in its poor acqueous solubility and in acute hypersensitivity 
reactions (HSRs) later attributed to the solvent Cremophor EL (a polyoxyethylated 
castor oil vehicle) and reduced by the use of corticosteroid premedication. In 1991, NCI 
started collaborating with Bristol Myers Squibb for the development of the drug, 
marketed as Taxol® 7. In 1996, a phase III study showed that survival time for women 
with advanced ovarian cancer treated with the first line paclitaxel-cisplatin combination 
was increased by 50% over the standard cisplatin-cyclophosphamide treatment 15. 
Shortly thereafter paclitaxel in combination with carboplatin (showing a better toxicity 
profile than paclitaxel-cisplatin) was introduced as the primary treatment of carcinoma 
of the ovary in patients with advanced disease or residual disease after initial surgery 16. 
Nowadays, paclitaxel has a wide clinical spectrum of activity being used for the 
b I h d d k d · 17-20 L treatment of reast, ung, ea an nec an ovanan cancers . ess common 
cancers, such as endometriaL unknown primary, testes, esophageal and Kaposi's 
sarcoma, also have meaningful response rates to paclitaxel either alone or in 
.. . h h 21-23 combmatlon WIt ot er agents . 
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Docetaxel entered phase I trials in 1990 and, of the several regimens studied, a I-hour 
infusion every 3 weeks given at a dose of 100 mg/m2 was selected for phase II 
evaluation 24. Thanks to the less toxic effects of docetaxel vehicle (polysorbate 80) in 
comparison to paclitaxel one, the phase I trials drew to a close without the use of 
premedication and with only infrequently documented reactions. However, in a phase II 
trial, in patients with metastatic breast cancer, HSRs were noted more often and the 
protocol of the study was amended twice to include the use of a premedication regimen 
25. Docetaxel is now given with premedication to ameliorate their severity. 
This taxane demonstrated evidence of antitumour activity in the course of phase I 
evaluation: responses were seen in breast, ovarian cancer and non-small cell lung cancer 
(NSCLC) 24-26. Much of the phase II development focused on these same tumour types. 
Docetaxel has shown activity against numerous cancers, including breast, lung, head 
and neck, ovarian, and prostate. At present, it is approved for use as a single agent for 
the treatment of patients with locally advanced or metastatic breast cancer after failure 
of prior chemotherapy, and in combination with doxorubicin and cyclophosphamide for 
the adjuvant treatment of operable node-positive breast cancer 26. It is also approved as 
a single agent for the treatment of patients with unresectable locally advanced or 
metastatic NSCLC after failure of prior platinum-based chemotherapy, in combination 
with cisplatin for patients with unresectable locally advanced or metastatic NSCLC who 
have not received prior chemotherapy, and in combination with prednisone for patients 
fr ) . 24-26 with androgen-independent (hormone-re actory metastatIc prostate cancer . 
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1.4. Pharmacology of taxanes (paclitaxel vs docetaxel) 
Most studies on the clinical activity of taxanes were performed on paclitaxel or 
docetaxel that are the two taxanes used in clinical practice. Only in the recent years. 
comparative data have been available thanks to direct clinical comparisons of the two 
taxanes in metastatic breast, ovarian, and lung cancer. These results suggest a more 
favourable benefit-to-risk ratio for docetaxel compared to paclitaxel when these drugs 
are used as single agents or in combination with other chemotherapeutic agents in an 
every-3-week dosing regimen. Paclitaxel and docetaxel are structurally similar but 
pharmacological data support the difference between the taxanes. 
Oligorov and Lotz 27 summarized the major differences between the two taxanes in 
terms of molecular pharmacology. 
Docetaxel exhibits greater affinity to ~-tubulin, targeting centrosome organization and 
acting on cells in three phases of the cell cycle (S, O2 and M), whereas paclitaxel causes 
cell damage by affecting the mitotic spindle in only two phases of the cell cycle, O2 and 
M. As regards the cell cycle phases, it is important to note that docetaxel is almost 
totally lethal against S-phase cells, while the maximum resistance to paclitaxel is early 
in the S phase. 
Bcl-2 (B-cell leukemia 2) is an anti-apoptotic protein over-expressed in several solid 
tumours: breast, lung, prostate and nasopharyngeal cancers. Both taxanes cause Bcl-2 
phosphorylation leading to apoptosis, but the concentration of docetaxel needed to 
cause apoptosis through Bcl-2 is 100 times less than paclitaxel 28. 
Moreover, in comparison to paclitaxel, docetaxel exhibits greater uptake into and slower 
effiux from P388 murine leukemia cell line 29. There is no definitive explanation for the 
greater uptake of docetaxel in P388 cells, but its slower efflux could be associated with 
its greater affinity for ~-tubulin. 
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As already mentioned, taxanes arrest cell cycle in the G2iM phase. which is the most 
sensitive stage to radiation. An in vitro study on human head and neck cancer cells 
(ZMK-I), and in cervical carcinoma cells (CaSki) clearly demonstrated that docetaxel is 
a better radiosensitizer than paclitaxel 30. 
On the basis of the advantages of docetaxel in respect to paclitaxel listed in the first part 
of this paragraph, it would be assumed that docetaxel anti-cancer activity is better than 
that of paclitaxel. 
A phase III study comparing paclitaxel with docetaxel, in patients with advanced breast 
cancer, proved that docetaxel was superior to paclitaxel in terms of median overall 
survival (15.4 vs 12.7 months), median time to progression (5.7 months vs 3.6 months) 
and overall response rate (320/0 vs 25%) 31. Although the incidence of treatment-related 
hematologic and non-hematologic toxicities was greater for docetaxel than for 
paclitaxel, the quality of life scores were not statistically different between treatment 
. 31 groups over tIme . 
In the following pages, I summarized: 
1- the pharmacokinetic principles useful to describe a drug behaviour inside the 
body and 
2- the available pharmacokinetic/pharmacodynamic data that explain the different 
clinical development strategies for the two molecules as well as the different 
clinical results. 
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1.5. Pharmacokinetic principles 
The phannacokinetics describes temporal patterns of response to drug administration 
following acute and chronic dosing. The phannacokinetics is necessary to provide a 
rational basis for drug design, drug selection and dosage regimen design. Poor 
phannacokinetic properties of a drug may limit its clinical application. In particular. the 
phannacokinetics studies how the body handles drug and that means how drug is 
absorbed, distributed, metabolized and eliminated. All these processes are influenced by 
genetics, body size, age, disease, other drugs and the phannacokinetic behaviour is a 
function of route of administration, dosage fonn, physicochemical properties of drug 
and physiology of the body. 
When a drug is administered intravascularly, no absorption step is required, but when a 
drug is administered extravascularly, it must be absorbed. The absorption is the process 
by which unchanged drug proceeds, within the body, from site of administration to site 
of measurement. Monitoring intact drug in blood or plasma offers an useful means of 
assessing the entry of drug into the systemic circulation. This fraction of an 
administered dose of a drug is available at the site of action and it is defined as drug 
bioavailability. By definition, when a drug is administered intravenously, its 
bioavailability is 100%, because all of the dose enters the general circulation. With no 
other route of administration, blood concentration can be promptly and better 
controlled: following an intravenous bolus dose, elevated concentrations of drug in the 
blood can be reached and following an infusion at a controlled rate, constant 
concentration can be maintained. 
When a drug is administered via other routes, its bioavailability decreases because of 
several possible sites of loss during absorption phase, especially for a drug given orally. 
A dnl!:!, decomposition may occur in the gastrointestinal lumen and there could be a low 
32 
Introduction 
intestinal permeability or metabolism by enzymes in the gut lumen or gut wall. Even 
though the drug leaves the gastrointestinal tract, it is not absorbed systemically. because 
firstly it passes in liver through the portal vein. The liver is a site of elimination and 
every drug loss during absorption phase is known as the first-pass effect. Moreover. 
absorption is not restricted to oral administration. It occurs as well following 
intramuscular, subcutaneous and other extravascular routes of administration. 
Once absorbed, a drug is distributed by blood to the various organs of the body. 
Distribution is a reversible transfer and is influenced by how much each organ is 
perfused, by organ size, by binding of drug within blood (plasma proteins) and in 
tissues, and by permeability of tissue membranes. A drug is distributed to all sites 
including the elimination organs and the elimination is the irreversible loss of a drug by 
all processes from site of measurement. Distinguishing between distribution and 
elimination as a cause for a decline in concentration in blood or plasma is often difficult. 
Disposition is the term used to indicate both processes. Disposition may be defined as 
all the events that occur subsequent to the absorption of a drug. 
Drug elimination occurs by two processes, excretion and metabolism; excretion is the 
irreversible loss of chemically unchanged drug in urine and in faeces, and metabolism is 
the conversion of one chemical species to another. The two principal organs of 
elimination are the kidneys and the liver. The kidneys are the main site for excretion of 
the unchanged drug and, through the nephron, the basic unit of the kidney, act by three 
different mechanisms: glomerular filtration, tubular secretion and tubular reabsorption. 
The liver is the usual organ for drug metabolism, where hepatic enzymes catalyze 
various biochemical reactions. Metabolites are products more polar and less lipid-
soluble than the original drug thanks to chemical modifications that ultimately promote 
the drug excretion from the body. Drug metabolism is obtained by two types of 
enzymatic reactions: phase I (biotransfomlation) characterized by reactions of 
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oxidation, hydroxylation, reduction and hydrolysis and phase II (conjugation) 
characterized by reactions of addition of a new functional group such as glucuronide. 
sulfate, methyl and acetyl groups, glutathione and amino acids. 
The phase I detoxification system is composed mainly of the cytochrome P450 
supergene family of enzymes which are a large group of monooxygenase enzymes 
responsible for the oxidative metabolism of toxic hydrocarbons. 
Over 60 key forms are known, with hundreds of possible genetic variations, and the 
main ones are: CYPIA, CYP2B, CYP2C and CYP3A: the last one metabolizes about 
50-60% of drugs. 
All these pharmacokinetic processes are defined by the variations of drug plasma (or 
blood) concentrations, because, in pharmacology, the concentration in plasma (or blood) 
is the only directly accessible parameter. Blood or plasma, besides being a practical and 
convenient site of measurement, is the most logical one for determining drug in the 
body. Blood receives drugs from the site of administration and carries them to all 
organs, including those in which the drugs act. So, drug plasma concentrations are 
correlated to those at sites of action. 
Measuring drug plasma concentration in samples collected at specific time points. it is 
possible to obtain plasma concentration-time profiles after different routes of 
administration. The shape and the mathematical elaboration of these profiles provide the 
main pharmacokinetic parameters during the different phases of absorption, distribution 
and elimination. 
When there is an absorption, the drug plasma concentration increases with time up to a 
maximum value, indicated as Cmax, maximal concentration, the highest drug 
concentration observed in plasma following administration of an extravascular dose. 
This parameter is important because therapeutic failure results both when the 
concentration is too low, giving ineffective therapy, and also when it is too high. 
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producing unacceptable toxicity. Between these limits of concentrations there is a 
region, known as "therapeutic window", associated with possible therapeutic success. 
The time at which the highest drug concentration occurs is called the time of maximum 
concentration, T max. Cmax and T max are correlated and both depend on how quickly the 
drug enters into and is eliminated from the body. 
Another fundamental parameter obtained by plasma concentration-time profile. useful 
to define the bioavailability of a drug, is the area under the curve (AUC). because it is a 
measure of the total systemic exposure to the drug. To calculate the AUC value, the 
concentration must be integrated with respect to time. The AUC value represents the 
amount of unchanged drug that has reached the general circulation. To determine the 
bioavailability of a drug is necessary to compare the AUC after intravenous 
administration with the AUC after extravascular administration. In particular, the 
bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided 
by AUC intravenous. Bioavailability must be considered when calculating dosages for 
non-intravenous routes of administration. 
The drug distribution phase, that has already begun during the absorption phase or soon 
after an intravenous bolus, is characterized by the volume of distribution. The volume of 
distribution is the apparent volume into which the drug is dissolved. The term 
"apparent" is used because this pharmacokinetic parameter has not a real physiological 
meaning, but it is the fictitious dilution space into which the drug distributes and it is 
useful to correlate the drug concentration in plasma with its amount in the body. The 
volume of distribution depends on binding to both plasma proteins and tissues 
constituents, and can vary widely, with values ranging from 3 L to 40000 L. When it 
has a consistent value, it is possible to assume that the drug is not in systemic 
circulation, but in tissues. Knowing plasma volume and volume of distrihution, the 
fraction of drug in body, in and outside plasma, can be estimated. 
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Once distribution equilibrium has been achieved, the time taken for the plasma 
concentration to fall by one half is called the elimination half-life (tll2) of the drug. The 
knowledge of the half-life is useful for the determination of the frequency of 
administration of a drug (the number of intakes per day) for obtaining the desired 
plasma concentration. The elimination half-life is independent of the amount of drug in 
the body and less drug is eliminated in each succeeding half-life. 
The rate of drug elimination by all routes normalized to the concentration of the drug in 
some biological fluid is defined as clearance. The clearance is the most useful parameter 
for the evaluation of an elimination mechanism. It is the apparent volume of plasma (or 
blood or plasma water) completely cleared of drug per unit of time. The clearance is an 
additive parameter and total clearance is the sum of all organs clearance, especially 
hepatic and renal clearance, the two major organs of elimination. Liver blood clearance 
is the product of liver blood flow and extraction ratio (E); the extraction ratio is the rate 
of drug extraction related to the rate at which it is presented to the organ and the value 
of E varies from 0 (no elimination) to 1 (complete elimination). The rate of drug 
extraction is the difference between the rate of presentation of a drug to an organ of 
elimination and the rate at which drug leaves this organ. Renal clearance is the ratio of 
the rate of urinary excretion to plasma drug concentration and it is the net effect of drug 
filtration, secretion and tubular reabsorption. 
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1.6. Pharmacokinetics of taxanes 
1.6.1. Paclitaxel 
1.6.1.1. Preclinical pharmacokinetics of paclitaxel 
Introduction 
The pharmacokinetics of paclitaxel after i.v., i.p., p.o., and s.c. administration of 22.5 
mg/kg were studied in mice by Eiseman et al. 32. Additional studies in mice were made 
after i.v. bolus dosing at 11.25 mg/kg or 3 h continuous i.v. infusions delivered at the 
infusion rate of 43.24 J1g/kg/min. After i.v. administration to male mice, pac Ii tax c I 
clearance resulted to be 3.25 mL/min/kg and the terminal half-life was 69 mm. 
Paclitaxel disappeared more quickly after i.v. administration to female mice, with 
clearance and half-life of 4.54 mL/min/kg and 43 min, respectively. The bioavailability 
of paclitaxel was <10%, 0%, and 0% after i.p., p.o., and s.c. administration, 
respectively. Pharmacokinetic parameters resulted similar after i.v. delivery of 
paclitaxel at 22.5 and 11.25 mg/kg; however, the clearance calculated in these studies 
was much lower than that found with 3-h continuous i.v. infusions, suggesting non-
linear pharmacokinetics. After i.v. administration, paclitaxel was distributed extensively 
to all tissues (V d = 250-325 mL/kg), particularly in liver, lung and kidney but not in 
brain and testicle. Other studies conducted in rats, to determine the distribution and the 
excretion of paclitaxel, showed similar results, with high distribution in the main 
organs, no evidence of distribution in brain and testis, extensive metabolism and >500/0 
of dose recovered in bile after 24 h of collection 33-35. Higher elimination was found in 
mice, in fact, Bardelmeijer et al. in a more recent study with eH]paclitaxel, recovered 
about 70% of the radioactivity including those of metabolites in faeces 36. 
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1.6.1.2. Clinical pharmacokinetics of paclitaxel 
Paclitaxel is insoluble in aqueous solution and it is therefore formulated in 50% ethanol 
and 50% cremophor-EL (a polyoxyethylated castor oil derivative) to improve its 
solubility 37. 
Paclitaxel is given only intravenously because of its poor oral bioavailability (5-8%). 
According to the initial clinical pharmacology data, elimination of paclitaxel from 
plasma appeared biphasic with linear pharmacokinetic behaviour. These early studies, 
however, used variable infusion schedules of the drug with 1, 6, and 24 hours infusions, 
and were hampered by suboptimal analytical techniques. Hamel et al. found the alpha 
(a) and beta (~) half-lives to be 0.045 and 0.75 h, respectively, with paclitaxel bolus 
intravenous administration 38. Further early phase studies in which the drug was 
administered with 6 or 24 hours infusions consistently showed a biexponential 
1· . . 14 39-42 L· k·· did· d d f e ImmatlOn' . mear metics was assume , as c earance see me m epen ent 0 
dose, especially with 24 hours infusion schedules 43,44. 
With refinement of measurement techniques, elimination of paclitaxel has been found to 
have a three-phase elimination curve and non-linear pharmacokinetic behaviour, 
particularly with shorter infusions. Typical values reported for the a, ~, and gamma (y) 
half-lives are 0.19 h (range 0.01-0.40 h), 1.90 h (range 0.50-2.8 h), and 20.7 h (range 
4.0-65.0 h), respectively 45.' 
Studies in mice and humans determined that paclitaxel exhibited nonlinear 
pharmacokinetics, a characteristic further augmented by the addition of cremophor-EL, 
as vehicle in the clinical formulation to improve its water solubility 46. Paclitaxel 
showed a disproportionate increase in plasma Cmax and AVe as the dose increased, 
suggesting saturation of elimination at higher concentrations of paclitaxel 47,48. Several 
studies with paclitaxel given as a 6 h infusion documented non-linear pharmacokinetics 
with doses higher than 250 mg/m2 14. 39, 40, while others reported that a lower dose of 
38 
Introdu(;lilm 
]35 mg/m2 is the critical threshold for non-linear kinetics 49, 50. Similar fmdings were 
noted with 3 h infusion schedules in patients who received doses of 135 and 175 mg/m2 
(> dose of 30%), where an over-proportion increase of 700/0 and 80% of C
max 
and AUC 
b d 49, 51, 52 d' h k' t' d"' hild h' . was 0 serve an III p armaco lne IC stu les III c ren s owmg non-hnear 
disappearance of paclitaxel with saturation of elimination pathways and tissue 
distribution 53. 
As expected the non-linear pharmacokinetic behaviour of paclitaxel with shorter 
administration schedules was accompanied to both saturable tissue distribution and drug 
elimination processes 47, 48. As paclitaxel Cmax and Aue disproportionately increase 
with the dose of drug administered, saturation must occur during drug elimination. 
though saturable tissue distribution cannot be ruled out 51,54. Implications of a saturable 
non-linear model include relative saturation of paclitaxel binding sites at lower ('max and 
more effective binding of paclitaxel with shorter infusion schedules compared with 
longer infusion schedules 55. Such implications have likely addressed to the adoption of 
shorter infusion schedules and lower drug dosages administered weekly rather than 
k 56 every three wee s . 
Paclitaxel is bound to proteins in plasma, tissues, and tubulins. In plasma, protein 
binding is 95-98% as determined with equilibrium dialysis and ultracentrifugation 
methods 14, 41. Paclitaxel is bounded mainly to a]- acid glycoprotein and to a minor 
extent to albumin and lipoproteins 57. Supporting extensive drug binding in vivo, total 
volumes of distribution have been reported as significantly variable, dependent from the 
dose/schedule and larger than that of total body water, ranging from 50 L/m2 to over 
650 L/m2 14.39,43.44. In addition, paclitaxel shows high distribution in specific tissue of 
organs as kidney, lung, spleen, and in third space fluids, including ascitic and pleural 
fluid '.1,58. As reported by Fujita et ai, the most impressive high distribution was found 
in liver and tumour tissues 59. Paclitaxel does not penetrate in tumour sanctuary tissues. 
39 
Introduction 
including testicles and brain, in which it is undetectable. and it is not present in cerebral 
spinal fluid 58,60. 
Despite the fact that paclitaxel is highly bound to plasma proteins and in tissues 
(tubulin), it is readily cleared from plasma. The major route of elimination is biliary 
excretion. Walle et al. and Monsarrat et al. demonstrated in rats and humans that one-
fifth of the dose of paclitaxel is recovered from bile within 24 hours after administration 
33,61. Paclitaxel metabolites are also measurable in bile, they account for the majority of 
drug elimination from the body via faecal excretion. Metabolite concentrations are 
higher than paclitaxel parent compound concentrations in bile if measured in vivo. 
In humans, renal excretion and other extrahepatic excretion mechanisms account for 
less than 10% of elimination 14, 41, 54. The literature suggests that there is a modest 
suppression of cytochrome P450 activity in patients with chronic renal failure; 
unfortunately no clinical studies have examined the impact of renal failure on paclitaxel 
pharmacokinetics 62-64. For patients with liver dysfunction there are few clinical studies 
that provide guidance with respect to dosing. Fennelly et al. showed that patients with 
either elevated liver enzymes or elevated total bilirubin are more likely to develop 
myelosuppression with paclitaxel treatment than those patients who have neither 
abnormal ity 65, 66. As such, it is prudent that dose reductions be considered for those 
individuals with hyperbilirubinemia and/or increased liver transaminases 67,68. 
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1.6.1.3. Metabolism of paclitaxel 
Paclitaxel undergoes hepatic oxidative metabolism by the cytochrome P450 family. The 
majority of the metabolites are excreted in the bile with only 5-100/0 in the urine. 
Monsarrat et al. were one of the first groups to examine hepatic metabolism and biliary 
excretion of paclitaxeL first in rats and then in humans 33, 34. They identified nine 
metabolites (see table 1) in rats and five in a patient who had external biliary drainage. 
Subsequently, among the known metabolites, five were also identified in mice 36. 
Structure Rl R2 R3 
Paclitaxel H H H 
7-epipacIitaxel H H H 
3 'p-hydroxypacIitaxeI OH H H 
6 a-hydroxypacIitaxel H OH H 
6 a,3'p-dihydroxypaclitaxel OH OH H 
A3 
R4 R5 
H OCOCH3 
H OCOCH3 
H OCOCH3 
H OCOCH3 
H OCOCH3 
R2 
H 
o 
R6 
OCOCH3 
OCOCH3 
OCOCH3 
OCOCH3 
OCOCH3 
Species 
-
Human 
Human, rat, mouse 
Human, mouse 
Human, mouse 
IO-deacetylpacIitaxel H H H H OH OCOCH3 Cell culture, human 
Baccatin III J3-0H H H H OCOCH3 OCOCH3 Human, rat 
I O-deacetyl baccatin III 13-0H H H H OH OCOCH3 Cell culture, human 
2-m-hydroxypaclitaxel H H OH H OCOCH3 OCOCH3 Rat, mouse 
I 9-hydroxypacI itaxe I H H H OH OCOCH3 OCOCH3 Rat, mouse 
4-deacety IpacI itaxel H H H H OCOCH3 H Rat 
2m-hydroxy-4-deacetyl paclitaxel H H OH H OCOCH) H Rat 
___ J 
Table I. Structure formulas of paclitaxel and its known metabolites I Bardelmeijer et al.1 36 
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Interestingly, most of the metabolites were hydroxylated though obvious significant 
differences exist in the site of hydroxylation and metabolite proportions found in bile. 
The major human metabolite discovered was 6a-hydroxypaclitaxel. This metabolite was 
not formed in rats and is modified from paclitaxel via stereospecific hydroxylation at 
the 6-position on the taxane scaffold as detennined by nuclear magnetic resonance 69. 
Two other major metabolites are 3'-p-hydroxypaclitaxel and 6a,3'-p-
dihydroxypaclitaxel. All the metabolites were commonly detected when paclitaxel was 
administered with 3 hours infusions 70. 
The main metabolite was not active when tested against ovarian and colorectal cancer 
cell lines; in fact, 6a-hydroxypaclitaxel is approximately 30 times less cytotoxic than 
paclitaxel and thus the 6a-hydroxylation reaction is felt to be a detoxification reaction 69, 
71. Activity of 3' -p-hydroxypaclitaxel was, in contrast, reduced but not absent in ovarian 
cancer cell lines. All the three metabolites cited before retained bone marrow toxicity 
when tested on human bone marrow cells 71. 
Studying paclitaxel metabolism by liver microsomes, Cresteil et al. demonstrated that 
diazepam inhibits the fonnation of the major metabolite, 6a-hydroxypaclitaxel, 
suggesting that a cytochrome P450 2C family member was responsible for 6a-
hydroxypaclitaxel formation 72. Subsequently, Rahman et al. and more recently 
Henningsson et al. showed the role of cytochrome P450 2C8 (CYP2C8) in metabolism 
of paclitaxel to 6a-hydroxypaclitaxel 73, 74. Cresteil et al. also showed that cytochrome 
P450 3A4 (CYP3A4) was responsible for the metabolism of paclitaxel to 3'-p-
hydroxypaclitaxel 72 and Harris et al. successively confinned it 75. 
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1.6.1.4. Pharmacodynamics of paclitaxel 
The main purpose of investigating and understanding pharmacokinetics of a drug is to 
determine whether there is a relationship between pharmacokinetic parameters and drug 
efficacy and toxicities. In the case of pac1itaxel, multiple studies have established 
relationships between pac1itaxel pharmacokinetics and pharmacological effects 39, 45. 47. 
53 54 76 b . 
, , . The est model to predIct the relationship between pac1itaxel's plasma 
concentration and effects is the threshold model, in which the length of time that 
pac1itaxel concentration exceeds a threshold concentration is predictive of toxicity. 
According to some studies, the duration of pac1itaxel concentrations above a threshold 
value correlates with not only the toxicity, but also the antitumor activity 45,51. 53, 55. 
The most concerning side effects of pac1itaxel are neutropenia and neuropathy. Gianni 
et al. studied pac1itaxel in 30 patients with varying doses and infusion schedules. A 
comparison between a 135 or 175 mg/m2 dose given by a 3- or 24-h infusion versus a 
225 mg/m2 dose by 3-h infusion was made 51. Neutropenia was the most significant 
toxicity and was correlated with pac1itaxel concentration above 0.05 ~mol/L; no 
relationship was noted with pac1itaxel AUC or Cmax concentrations. Similarly, Huizing 
et al. studied paclitaxel in 18 heavily platinum pre-treated ovarian cancer patients 70. 
Women were treated with pac1itaxel 135 or 175 mg/m2 on a 3 or 24 hours infusion 
schedule. A relationship was again found between neutropenia and the duration that 
paclitaxel exceeding a certain concentration threshold; in this study the concentration 
threshold was 0.1 ~mo1JL. Again there was no relationship between AUC or Cmax and 
toxicity. Further studies confirmed the threshold model, Henningsson et al. treated 26 
patients with paclitaxel doses ranging from 135 to 225 mg/m2 47. Total and free (fraction 
unbound to protein) pac1itaxel plasma concentrations were measured and again. 
duration of total paclitaxel above a threshold concentration, 0.2 ~mol/L, predicted for 
neutropenia. A subsequent study on a larger group of 45 patients found that frcc 
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paclitaxel concentrations were a slightly better predictor than total paclitaxel 
concentrations for toxicity but did not improve the goodness of fits of their 
pharmacodynamic model 76. 
Two studies suggested a trend for increased neurotoxicity with increased paclitaxel 
Aue 53. In the first study, conducted in children with solid tumours, using paclitaxel in 
a dose range of 200-420 mg/m2, Sonnichsen et al. observed a trend for higher paclitaxel 
Aues in children with neurologic toxicity compared to children without toxicity 53. In 
children with neurotoxicity, paclitaxel AUe was 54 JlmollL h compared to 30 JlmollL h 
in those without neurotoxicity (p = 0.062). In the second study, breast cancer patients 
were treated with paclitaxel and it was observed that patients developing neurotoxicity 
had higher AUes than the others. In contrast, a study performed in non-small cell lung 
cancer patients by Rowinsky et al. failed to show an association of paclitaxel plasma 
I I d .. 77 eve s an neurotoxIcIty . 
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1.6.2. Docetaxel 
1.6.2.1. Preclinical pharmacokinetics of docetaxel 
The pharmacokinetics of docetaxel was evaluated in a number of animal species prior to 
clinical testing during 1990-1998 period 78-80. In normal and tumour-bearing mice, the 
plasma pharmacokinetics of docetaxel were biphasic with a and ~ half-lives of 7 min 
and 1.2 h 78,80. Both the e max and the Ave increased proportionally with dose over the 
range from 13 to 62 mg/kg 81. The total body clearance was 2.2 L/h/kg at the dose of 37 
mg/kg, whereas the corresponding volume of distribution at steady state was 2.2 Llkg, 
indicating appreciable tissue uptake and binding. The AUf' at the maximum tolerated 
dose in mice was found to be 17 mg/L h, which is approximately 3-fold higher than the 
one observed in clinical studies (approximately 5 mg/L h at 100 mg/m2 - see clinical 
pharmacokinetics -). 
The kinetics of docetaxel in rats has also been described as being linear over the 
clinically relevant range of doses, although there was a trend towards a decreased 
clearance at the highest dose (20 mg/kg) 80, 81. This is consistent with the nonlinear 
elimination of docetaxel by the isolated perfused rat liver over the concentration range 
from 5 to 50 mmollL 82. 
In dogs, administration of docetaxel 30 mg/m2 over 10 minutes yielded biphasic 
pharmacokinetics with plasma half-lives of 4 minutes and 6.6 hours. Averaged AUC 
and clearance were 1.7 mgIL h and 17.6 Llhlm2, respectively 78. The dose of 30 mg/m2 
corresponds to the ""toxic-dose" generating the highest concentration in this species 83, 
and the relatively low Aue observed (1.7 mg/L h) is in support of the higher sensitivity 
of the dog to docetaxel compared with rodents (AVe at MTD in mice = 17 mg/L h). 
The binding of docetaxel to plasma proteins ranges from 70 to 95% in mice, rats and 
dogs 78.84. The kinetics and biodistribution of 114C]-labelled docetaxel have heen studied 
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in mice (111 mg/m2) and dogs (15 mg/m2) 84. The elimination of radio labelled docetaxel 
from nonnal tissues in mice was biphasic with terminal half-lives of 2 to 4.5 h. In 
contrast, the elimination from colon adenocarcinoma xenografts was appreciably 
slower, with half-life of approximately 22 h. As a result, the AUC of docetaxel in 
tumour tissue significantly exceeded that in plasma at all doses despite the fact that the 
Cmax in tumour was less than 10% of those in plasma 81. 
In mice and dogs, the uptake of radio labelled docetaxel has been shown to be wide in a 
range of tissues including liver, gastrointestinal tract, biliary tree, pancreas, muscle and 
haemopoietic tissues 78, 79. Immediately after administration, the highest concentrations 
of radioactivity were found in liver, bile and intestine, consistent with hepatobiliary 
excretion. There was no detectable uptake of radio label led docetaxel into the central 
nervous system. 
1.6.2.2. Clinical pharmacokinetics of docetaxel 
Unfortunately, as reported for paclitaxel, docetaxel has low «100/0) and highly variable 
oral bioavailability 85. There is a number of important mechanisms that explains the low 
oral absorption of taxanes, including high affinity for drug transporters in the 
gastrointestinal tract, such as P-gp (ABCB 1), which limits absorption, and high 
extraction of the drug by extensive metabolism in the intestine and/or liver (first-pass 
effect) by CYP3A 86. Evidence of this, is that the AUC of oral docetaxel increased 9-
fold when coadministered with ciclosporin, a competitive inhibitor of ABCB 1 and 
87 
substrate of CYP3A4 . 
In general, the phannacokinetic profile of intravenous docetaxel is characterized by 
substantial inter-patient variability 88-90. In a population pharmacokinetic study of more 
than 600 patients receiving docetaxel 75-100 mg/m2, the median clearance was 36 Lfh 
(5 th_95th percentile: 17-59 Lih), representing approximately a variation of 3.5-fold in 
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this population 89, In a more recent study in which patients received docetaxel 75 mg/m2 
approximately 10-fold variation in drug clearance was observed 91, 
The docetaxel dosage used for treating cancer patients ranges from 35 to 100 mg/m2 as 
a 1 hour intravenous infusion administered once every 3 weeks or once a week for three 
consecutive weeks (3-weeks), The comparative pharmacokinetic parameters of 
docetaxel administered weekly at a dose of 35 mg/m2 and 3-weekly schedules were 
summarized by Baker et al. 92. Mean ± SD docetaxel clearance values were similar for 
both weekly and 3-weekly schedules (overall means 25.2 ± 7.7 and 23.7± 7.9 L/h/m2, 
respectively; p = 0.5467). Values for terminal elimination half-life were also similar 
with both schedules of administration (overall means 16.5 ± 11.2 and 17.6 ± 7.4 hours, 
respectively; p =0.6990). On average, Cmax values with weekly docetaxel 35 mg/m2 over 
30 minutes were comparable with those achieved with 3-weekly docetaxel 75 mg/m2 
over I hour, but less than those achieved with 3-weekly docetaxel 100 mg/m2 over 1 
hour. On the other hand, estimated cumulative AUC:o during 3 weeks of treatment was 
larger following docetaxel 35 mg/m2 weekly (4.44 ± 1.24 llg/mL *h) than with docetaxel 
60 mg/m2 (2.85 ± 1.40 llg/mL *h) and 75 mg/m2 (3.05 ± 0.85 llg/mL *h) administered 3-
weekly, but in the range of that achieved with 100 mg/m2 (5.62 ± 2.12 llg/mL *h) 
administered 3-weekly. 
Considering the differences in the incidence of severe myelosuppression between the 
two schedules of administration and the exposure-toxicity relationships for 3-weekly 
regimens (see pharmacodynamics of docetaxel), pharmacokinetic data showing similar 
exposure (AU Coo) over a 3-week period for both weekly and 3-weekly regimens suggest 
that the exposure-toxicity relationships for 3-weekly administration do not apply to 
weekly regimens. 
In l'ilro studies have demonstrated that docetaxel is extensively bound to albumin and 
a I-acid glycoprotein and that the latter is the main determinant of variahilitv in 
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docetaxel serum binding 93. From a population pharmacokinetic model involving 547 
patients, a I-acid glycoprotein was identified as a significant predictor of docetaxel total 
clearance. In patients with high plasma levels of protein (>2.6 mg/mL) total clearance of 
docetaxel decreased by 1 9% 94. 
The pharmacokinetic profile of docetaxel has been evaluated in patients with variable 
degrees of hepatic impairment achieving the conclusion that docetaxel dose reductions 
of 20-40% are required in patients with moderate or severe liver function impairment 95. 
Previously, Bruno et al. in their population pharmacokinetic analysis of patients, 
receiving docetaxel 75-100 mg/m2 3-weekly, identified a subset of patients with mild 
hepatic impairment defined as total bilirubin <1.5 times the normal level (ULN). 
elevated transaminases (> l.5 to :s 3.5 times the ULN) concurrent with increased 
alkaline phosphatase (> 2.5 to < 5 times the ULN) 89. These patients showed a 27% 
reduction in docetaxel total clearance, whereas in studies conducted in patients with 
moderate (total bilirubin ~ 1.5 to < 3.0 times the ULN) and severe (total bilirubin ~ 3.0 
times the ULN) impairment the reduction of clearance was found to be 50% 92. 
1.6.2.3. Metabolism of docetaxel 
Pharmacokinetic studies in mice, rats and dogs have demonstrated that docetaxel IS 
extensively metabolized 82,84,96. The major docetaxel metabolites and less than 10% of 
the parent drug are excreted into the faeces, whereas the total urinary excretion is <100/0 
79. The metabolites amounted to 75% of the dose injected and similar data were 
obtained in clinical studies. This suggests that sequential metabolism and biliary 
excretion are the principal pathways of excretion of docetaxel. Therefore, the 
mechanisms of elimination appear to be very similar to those ofpaclitaxel 33. 
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CYP3A4 and CYP3A5 are the most important enzymes among the four members of the 
CYP3A subfamily (CYP3A4, CYP3A5, CYP3A 7, CYP3A43) involved in docetaxel 
metabolism and elimination 97, 98. The metabolites demonstrate substantially reduced 
cytotoxic activity against cancer cells and bone marrow compared with the parent drug, 
making biotransformation a major route of inactivation 96,99. Table 2 reports the 4 major 
docetaxel metabolites which were identified in animals and humans and synthesized 82, 
90,100, lOt 
R 
Structure 
Docetaxel 
Metabolite Ml and M3 
Metabolite M2 
Metabolite M4 
o 
~ 
o 
- NH 
o 
\\ 
NH 
HO 
R 
o CH:! 
Table 2. Chemical structure of docetaxel and its principal known metabolites 
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The principal site of metabolism is the tert-butylpropionate side chain (R2 of docetaxel 
structure) which undergoes a series of oxidation reactions beginning with the oxidation 
of one of the methyl groups leading to M2. This is probably followed by cyclisation of 
putative unstable aldehyde and acid metabolites of the alcohol to 2 diastereoisomers 
(Ml and M3) and a ketone metabolite (M4). The last one was determined as the most 
abundant metabolite present in plasma of cancer patients treated with 100 mg/m2 of 
docetaxel with Cmax between 0.022 and 0.23 mgJL 90. There was no evidence of the 
formation of glucuronide or other conjugates for docetaxel and its metabolites. 
Unlike for paclitaxel, oxidation of the taxane nucleus and the C-3' phenyl of the C-13 
side chain does not take place to any significant extent \02. There is also little 
interspecies difference in the spectrum of metabolites produced. Correlations between 
the production of the tertbutyl alcohol and N-erythromycin demethylation and 6 p-
testosterone hydroxylation in human liver microsomes, implicate cytochrome P450 
. h b 1· f d 1· h 99 102 \03 Th· . d b (CYP3A) In t e meta 0 Ism 0 ocetaxe In umans ' . . IS IS supporte y 
inhibition studies carried out with ketoconazole, troleandomycin and antibodies directed 
to CYP3A. 
1.6.2.4. Pharmacodynamics of docetaxel 
The observed large pharmacokinetic variability for docetaxel has important clinical 
consequences. In the above mentioned population pharmacokinetic studies (dose 
administered: 75-100 mg/m2 and 75 mg/m2, respectively, see 1.6.2.2.), decrease of 
docetaxel clearance (Cl) was accompanied by an increase frequency of grade 4 
neutropenia and fever. For a 500/0 decrease of Cl, neutropenia increase of 4500/0 88 and 
even a 250/0 decrease of CI comported a 1500/0 increase of cases with febrile 
neutropenia. Another study, with docetaxel administered as a 3-weekly regimens, 
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demonstrated that AUC was the only significant predictor of toxicity, as grade 3/4 
mucositis, grade 3/4 diarrhoea, severe asthenia and febrile neutropenia 94. 
Docetaxel exposure has also been related to the efficacy of treatment in particular AUC 
was a significant predictor of time to tumour progression in NSCLC 88. Low docetaxel 
AUC (because of increased clearance) was associated with a shorter time to progression 
and time to death 104. The use of growth factors has the potential benefit of maintaining 
docetaxel AUC while reducing the incidence of febrile neutropenia. 
More recently, the association between exposure to unbound docetaxel and neutropenia 
in cancer patients was studied 105. Docetaxel was administered 3-weekly at a dose of 75 
mg/m2 to 104 patients. From this analysis, unbound docetaxel AUC was better 
correlated than total AUC, with both percentage of decrements in absolute neutrophil 
count (p = 0.002 vs P = 0.029) and worst grade of neutropenia (p = 0.013 vs p = 0.220), 
in the way that higher exposure was associated with worse haematological toxicity. The 
conclusion was that unbound docetaxel is more closely related to the induced 
myelosuppression than the total drug. Finally, a paper by Charles et al. reported the first 
description of factors predictive of toxicity and survival. Patients with reduced 
docetaxel clearance and elevated aI-acid glycoprotein levels evidenced bad adverse 
ffi d . I 106 e ects an worse survlva . 
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1.7. New taxanes 
Despite the relevant contribution of taxanes in modern chemotherapy, in improving the 
overall survival and the quality of life of cancer patients, there are some limitations in 
the therapeutic use of these drugs because of the following reasons: 
• the water solubility of both paclitaxel and docetaxel is very low. For this reason, 
paclitaxel is formulated in the nonionic surfactant cremophor-EL and dehydrated 
ethanol (l: 1 by volume) to enhance its solubility 37. Docetaxel is slightly less 
hydrophobic and it is formulated in tween 80 (polysorbate 80). Both cremophor-
EL and tween 80 are biologically and pharmacologically active compounds with 
clinically important adverse effects, including hypersensitivity reactions and 
peripheral neuropathy 107, 108; 
• the limiting toxicities for these drugs are neutropenia, mucositis and neuropathy; 
• the drug resistance to these compounds. Many patients, even those responding 
initially to therapy, fail to respond further when disease relapses (acquired 
resistance), and a minor number does not even respond at the first cycle of 
therapy (intrinsic resistance); 
• poor bioavailability; 
• lack of penetration of the blood brain barrier (BBB). 
To get round these problems, two different strategies were chosen: 
1- To improve the efficacy of the existing members of taxane family getting their 
formulations better; 
2- To synthesize new analogues having an enlarged antitumor activity profile, in 
particular on taxanes-resistant tumours, with more favourable chemical-physical 
properties and pharmacological profile in tenns of selectivity and tolerability. 
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1.7.1. New formulations 
As regards new formulations of paclitaxel and docetaxel, they are under development to 
improve delivery, pharmacokinetic properties and to reduce drug resistance. As I 
described before, paclitaxel exhibits nonlinear pharmacokinetics with saturable 
metabolism and distribution to tissues 51,53. The nonlinear behaviour of paclitaxel has 
been in part attributed to the formulating reagent, cremophor-EL. Cremophor-EL also 
contributes to decrease the oral bioavailability of paclitaxel 109, 110, thereby limiting the 
usefulness of this formulation for oral use. Cremophor-EL systemic exposure is higher 
when this formulation is given over 1 h than longer infusions Ill. This result explains the 
higher incidences of hypersensitivity reactions and peripheral neurotoxicity observed 
with infusions of 1 h rather than with 3 and 24 hours infusions 112,113. 
Docetaxel formulated with tween 80 shows linear pharmacokinetics and has lower 
incidence of neurotoxicity and hypersensitivity reactions in comparison with paclitaxel 
114 
All the above mentioned limitations of formulating paclitaxel with cremophor-EL 
prompted the development of novel formulations, but only three, Abraxane, Genexol-
PM and MBT -0206 achieved clinical relevance. 
• . 1I5-117 I' I' I Abraxane (ABI007) seems to be the most mterestmg one . t IS pac ltaxe 
formulated as an albumin-bound nanoparticle (diameter of 130-nm) free from any kind 
of solvent. In a phase III study performed in metastatic breast cancer patients, the 
formulation showed greater efficacy and a favourable safety profile compared to 
standard paclitaxel formulated in cremophor-EL 118. 119. Abraxane showed linear 
pharmacokinetics and improved therapeutic index, also avoiding the use of 
corticosteroid premedication required for solvent-based taxanes 119. 120. FDA approved 
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abraxane for the treatment of breast cancer after failure of combination chemotherapy 
for metastatic disease or relapse 115,116. 
The second formulation is Genexol-PM, a sterile, lyophilized polymeric micellar 
formulation of paclitaxel solubilized in methoxy polyethylene glycol-poly (D,L-Iactide) 
121. It has better tissue distribution in mouse models than Taxol® with good anti tumour 
fli 121 e lcacy . In a first phase I study of Genexol-PM on a 3-weekly schedule, dose-
limiting toxic effects of neuropathy and neutropenia were observed at 390 mg/m2 122. In 
contrast, in a recent phase I study conducted on a weekly basis for 3 weeks, doses of 80-
200 mg/m2 given as I-h infusion were well tolerated 123. Genexol-PM showed linear 
pharmacokinetics, and responses were observed in patients with refractory tumours. 
including patients who had previously failed taxane-based chemotherapy 123. 
The last formulation, MBT -0206, is cationic lipid complexes of paclitaxel and is now 
under clinical phase II investigation. It has been shown to be bound and internalized 
selectively by angiogenic tumour endothelial cells after intravenous injection providing 
a vascular targeting agent 124. In a phase Ib study, conducted in patients with metastatic 
breast cancer and tumour progression after anthracycline based chemotherapy, MBT-
0206 showed a favourable safety profile together with promising efficacy data. Good 
tolerability as well as the different mechanism of action of MBT -0206 offer the 
possibility of prolonged treatment or combination therapy 125. 
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1.7.2. New analogues 
1.7.2.1. New analogues under clinical evaluation 
As mentioned before, in addition to the drawback of the low solubility of taxanes -
responsible for the formulation in cremophor-EL and tween 80 - the main disadvantages 
of both paclitaxel and docetaxel are drug resistance, poor bioavailability and no 
penetration in the blood-brain barrier. 
A well characterized mechanism of resistance is over-expression of the MDR-I gene 
encoding for P-glycoprotein (P-gp) which is involved in pumping out the drug from 
cells that express this protein in different tissues. 
Figure 4. Schematic representation of the transport of paclitaxel by P-glycoprotein. Elimination of 
paclitaxel from the liver to tbe bile, from the central nervous system as well as the 
reduced absorbtion of paclitaxel in the gastro-intestinal tract is believed to be associated 
with P-gp transport Ifrom web sourcel· 
Paclitaxel and docetaxel are substrates of P-gp having 3 important effects: 
., . P . turn 126, 127 1- They are macbve agamst -gp over-expressing ours . 
2- Being P-gp expressed in the luminal side of plasma membrane of gut epithelial 
cells 128. 129, the ab orption in the gut of paclitaxel and doceta:: cl i . pre cntcd 130, 
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explaining their low bioavailability. In fact. the use of inhibitors of P-gp blocks 
the efflux of taxanes from intestinal cells, thus increasing the absorption of these 
compounds 87, 131. 
3- P-gp is also present in brain endothelial cells which are a constituent of the 
blood brain barrier (BBB) 132. As a result of complex tight junctions that cause 
severe restriction of the paracellular pathway, BBB is much tighter than 
peripheral microvessels. Therefore, penetration across BBB is confined to 
transcellular mechanisms 133. But, due to P-gp on the luminal side of plasma 
b . b· d h I· I II 132 134 . mem rane m ram en ot e la ce s ' ,pachtaxel and docetaxel hardly 
penetrate into the brain parenchyma through brain endothelial cells. For this 
reason, paclitaxel cannot reach tumour cells in the brain parenchyma - unless 
combined with P-gp inhibitors 135 - and cannot make its effect even though 
tumour cells do not express P_gp 136, 137. 
Other mechanisms of resistance are directly related to the taxane binding site on p-
tubulin, identified both as point mutations in tubulin 138 and as differential expression of 
p-tubulin isotypes, discovered for paclitaxel-resistant ovarian cancer cells 139. 
These considerations explain why it is potentially of great interest to identify and 
develop new taxanes with a low binding affinity for P-gp and/or different affinity 
toward tubulin isotypes. In particular, taxanes characterized by the low binding affinity 
for P-gp should be not cross resistant to paclitaxel and docetaxel and possess good oral 
bioavailability as well as crossing the BBB. The oral route for a taxane is of clinical 
interest, not only because of practical convenience for patients as well as reduced costs, 
but also because prolonged administration of low doses of taxanes may be clinically 
very effective and may possibly involve mechanisms other than anti-mitotic, e.g. anti-
• • 140-1.t2 
angIOgenesIs 
Introduction 
Numerous novel taxane derivatives with improved biological activity, synthesized in the 
last ten years, were available for pharmacological evaluation and reached the phase of 
clinical development. 
In this part of the introduction, I summanze the derivatives possessmg the most 
interesting pharmacological profile and, at the end, I described those that I studied in 
my thesis. 
Table 3 reports a list of analogues that either entered clinical trials or are currently under 
clinical investigation as ortataxel 143, 144, BMS-275183 145, 146, BMS-188797 147, 148, 
I I 149 b' I 150 '1 I 151 I 152 d 'I'L 310 I'd 'I'h bl arotaxe ,car azltaxe ,ml ataxe ,tesetaxe an - --. e ta e 
summarizes the status of the clinical development and their main pharmacokinetic 
properties. Some of them are characterized by high oral bioavailability. 
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DRUG STRUCTURE STATUS PROPERTIES 
H~CH 
HaC 0~0 0 HC~O Oral bioavailable DH'C a Phase II (i.V.) HC 0 Phase I (oral) Linear a " phannacokinetics 
ORTATAXEL HO' CHa 0"'" 
(IDN 5109) Formulation: Half-life: 25 h Polysorbate o 0 (range 22-35 h) YoO 0/ 80lEthanoVCitric F O acid Blood Brain I :: HaC Barrier crossing 
HaC 
X CHa HaC O~O 0 Hac~O CHa NH ~-fS-< H~ Oral bioavailable 
HaC " Phase II (oral) 
HO' Non linear 0"'" 
BMS-275183 Formulation: phannacokinetics 
Lipophilic solvent 
0° (i.e. Peceol) Half-life: 22 h " 0 (range 19-73 h) F O 0 '\ CHa 
0-< 
D--S--< Phase I (i.v.) ~;; ":, H3C - Formulation: Linear 
HO 0"'" Cremophor phannacokinetics 
BMS-188797 ELlEthanol (1: 1) 
in reduced conc. Half-life: 2S h 
6
6 
" (-35%) compared to (range 14-37 h) 
.' 0 
ro paclitaxel 
0 
\ 
CH3 
HaC 
X CH3 
H3
C
_o-<H 
Non linear ~H~ Phase III (i. v.) pharmacokinetics 
LAROTAXEL HO 0"'" Formulation: Half-life: 19 h (XRP9881) Polysorbate (range 13-36 h) 
80lEthanoVWater Blood Brain 
Barrier crossing 
Table 3. Taxanes analogues approved or under clinical develop.ent for cancer treament (til) 
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DRUG STRUCTURE STATUS PROPERTIES 
H.C 
X CH3 H.C 0-<0 
H.C, 
D--S--< Linear ~ A':. 0 H3C 0 Phase II (i.v.) phannacokinetics CARBAZITAXEL HO 0"" Half-life: 77 h 
(XRP6258) Formulation: 
Polysorbate 801 (range 51-96 h) 
6 .......... EthanoVwater Blood Brain Barrier 0 ~o crossing H3C 
"~X~ Phase II (i.v.) o 0 Phase I (oral) O~H ~ H3
C 
HO 0~CH3 Oral bioavailable 
0 Formulation: 
MILATAXEL HO'" 0''''- Cremophor- Non linear 0 
(MAC 321) ELlEthanoV phannacokinetics 
water Half-life: 45 h (in reduced 
conc. compared (range 20-228) 
to paclitaxel) 
H3C r3 X CH3 H3C o-;-{ N ~'CH' 
Oral bioavailable ~ ~ J .:. 0 H.C 0 Phase IIII (oral) Nonlinear TESETAXEL HO 0'"'' Formulation: phannacokinetics 
(OJ 927) not specified 
(compound Half-life: 167±77 h 6 0" highly soluble) )=0 
I : H3C 
"'c'C"' 
o 0 
O==\H Phase I (oral) 
Formulation: Oral bioavailable 
TL-310 0"'" not specified 
(compound Half-life: 80 h 
6 .......... highly soluble) ° "F0 H.C 
Table 3. TaxaDes aDalogues approved or uDder cliDical developmeDt for caDeer treatmeDt (2/2) 
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Many of these taxanes were obtained by modifying substituents at C3 t of the C13 side 
chain (figure 5), where one or both the phenyl groups in paclitaxel structure were 
replaced by other functional groups 146, lSI, 153, 154. 
Figure 5. Paclitaxel chemical structure 
These structural modifications made the novel taxanes more soluble, more potent and 
effective against paclitaxel-resistant tumour cells, It is still not clear how these structural 
changes at C3 t affect the metabolism of taxanes, which is crucial to efficacy, toxicity, 
f dm" , h k" d h d ,155 156 route 0 a 11l1stratlOn, p armaco InetIcs an p armaco ynamICS ' , 
Paclitaxel, because of its molecular complexity, is an ideal candidate for systematic 
modification to develop an understanding of its structure-activity relationships. For this 
reason, besides the modification of the side chain in position 13, many other structural 
changes were introduced on taxane structure such as the modification of the C-7 
position with hydrophobic arenecarbonylcinnamoyl groups 157, the replacing of the 2-
benzoyl group with substituted 2-aroyl groups, the synthesis of D-secotaxanes 158 and so 
on, 
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1.7.2.2. New analogues studied in this thesis 
The derivatives considered in this thesis - IDN 5390, IDN 5614 IDN 5738, IDN 5839 
and IDN 6140 - were obtained by two different main modifications on taxane structure: 
the C-ring opening through the cleavage of bond 7-8 and the introduction of a 
functional group in position 14 (figure 6) . 
/ HO  
functional ~ 
IDN 6140, ION5839, ION 5738 = 
group 
Figure 6. Main structural modifications introduced on taxane scaffold to obtain the studied 
derivatives 
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1.7.2.2.1. C-seco derivatives 
The opening of C-ring led to C-seco paclitaxel analogues 159 and among them, ION 
5390, [13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-l O-deacetylbaccatin III, figure 7]. 
was initially selected for its ability to inhibit endothelial cell motility 160. This 
antiangiogenic effect was confirmed in a paclitaxel-resistant tumor model 161. 
o 
o 
0' , ' 
Figure 7. ION 5390 chemical structure 
Moreover, ION 5390 has a favourable bioavailability, it is well tolerated without 
causing any apparent toxicity (i.e. no body weight loss at therapeutically active dose). 
even upon repeated oral treatment, and showed a significant antineoplastic activity on a 
panel of different tumour models, including some paclitaxel-resistant tumours 161, 162. A 
variety of mechanisms have been proposed to explain taxane resistance, but one of the 
most prominent mechanism of drug resistance seems to be the overexpression of 
specific tubulin isotypes: class III B-tubulin 139. The expression of class III P-tubulin 
confers intrinsic resistance to paclitaxel, but ION 5390 is not conditioned by this class 
of tubulin. This finding might explain why the combination ION 5390/paclitaxel yields 
a strong synergism in tubulin polymerization experiments as well as in whole cells 163, 
providing the rational for the combined use of two taxanes with different affinity toward 
tubulin isotypes as a novel approach to overcome paclitaxel resistance. 
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On the basis of my pharmacokinetic results, in particular about the metabolism of ION 
5390, Indena S.p.A. synthesized and provided me a new derivative, ION 5614, 
structurally related to ION 5390. 
1. 7.2.2.2. 14-functionalized derivatives 
The other mentioned modification is concerned the "southern hemisphere" of taxanes 
structure comprising the C 14 and C 1 to C5 positions. From extensive studies performed 
by many research groups on the structure-activity relationship of paclitaxel, docetaxel 
and their analogues, it has emerged that structural changes in this region of the 
molecules exert a major role on taxane biological activity 164. 
In particular, the introduction of a hydroxyl group in position 14 of IO-deacetylbaccatin 
III confers to that a better water solubility 165. 
For this reason, several derivatives of 14-p-hydroxyl-1 O-deacetylbaccatin III have been 
screened and the research conducted to the identification of ortataxel (see table 3), 
characterized by the presence of a carbonate group between positions 1 and 14 
[(3aS',4R,7 R,8aS',9S, 1 OaR, 12aS', 13S, 13aS)-7,12a-bis(acetyloxy)-4-( {(2R,3S)-3-[ lerl-
butoxycarbonyl)amino ]-2-hydroxy-5-methylhexanoyl }oxy)-9-hydroxy-5,8a, 14, 14-
tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,1 0, 1 Oa,12, 12a, 12b, 13-dodecahydro-6, 13amethano 
[1 ,3]dioxolo[8,9]cyclodeca[1 ,2-d] [1 ]benzoxet-13-yl benzoate] 166, 167. 
Ortataxel was selected in pre-clinical studies because it did not show any appreciable 
neurotoxicity or cardiotoxicity and exhibited much less general toxicity while 
maintaining excellent cytotoxicity, which provides a wider therapeutic window 154. 
Ortataxcl is a poor substrate of P-gp system, having 3 important effects: 
1- this taxane is active against paclitaxel-resistant tumours overexpressing P-gp; 
2- ortataxel shows a good bioavailability and it was found to be highly active when 
. II 168-170 given ora y : 
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3- ortataxel can reach the brain tissue passing through the BBB 154. Taking into 
account also that paclitaxel is active on human glioblastomas 171 and on human 
glioma cells in vitro 172 and on melanoma brain metastasis animal model and 
glioblastoma animal model - when administered with a P-gp inhibitor 173 - it is 
easy to explain the observed ability of ortataxel to affect the growth of 
. . I 174 IntraCranla tumours . 
For these reasons, ortataxel was selected for further developments and entered phase I-II 
clinical trials. It showed encouraging activity and clinical benefit in heavily pre-treated 
metastatic breast and non-small cell lung cancer patients 143,144,175. 
With the aim of further improving the pharmacological properties of ortataxeL a new 
family of 1,14 substituted taxanes was synthesized by Indena S.p.A. by quenching the 
potassium enolate of the 13-oxo-7 -protected-baccatin with different electrophile 
substituents (figure 8), generating a wide number of C-14 modified derivatives, which 
were further developed to the corresponding taxoids 176, 177. 
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3Reagents and Conditions: (i) 'BuOK, THF , -60°C then CHOC02Et; (ii) X = OH: 'BuOK, THF/DMPU, -
70°C then oxaziridine; (iii) X = N3: 'BuOK, THFIDMPU, -70°C then TsN3 then NH4Cl; (iv) COCI2, Py; 
(v) H2, PdlC, AcOEt; (vi) N-Boc-norstatinic acid, DCCIDMAP, CH2CI2; (vii) NaBH4' EtOH; (viii) H2, 
PdlC, (ix) Z = S (2-PY)2CS, (x) Py/HF then MeCOCI, MeOH. 
Figure 8. Synthetic procedures for the preparation of IDN 5738 and IDN 5839 
Two derivatives, IDN 5738 and IDN 5839 (figure 9, panel A and B, respectively) were 
selected for preclinical evaluation. 
A B 
Figure 9. Chemical tructure of 10 5738 and ION 5839 
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These derivatives showed a good cytotoxic activity on two human breast tumour cell 
lines resistant to paclitaxel (table 4), LCC6-MDRl (subline transfected with MDRI 
gene) and MCF7-R (subline with acquired resistance to doxorubicin and collateral 
resistance to paclitaxel) 178, 179. 
Compound 
aICso (oM) ± SE 
MCF7 MCF7-Rb R.I.c LCC6 LCC6-Rb R.I.c 
paclitaxel 1.4±0.3 354.0±35.0 253 2.0±0.1 221.0±6.6 III 
docetaxel 0.5±0.1 230.0±16.0 460 1.2±0.1 110.2±4.6 92 
ortataxel 1.6±0.1 32.0±2.4 20 2.8±0.1 14.3±0.4 5 
IDN 5839 0.4±0.1 17.0±1.4 43 1.9±0.2 12.0±0.9 6 
IDN 5738 22.3±1.8 188.0±12.0 8 9.3± 1.1 74.2±11.1 8 
aConcentration required for 50% reduction of cell growth compared with untreated controls after 72 h of 
exposure to the drug. Mean ± standard error values are reported from at least three experiments. 
bCell lines expressing high levels of P-gp. 
cIC50 drug-resistant line/IC5o drug sensitive line. 
Table 4. In vitro growth inhibitory activity (ICso) of 14-substituted taxanes, in comparison with 
paclitaxel and docetaxel, on human breast cancer cell lines. 
The collected data showed that on sensitive cell lines, IDN 5738 and IDN 5839, were 
cytotoxic at nanomolar concentrations and, in particular, IDN 5839 was characterized 
by an ICso value comparable to that of paclitaxel, docetaxel and ortataxel. 
On multi drug resistant MCF7-R and LCC6-MDR cell lines, both of them resulted more 
cytotoxic than docetaxel and paclitaxel. In particular, IDN 5839, having an ICso value 
comparable to that of ortataxel on both resistant cell lines, is 18-21 and 9-14 fold more 
active than paclitaxel and docetaxel, respectively. 
Despite its one order magnitude milder cytotoxicity, ION 5738 had the most interesting 
resistance index on MCF7-RlMCF7 cell lines. ION 5738 and IDN 5839 showed a lower 
resistant index (R.I.) compared to paclitaxel and docetaxel, confinning the ability of the 
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14 modified taxanes to overcome multi drug resistance effect (MDR), as it wa 
demonstrated for ortataxel 180. 
In order to better characterize these compounds, the tubulin interaction was investigated 
evaluating the ability of IDN 5738 and IDN 5839 to stabilize tubulin and promote its 
polymerization. Experiments were carried out using bovine brain purified tubulin and 
densitometry testing the two compounds at the same concentration (10 JlM). IDN 5738 
and IDN 5839 were effective in inducing tubulin polymerization. Moreover, the results 
obtained with IDN 5839 were very close to those obtained with docetaxel and ortataxel 
(Indena S.p.A. internal report). 
Afterwards, on the basis of pharrnacokinetic data produced about IDN 5738 and IDN 
5839, I obtained and studied a third derivative, IDN 6140 (figure 10) synthesized by 
Indena S.p.A. 
II 
o 
Figure 10. ION 6140 chemical tructure 
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The interest for ION 6140 was based on a well known and reported characteristic of 
paclitaxel chemistry. The meta derivatives, and in particular methoxy derivatives. were 
much more cytotoxic than paclitaxel, thanks to the "meta-effect" that it is the enhanced 
interaction between the C-2 ring and asp224 in the p-tubulin binding pocket 181. 182. ION 
6140 was in fact obtained by the introduction of a methoxy meta-substituent on the 2-
benzoate oftaxane scaffold of ION 5839 structure. 
Even ION 6140 was selected for the subsequent preclinical evaluation on the basis of its 
cytotoxic activity. On a human lung cancer cell line (H460), it showed a potent 
cytotoxic activity, superior not only respect to paclitaxel (40-fold), but even to ortataxel 
(9-fold) 183 (table 5). 
8compouod bICso (oM) ± SD 
paclitaxeI 21.0±3.2 
ortataxel 4.47±1.10 
ION 5738 26.42±5.71 
ION 5839 1.31±0.1l 
ION 6140 0.49±0.03 
BCompounds were dissolved in 10% DMSO and further diluted in complete culture medium. 
bConcentration required for 50% reduction of cell growth compared with untreated controls after 72 h of 
exposure to the drug. Mean ± standard deviation values are reported from at least three experiments 
Table 5. Cytotoxic activity of 14-substituted taxanes, in comparison with paclitaxel and docetaxel, 
on human lung tumour cell line ("460) 
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The general aim of my thesis is the characterization of the preclinical pharmacokinetic 
profile of the aforementioned new taxane derivatives. To do that, firstly I developed and 
validated the assays to determine the concentration of the new compounds in biological 
specimens, and then I have applied them to study the pharmacokinetics in mice. The 
methods were based on high-performance liquid chromatography coupled with tandem 
mass spectrometry (LC-MSIMS) technique. The following pages will summarize the 
principles of mass spectrometry. 
1.8. Mass spectrometry 
The application of pharmacokinetics is very important to evaluate the drug disposition 
and, consequently, to optimize the therapy. 
In order to define the pharmacokinetic profile of a compound, the method and the 
analytical technique used are fundamental. The higher the sensitivity of the method is, 
the better the description of the drug kinetics will be, in terms of a much longer 
monitoring of drug concentration, which also means a better description of the terminal 
elimination phase thanks to an appropriate limit of quantitation. 
In the last 30 years, there has been significant improvements in analytical technologies 
applied in cancer pharmacology to measure drug concentration and to study drug 
metabolism. At the beginning, the concentration data from plasma or other biological 
matrix were usually obtained by HPLC-UV NIS methods; the next step was to prefer, 
when it was possible, the use of a fluorescence detector, but the real change in 
bioanalysis was the development of bench-top mass spectrometry as a method of 
detection, combined with liquid chromatography (LC-MS). Within a few years, LC-MS 
has become the method of choice for quantitative drug analysis to support 
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pharmacokinetics and drug metabolism studies. Besides the possibility to reduce time of 
analysis, coupling the mass spectrometer with LC provides significant improvements in 
assay sensitivity and specificity, in fact this technique makes possible the determination 
of picomolar drug concentrations in body fluids. The increase in sensitivity and 
specificity caused 3 important effects: 
1- the possibility to detect species at very low concentration; 
2- the possibility to use very small amount of sample, that is particularly important 
in pediatric studies or in preclinical studies conducted in small animals. In small 
animal studies, this is relevant for the analysis of fluids produced in small 
amount such as bile, or in blood microsampling. The use of serial bleeding is 
increasingly employed because of the following advantages: it leads to a 
reduction in animal usage - associated with a reduction in compound required 
for such experiments -, in differences due to dosing error and in animal to 
animal variation. According to these advantages, the euthanasia of animals is not 
required or greatly reduced, as they may be reused after several weeks recovery 
and washout; 
3- the drug and its metabolites can be detected from complex matrices such as 
tissues or whole blood. 
Mass spectrometry is a powerful analytical tool both for drug quantitative and 
qualitative analysis. The quantitative information is obtained by using a mass 
spectrometer capable of MSIMS fragmentation. MSIMS is necessary because many 
compounds have the same intact mass, while the fragmentation pattern is compound 
specific. The combination of parent mass and its fragment ions is used to monitor 
selectively the compound that has to be quantified. 
MSIMS fragmentation is also fundamental for qualitative information. because the mass 
spectrum of every compound is unique and it can be used like a chemical fingerprint to 
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characterize the sample, even III case where only picogram amounts of analyte are 
available. 
In my thesis, I performed the quantitative bioanalysis by using a triple quadrupole mass 
spectrometer, while I studied the metabolic profile by using an ion trap mass 
spectrometer. 
In LC-MS the sample is introduced into the mass spectrometer after its separation in an 
HPLC column. Charged ions of the analytes are then produced into the ion source of the 
mass spectrometer. These ions are separated by the MS analyser on the basis of their 
mass to charge (mlz) ratio. There are different types of MS ion sources, but the most 
commonly used in pharmacokinetic studies is Electrospray Ionization (ESI), an 
atmospheric pressure ionization (figure 11). 
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Figure 1 t. A scheme of an Electrospray Ionization source [from web source) 
Electrospray spectra are produced by passing a liquid stream through a metal capillary 
maintained at high voltage (2000-5000 V). This forces the spraying of charged droplet 
from the needle with a surface charge of the same polarity of the charge on the needle. 
Th droplets are repelled from the needle towards the ource ampling orifice n the 
counter electrode. As the dropicL traverse the space between the needle tip and the 
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orifice, solvent evaporation occurs thanks to the presence of a nebulizer and a heated 
desolvation gas. This causes the reduction of the droplet size to a point in which the 
repulsive forces between charges, on the surface of the droplets are sufficient to 
overcome the cohesive forces of surface tension, leading to the "coulombic explosion 
and, consequently, the droplet is ripped apart. This produces smaller droplets that can 
repeat the process as well as naked charged analyte molecules. These analyte ions can 
be singly or multiply charged and are emitted into the gas phase where they are focused 
and introduced into the MS analyser, kept under high vacuum (figure 12). 
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Figure 12. A scheme of the mechanism of ion formation in ESI (from web sourcel 
The production of smaller droplets is enhanced by lower mobile phase flow rate and use 
of volatile mobile phases. ESI is a soft ionization technique - as very little residual 
energy is retained by the analyte after ionization - and does not cause decomposition of 
labile compounds. It is characterized by an efficient ion production and it can operate in 
either positive or negative ion mode. 
From the ion source, ions are transferred to the mass spectrometer, where they are 
analysed. 
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A triple quadrupole mass spectrometer is characterized by three consecutive quadrupole 
analysers: the first and the third ones work as mass filters, while the second as a 
collision cell. A quadrupole consists of four parallel rods arranged symmetrically 
around a central axis (figure 13). 
+/- (U + Vcos wt) 
Figure 13. Circuit diagram of tbe four quadrupole rods with RF voltage V cos wi and the 
superimposed DC voltage U 
Opposite rod pairs are connected electrically and a voltage, consisting of both 
radiofrequency (RF) and direct-current (DC) components, is applied with the RF 
components on the different pairs being 1800 out of phase. The RF value is a constant of 
a specific quadrupole type, while the DC voltage is varied in order to allow only ions of 
a particular mlz to follow a stable trajectory through the rods and reach the detector 
while all other ions hit the quadrupoles because of their unstable path (figure 14). 
Pre-filter Quadrupole Mass Filter Post-filter 
Rejected ions Stable (resonant) ion 
Figure 14. cherne of a quadrupole filter 
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According to the aims of the analysis, the fust and the third quadrupole can be used in 
different scan modes to acquire and visualize data. Each quadrupole can be set to filter 
only one mlz ratio or to scan over a wide mlz range. The most common scan mode for a 
quantitative analysis is defined as Selected Reaction Monitoring (SRM), characterized 
by the use of two quadrupoles as mass filters: the first quadrupole selects the precursor 
ion of the analyte and the second, after fragmentation in the collision cell, selects the 
specific product ion (figure 15). 
QI 
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Collision 
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Figure 15. Selected Reaction Monitoring in a triple quadrupole 
This acquisition mode maximizes the signal/noise ratio of the compound and it is highly 
specific. 
The study of the metabolic profile of a drug needs qualitative analyses for structural 
identifications, that can be made using full scan MS and MSIMS spectra obtained with 
an ion trap mass spectrometer (figure 16). 
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The quadrupole ion trap consists of three electrodes: a ring and two end cap electrodes. 
The end caps are usually at ground potential, while a RF voltage is applied to the ring 
electrode, generating a quadrupole field to trap the ions. Changing the RF voltage in a 
systematic way, a complete mass spectrum may be obtained: all ions, created during a 
given time period, are trapped until an RF voltage is applied to the ring electrode and 
then, on the basis of their m/z ratio, sequentially ejected from the analyser and directed 
towards the detector. Helium gas in the trap favours the trapping efficiency by 
contracting the ions trajectories to the centre of the trap and reducing the kinetic energy 
of the ions. This allows ions of a given m/z to form a packet. The ion packet is ejected 
more quickly and efficiently than a diffuse cloud of ions, thus improving resolution. 
During the analysis, all ions (in gas phase) generated from the sample, are acquired in a 
wide and fixed mass range and it is possible to observe the MS and MSIMS spectra 
corresponding to the peaks appeared in the LC-MS trace. The obtained fragmentation 
profile is useful to have structural infonnation and allows the study of possible 
metabolites. With an ion trap spectrometer. it is possible to work in MS/MS mode. hut. 
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since the ion trap consists of a single element, it is usually indicated as MSIMS "in 
time". As well, even sequential MSIMS analysis (MSn) can be undertaken by the ion 
trap. By using appropriate scanning modes, the ion trap excludes all non-interesting ions 
and selects the wanted precursor ion; then, by applying an appropriate RF voltage, 
causes its fragmentation and the ejection of fragments to the detector. The ability of the 
ion trap technique to perform multiple stages of mass spectrometry increases greatly the 
amount of structural information that can be obtained for a given molecule. 
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Aims of the thesis 
The general aim of my thesis is the characterization of the preclinical pharmacokinetic 
profile of new taxane derivatives, C-seco and 14-~-functionalized analogues, 
synthesized by Indena S.p.A. 
At the beginning of this thesis work, only three new compounds were available: IDN 
5390 - obtained by the opening of C-ring -, IDN 5738 and ION 5839, both of them 
derived from the introduction of a functional group in position 14 of taxane scaffold. 
Successively, on the basis of pharmacokinetic data collected about these three 
analogues, two more compounds were synthesized by Indena S.p.A.: IDN 5614 and 
ION 6140, the former structurally related to ION 5390 and the latter to IDN 5839. 
To describe the pharmacokinetic profile of a drug within an organism, it is necessary to 
define its absorption, distribution, metabolism and excretion. All these steps influence 
the drug plasma levels and the kinetics of drug exposure to the tissues and hence 
influence the pharmacodynamics of the compound. To elucidate the metabolic pathway 
of the new taxane derivatives, whenever necessary, metabolic studies are performed 
both in vitro, using mouse and human liver microsomes or S9 fraction, and in vivo in 
rodent models. 
To describe the pharmacokinetic/metabolic profile of a compound, as first step, it is 
necessary to develop and validate the assay to determine the concentration of the new 
derivative in biological specimens. Consequently, the validated assay is applied to 
characterize the pharmacokinetics and the bioavailability of the compound in mice after 
oral and intravenous administration. The methods currently applied are generally based 
on high-performance liquid chromatography coupled with tandem mass spectrometry 
(LC-MSIMS) technique, because of its high sensitivity and specificity that is required 
for pharmacokinetic studies with potent small molecules that are used at relatively low 
doses. 
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3.1. Materials and animals 
3.1.1. Standards and reagents, chemicals, control mouse plasma, mice, 
materials and supplies and instrumentation 
3.1.1.1. Standards and reagents 
IDN 5390 (lot no. 553/16), paclitaxel (lot no. 277591K3, used as internal standard, IS, in 
the quantitation method of IDN 5390), ION 5614 (lot # PGB646), ION 5738 (lot # 
624/12, ba 02/957/LR), IDN 5839 (lot # 638/41), IDN 5127 (ba 186118-CoA 
n.9110611LR, used as IS in the quantitation method of ION 5738 and ION 5839) and 
IDN 6140 (708/30 - ba. 06/0335 LR3) were obtained from Indena S.p.A., Settala, 
Milan, Italy. 
7-ethoxycoumarin (lot # 054K3687), NADPH generating system: BNAOP, uridine 
diphosphate glucuronic acid (UDPGA), glucose-6-phosphate dehydrogenase, glucose-6-
phosphate, magnesium chloride and D-saccharic acid 1,4 lactone, PAPS and Bovine 
Serum Albumin (BSA) were obtained from Sigma Aldrich, St Louis, MI, USA. 
7-hydroxycoumarin (lot. # 1123370) was obtained from Fluka Chemie, Sigma Aldrich, 
St Louis, MI, USA. 
Metabolic profiles of IDN 5390 and IDN 5614 were determined in hepatic microsomes 
(batch 0410046) of CDI female mice obtained from Xenotech, LLC (KS, USA). 
Metabolic profile of ION 5390 was determined also in human hepatic microsomes 
(batch 0212063) from Xenotech, LLC (KS, USA). Metabolic profile of ION 6140 was 
determined in pooled CO-l mouse liver S9 fraction (M 1500.S9 Lot. No. 0310217) 
obtained from Xenotech, LLC (KS, USA). 
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3.1.1.2. Chemicals 
Methanol and acetonitrile of HPLC grade, glacial acetic acid and formic acid for 
analysis were obtained from Carlo Erba (Milan, Italy). 
Water of HPLC grade was obtained from a Milli Ro 60 Water System, Millipore 
(Milford, MA, USA). 
0.9% NaCl solution was obtained from SALF S.p.A. (Bergamo, Italy). 
3.1.1.3. Control mouse plasma 
Female CDFI control mouse plasma was obtained from IFFA (Credo, France) for 
experiments with ION 5390. For evaluating the pharmacokinetics of ION 5738, ION 
5839 and ION 6140 female COl control mice plasma was used and it was obtained 
from Charles River Laboratories Italia (Caleo, Italy). Three different batches of plasma 
were used: lot. 09-02/03/05, lot. 12-21103/05 and lot. 49-04112/06 for ION 5738, ION 
5839 and ION 6140, respectively. 
3.1.1.4. Mice 
Female CDFI mice (body weight 20±2 g) were obtained from IFFA (Credo, France). 
CD 1 female mice (body weight 25±2 g) were obtained from Charles River Laboratories 
Italia (Calco, Italy). They were housed and handled according to the institutional 
guidelines (Legislative Decree 116 of Jan 27, 1992. Authorisation n.169/94-A issued 
Dec. 19, 1994 by Ministry of Health) and intemationallaws and policies (EEC Council 
Directive 86/609, OJ L 358. 1, Dec. 12, 1987; Standards for the Care and Use of 
Laboratory Animals, United States National Research Council, Statement of 
Compliance A5023-0 1, Nov. 6, 1998). 
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3.1.1.5. Materials and supplies 
Pipets, models P20, PIOO, P200 and PIOOO Pipetman, were obtained from Gilson 
Medical Electronics S.A. (Villiers-Ie-Bel, France). 
Disposable Pipets Tips, for P20, PIOO, P200 and PIOOO Pipetman, were obtained from 
Rainin Instruments (Woburn, MA, USA). 
Vials (for Alliance autosampler), were obtained from Waters (Milford, MA, USA). 
Disposable borosilicate glass tubes, 16 x 100 nun, were obtained from Coming Inc. 
(Coming, NY, USA). 
Vials and limited volume inserts for WISP 717 autosampler were obtained from Waters. 
3.1.1.6. Instrumentation 
The HPLC-UV system, consisting of a Model 717 WISP autosampler, a Model 510 
pump, a detector Model W2487 at variable wavelength UV -VIS and an acquisition 
system Empower Software Chromatography Manager, came from Waters Associates 
(Milford, MA, USA). 
Three different HPLC-MSIMS systems were used: 
1- A system consisting of a Surveyor autosampler and Surveyor MS pump 
combined with an LCQ Deca XP Plus ion trap mass spectrometer was obtained 
from Thermo Electron (Waltham, MA, USA); 
2- A system consisting of an Alliance series 2695 HPLC coupled with a Micromass 
Quattro Ultima Pt triple quadrupole mass spectrometer was obtained from 
Waters (Milford, MA, USA); 
3- A system consisting of an HPLC Series 200 autosampler and micropump (Perkin 
Elmer), coupled with an API 4000 triple quadrupole mass spectrometer, was 
obtained from Applied Biosystems (Foster City, CA, USA). The instrument was 
equipped with a Turbo V ESI source. 
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3.2.1. Stock solutions 
Materials and Methods 
ION 5390 stock solution was prepared in methanol at a concentration of I mg/mL. The 
stock solution was diluted with methanol to obtain working solutions at concentrations 
of 100, 10 and 1 Jlg/mL. Paclitaxel stock solution was prepared in ethanol at the 
concentration of 100 Jlg/mL. It was diluted with ethanol to obtain a working solution at 
the concentration of 20 Jlg/mL. ION 5614 solution was prepared in methanol at the 
concentration of 4 mM. 
3.2.2. Treatment formulation 
Vials of ION 5390 formulated in polysorbate 80 (Montano x 80 VG OF) at the 
concentration of 80 mg/mL were provided by Indena S.p.A. (Settala, Milan, Italy). The 
stock solution was diluted with 0.9% NaCI just before use and administered in a volume 
of 10 mL/kg body weight. 
3.2.3. Mouse treatment 
The animals used for ION 5390 experiments were female COFI mice (body weight 
20±2 g). To determine the faecal and urinary excretion of ION 5390, six groups of five 
mice were given 60, 90 and 120 mg/kg of the compound intravenously or oraBy. 
To determine whether liver metabolic induction was responsible for the decrease in IDN 
5390 AUC after repeated oral treatment, two groups of female mice were treated on day 
7 with an i.v. dose of90 mg/kg. The two groups had been previously treated once a day 
for 7 consecutive days with 90 mg/kg of oral IDN 5390 or with vehicle diluted in 0.9% 
NaCI solution. 
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3.2.4. Sampling 
Faeces and urine were collected from mice housed in metabolic cages, before dosing 
and after 24 and 48 hours. The fractions were immediately measured and frozen stored 
at -20°C until HPLC-MSIMS analysis. 
The pharmacokinetic study was done on day 7 after one week of daily oral treatment 
with saline or IDN 5390 at the dose of 90 mg/kg. Blood samples were collected at 5, 15, 
30 min and 1, 1.5, 2, 4 and 24 hours after i.v. injection of IDN 5390. Four mice were 
used per time point. Blood was obtained from the retro-orbital plexus under diethylethcr 
anesthesia and collected in heparinized tubes. The animals were sacrificed by cervical 
dislocation. The plasma fraction was immediately separated by centrifugation (2500 
rpm, 10 min, 4°C) and stored at -20°C until analysis. 
3.2.5. Analysis 
3.2.5.1. Faeces and urine 
IDN 5390 was assayed in faeces and urine by LC-MSIMS. Briefly, urine samples (100 
fJL) were spiked with 200 ng of paclitaxel as IS. After dilution (l :1) with CH3CN/H20 
10:90 containing 0.1 % HCOOH, 5 fJL were injected into the HPLC system. 
Weighed faeces were homogenized 1:4 (w/v) with 40/0 bovine serum albumin (BSA) 
solution and diluted (l :4) in water, then 1 mL was added with 400 ng of paclitaxel as [So 
Finally, for extraction, 3 mL of acetonitrile were added and then the samples were 
vortexed and centrifuged at 4°C for 10 min at 4000 rpm. The obtained supernatant was 
dried under nitrogen and reconstituted with 200 fJL of mobile phase. Five fJL were 
injected into the HPLC system consisting of an Alliance series 2695 coupled with a 
Micromass Quattro Ultima Pt triple quadrupole mass spectrometer operating in positive 
ion mode. This mass spectrometer was used to obtain both the mass spectra (MS ') and 
the product ion spectra (MS2). The instrument was equipped with an electrospray 
84 
Materials and Methods 
ionization interface. The biological samples were analysed with the ion-spray needle 
operating at +3500 V and the cone voltage at 60 V. The mass spectrometer was 
programmed to allow the [M+Ht ions of ION 5390 and paclitaxel at mlz 788.4 and 
854.6 to pass through the first quadrupole into the collision cell. The characteristic 
product ions of these two compounds were monitored in the third quadrupole at m!:: 
309.0, 327.0 for ION 5390 and 286.4 and 509.5 for paclitaxel. The chromatographic 
separation was carried out on an Omnispher 3 CI8 column (100 x 2.00 mm x 1;4") 
Varian (Palo Alto, CA, USA) using a mobile phase gradient of 0.1 % HCOOH in water 
(MPA) and 0.1 % HCOOH in acetonitrile (MPB). The gradient conditions were from 
10% to 100% of MPB in 27 min at the flow rate of 0.2 mL/min. 
Extracts of urine and faeces were also analysed by HPLC coupled with an LCQ Oeca 
XP Plus ion trap mass spectrometer for the search of ION 5390 metabolites. 
3.2.5.2. Plasma samples 
On plasma samples of mice given 90 mg/kg were performed the quantitation of ION 
5390 concentrations and the identification of the circulating metabolites both by LC-
MS/MS analysis. Each plasma sample was analysed for the pharmacokinetic study, 
whereas pooled plasma obtained from four mice at each time point was analysed for the 
metabolic study. Plasma samples were extracted with HCOOHlCH3CN (1 :1000) in 
proportion 1:4 (v/v), centrifuged at 13000 rpm for 10 min and the collected supernatant 
was dried under nitrogen. The residue was dissolved in 30 JlL of initial mobile phase 
and injected into the HPLC coupled with a Quattro Ultima Pt mass spectrometer (for the 
quantitation) or with an LCQ Oeca XP Plus ion trap mass spectrometer (for the 
identification of circulating metabolites). 
For quantitation analysis, a chromatographic separation was carried out on a column 
SunFire C 18 (3.5 Jlm, 2.1 x 150 mm), Waters (Milford, MA, USA) using a mobile phase 
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gradient of 0.1 % HCOOH in water (MPA) and 0.1 % HCOOH in acetonitrile (MPB). 
The gradient conditions were from 40% to 100% of MPB in 12 min, maintenance for 2 
min, changing from 100% of MPB to 400/0 in 1 min and re-equilibrium of the column 
for 6 min at the flow rate of 0.2 mL/min. 
To detect the circulating metabolites, the chromatographic separation was carried out on 
an Omnispher 3 CI8 column (100 x 2.00 rom x Y4") using a mobile phase consisting of 
MP A and MPB. The gradient conditions were from 100/0 to 100% of MPB in 27 min at 
a flow rate of 0.2 mL/min. 
3.2.5.2.1. Pharmacokinetic analysis 
The concentration data at each time point obtained for pharmacokinetic elaborations 
were the means ± standard deviation calculated from four animals. Plasma samples with 
a concentration above the highest standard point of the calibration curve were diluted 
with control plasma and re-assayed. 
Pharmacokinetic parameters were calculated usmg WinNonlin Pro Node 4.1 
pharmacokinetic software Pharsight Co. (Mountain View, Ca., USA). 
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3.2.6. In vitro metabolism of IDN 5390 and IDN 5614 after incubation with 
mouse and/or human liver microsomes 
3.2.6.1. Sample preparation 
IDN 5390 and IDN 5614 solutions were prepared in methanol at the concentration of 4 
mM to study the metabolism in vitro with human and/or mouse liver microsomes. 
Six groups of samples were prepared according to the following scheme: 
SAMPLES INCUBATED WITH ION 5390 or ION 5614 
Group nO of samples Incubation time Incubated with microsomes Added UOPGA 
A 3 o minutes YES NO 
B 3 o minutes NO NO 
C 3 240 minutes YES NO 
D 3 240 minutes NO NO 
--
E 3 240 minutes YES YES 
--
SAMPLES INCUBATED WITHOUT ION 5390 or ION 5614 
Group nO of samples Incubation time Incubated with microsomes Added UOPGA 
F I o minutes YES YES 
The same scheme was used for incubation of 7 -ethoxycoumarin to evaluate the 
metabolic activity of the microsomes: 7-hydroxycoumarin was identified on the basis of 
the retention time in comparison with the standard and used as a marker of oxidative 
metabolism. 
Two mg of 7-ethoxycoumarin were dissolved in 1 mL of methanol and diluted to 2 mL 
with 0.1 M pH 7.4 KH2P04 buffer. 1 mL of such solution was further diluted to 10 mL 
with 0.1 M pI I 7.4 KlhP04 buffer. 
Both the compounds under study and 7 -ethoxycoumarin were incubated at 37°C up to 
240 minutes. 
IDN 5390 or IDN 5614 and 7-ethoxycoumarin, mlcrosomes and reagents nominal 
concentrations used in the samples are reported in the following table: 
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Substance Concentration Used in group 
ION 56) 4 or ION 5390 40llM A to E 
7 -ethoxycoumarin 1llglmL A, C and E 
---' 
Microsomes 0.5 mglmL A, C, E and F 
MgCh 4mM All groups 
p-O-gl ucose-6-phosphate 10mM All groups 
PNAOP ImM All groups 
G lucose-6-phosphate 
dehydrogenase 1.5 units/mL All groups 
UOPGA 5mM E and F 
Saccharic acid 1,4 lactone 5mM E and F 
Table 6. Concentrations of the test compounds and reagents used in the incubation reaction with 
microsomes 
MgCh, J3-D-glucose-6-phosphate, J3NADP and glucose-6-phosphate dehydrogenase 
were used to prepare the NADPH regenerating solution (NRS). UOPGA and saccharic 
acid 1,4 lactone were added to a portion ofNRS, obtaining the NRS for groups E and F. 
Samples were prepared by adding 250 ilL of 0.1 M pH 7.4 KH2P04 buffer, 100 f.lL of 
NRS (with or without UOPGA and saccharic acid 1,4 lactone), 45 f.lL of deionized 
water and 5 ilL of ION 5614 or ION 5390 and 7 -ethoxycoumarin standard solution. In 
the samples, incubated either without micro somes or drugs, an equal volume of 0.1 M 
pH 7.4 KH2P04 buffer was added. 
The reaction was started by adding 100 ilL of the microsomal suspensIOn to the 
samples. The reaction was stopped at selected times by adding 500 ilL of methanol. 
Samples were shaken, centrifuged at 13000 rpm for 10 minutes (4°C) and the 
supernatants used for HPLC-MS/MS analysis. 
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3.2.6.2. Sample analysis 
7-ethoxycoumarin and 7-hydroxycoumarin were analysed according to the HPLC-
UV NIS method described in Appendix 1. IDN 5390 was analysed, as reported above, 
with the same method used to determine the metabolites in faeces and urine. IDN 5614 
was analysed by HPLC-MSIMS method as described in Appendix 2. 
3.2.6.3. Results evaluation 
The chromatograms obtained were compared among the groups with reference to the 
generated metabolites. 
Furthermore, a quantitative evaluation according to the following formulas was carried 
out. For each group, the average values were used. 
(peak area of sample C - peak area of sample E) 100 % of 7 - hydroxycoumarin lost adding UDPGA = x 
peak area of sample r 
(peak area of sample A - peak area of sample C) 
% of ION 5390 or ION 56 14 metabolized without UDPGA= x 100 
peak area of sample A 
(peak area of sample A - peak area of sample E) 
% of ION 5390 or I DN 5614 metabolized with UDPGA = x 100 
peak area of sample A 
peak area of sample D 
ION5390or ION5614stability (%)during the incubation = x 100 
peak area of sample B 
peak area of sample A 
ION 5390 or ION 5614 recovery (0/0) from microsomes = xl 00 
peak area of sample B 
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ION 5738, ION 5839 and ION 6140 
The following section is relative to the phannacokinetic study of ION 5738, ION 5839 
and IDN 6140. In order to define the phannacokinetics of a new compound, the first 
step is to set up and validate a method for its quantitation. 
The most important thing to verify and define when developing a quantitation method 
using a mass spectrometer, is the effect of the matrix - in which the compound of 
interest is contained - on the response of the instrument. For this reason, I summarized 
in the following paragraph the description of this phenomenon and the ways to 
overcome this problem. 
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3.3. Matrix effect 
The HPLC-MSIMS technique offers the possibility to measure small amounts of drug in 
complex biological matrix, thanks to its high sensitivity and selectivity. These 
characteristics allow the analysts to develop methods based on an easy sample 
preparation and a simple chromatographic separation, even with these problematic 
matrices, because endogenous components of biofluids are not detected and the signal 
in a SRM trace is only due to the analyte of interest. However, to be further confident 
about the analyte quantitative determination, it is necessary to consider that these 
undetected matrix components could coelute with the analyte and interfere with the 
ionization, causing suppression or enhancement of the signal. 
Current FDA requirements underline the importance to assess this phenomenon, known 
as "matrix effect" in mass spectrometry, because it may compromise the precision, the 
accuracy, the sensitivity and the selectivity of the developed method and, consequently, 
the reliability of analytical data produced. 
A common method to evaluate qualitatively the matrix effect is the post-column 
infusion, that permits to identify the chromatographic region where the matrix effect 
manifests itself. A constant concentration of the analyte is introduced in the ion source 
of the mass spectrometer by using an infusion pump connected with a T junction after 
the HPLC column, while a blank extracted sample is injected onto the chromatographic 
system. The signal of the infused drug, followed in a SRM scan mode, is steady, unless 
endogenous components eluting from the column cause a reduction or a gain of the 
response. To assure the reliability of the results, it is important that these Ion 
suppression or enhancement effects do not happen near the analyte's retention time. 
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A quantitative evaluation of matrix effect is achieved by comparing the response of the 
analyte in solvent to the response obtained by spiking the analyte into blank matrix 
sample after the entire procedure of extraction 184. 
It is not fully clear how the matrix effect occurs, but endogenous matrix components, 
such as salts, fatty acid, triglycerides, amines or metabolites, and exogenous 
components, such as polymers from analitycal material, vehicles as tween 80 or 
anticoagulants, could compete with the analyte of interest in the ionization process. In 
particular, there is an analyte ion suppression if the interferences are preferentially 
ionized and there is an analyte ion enhancement if the interferences favour the 
ionization of the analyte. Anyway, the analyte's response in matrix could change in 
comparison to the response of the same analyte in solvent, because of the different 
conditions at which the ionization occurs. The presence of matrix material influences 
the droplets' properties in the ESI source: it could increase the surface tension in 
droplets, reduce the solvent evaporation, change the viscosity or react with analyte ions. 
If the matrix effect is present and not negligible, it may be eliminated or reduced to 
guarantee the quality of the analytical data produced. There is not a unique solution to 
resolve the suppression or the enhancement of the signal, because the matrix effect is 
compound dependent and the biological matrices are always different. One of the 
easiest ways consists of a sample dilution, but it is possible only if there are not 
problems of sensitivity. Other approaches to overcome the matrix effect are based on 
the attempt to obtain cleaner samples through different preparation procedures. 
Different solvents or different mixtures of solvents in various proportions could be used 
to favour the precipitation of interfering substances, on the basis of solvents properties -
viscosity, density, volatility. polarity -. Moreover, it could be also useful to consider the 
role of additives and buffers in mobile phases 185: 
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- trifluoroacetic acid is not recommended, because it causes ion suppression at an) 
concentration level, both in negative and positive acquisition modes; 
- formic acid and acetic acid at high concentrations (0.50% - 1.00%) cause a signal 
reduction of the analyte, while their effect (suppression or enhancement) is variable 
at lower concentrations (0.05% - 0.10%); 
- ammonium hydroxide has the same role of formic and acetic acid in negative ion 
mode, but in positive ion mode, generally, it favours an increase of signal; 
- ammonium formate, biphosphate, bicarbonate and nonafluoropentadecanoic acid 
diminish the signal both in negative and positive ion acquisition mode, and both at 
high and low concentrations (5 - 50 mM). 
Other possibilities to reduce the matrix effect are based on the changes in mass 
spectrometric and chromatographic conditions. As regards mass spectrometry, an 
attempt could be the use of a different ion source to modify the mechanism of ion 
formation, while the aim of changes in chromatography would be to separate interfering 
substances from the analyte. If the analyte elutes in a region of the chromatogram where 
the signal undergoes a suppression or an enhancement, it is possible to shift the 
retention time of the analyte by changing the chromatographic column or gradient 
conditions. However, they are often time-consuming experimentations and the risk is 
that the suppression or the enhancement region could also shift. 
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As regards the validation of the quantitation methods of ION 5738, ION 5839 and ION 
6140, as the study of these new taxane derivatives was in a preliminary phase of the 
preclinical study, I chose to follow the FOA guidelines, issued in 2001, for the method 
validation - in order to guarantee a good reliability and precision of the calculated data _ 
but using a simplified protocol. For this reason, the method validation was set up on 
three days. 
In the following two paragraphs, I summed up the parameters considered during the 
validation study of the three new taxane derivatives and the pharmacokinetic parameters 
calculated after the quantitation of their concentrations. 
3.4. Validation parameters 
The main parameters considered for the validation of the quantitation methods were: 
recovery, linearity of the calibration curve, precision and accuracy, limit of detection, 
limit of quantitation and stability. 
The recovery of an analyte is obtained from the comparison of the peak area of the 
analyte of interest obtained from extracted samples with that obtained from external 
standards prepared in solvent. The recovery of IS is evaluated in the same way. The 
recovery experiments were perfonned at two or three different concentrations. It is 
important that the extent of recovery is consistent, precise and reproducible. 
The linearity of the calibration curves was validated over three days. Each day, a 
calibration curve was prepared by spiking the biological matrix with known 
concentrations of the analyte to define the relationship between concentration and 
instrument response. It consisted of six or seven standard points in a range chosen on 
the base of expected concentrations in the samples and was obtained using the same 
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biological matrix of samples to measure. The linearity of the standard curves was 
calculated by the HPLC-MSIMS peak areas ratio for the analytelIS to the nominal total 
amount of the analyte in the standard sample. In particular, the linearity for each 
calibration curve was assessed by weighted least squares method, using 1 Ix as 
weighting factor. 
The y axis intercept (q) and the slope (m) of the equation y = mx + q were calculated 
elaborating the Yj and Xi values obtained from the calibration points, where: 
in which Aj = peak area of j -erne anal yte 
AIs = peak area of the Internal Standard 
Xi = actual concentration of the analyte in the curve point sample. 
The goodness of the fitting was evaluated by the Pearson's determination coefficient R2. 
The reproducibility of each calibration curve was assessed by the mean, standard 
deviation (SD) and coefficient of variation (CV%) of the estimated m and R2. The back-
calculated values of individual calibrants had to be within < 15% of their theoretical 
concentration « 20% at the limit of quantitation). 
Precision and accuracy of the method were evaluated on three different days by 
determining the analyte in three replicates of three quality control (QC) samples at 
different nominal concentrations. Three different standard calibration curves were 
prepared and processed each day to analyse the QCs. The precision of the method at 
each QC concentration was reported as a CV%, expressing the standard deviation as a 
percentage of the mean calculated concentration and it must not exceed 15% of CV. The 
accuracy of the measure was determined by expressing the mean calculated QC 
concentration as percentage of the nominal concentration. The mean value must be 
within 15%. 
The limit of detection (LOD) was defined as the concentration at which the signal-to-
noise ratio was 3. The limit of quantitation (LOQ) was defined as thc smallest amount 
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of the analyte that could be measured in a sample with sufficient precision and accuracy 
(within 20% for both parameters) and as the concentration at which the signal-to-noise 
ratio was at least 10. The LOQ was chosen as the lowest concentration on the 
calibration curve. 
The stability of the analyte of interest was evaluated by analyzing the QC matrix 
samples in triplicate at each QC concentration level, immediately after preparation and 
after approximately one month of storage nominally at -20°C. For the assessment of the 
stability, the analyte was quantified in the stored samples using a freshly prepared 
calibration curve and a set of freshly prepared QC samples. The stability was also 
evaluated after three freeze and thaw cycles, at one concentration and in triplicate. 
The three derivatives were considered stable at each concentration when the differences 
between the freshly prepared samples and the stability testing samples were found to be 
not exceeding 15% of the nominal concentration. 
3.5. Pharmacokinetic analysis 
Concentration-time data of taxane derivative analogues obtained from CD 1 female mice 
after i. v. and p.o. administration were collected and were evaluated for pharmacokinetic 
analysis. For each time point, the found concentration was a mean of three 
concentrations gathered from three animals. A non-compartmental analysis was applied 
and the pharmacokinetic data were elaborated by using the specific software 
WinNonLin Pro Node 4.1 (Pharsight Co, Mountain View, Ca, USA). 
The considered parameters were: 
CmilX 
Tmax 
maximum plasma concentration 
time until Cmax is reached 
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AUC area under the concentration-time curve from time 0 to the last detectable 
CI 
sample 
area under the concentration-time curve extrapolated to infinite 
plasma half-life in the terminal phase 
plasma clearance 
volume of distribution 
bioavailability 
Ratio AUC accumulation factor for AUC values determined In different 
compartments 
Ratio Cmax accumulation factor for Cmax values determined in different 
compartments 
In detail, Cmax and T max were directly determined from the experimental data. AUC was 
determined by the trapezoidal rule. The trapezoidal rule is a numerical method to 
approximate the area under a curve first involves dividing the area into a number of 
strips of equal width. Then, approximating the area of each strip by the area of the 
trapezium formed when the upper end is replaced by a chord. The sum of these 
approximations gives the final numerical result of the area under the curve. 
TII2 was calculated by the formula: TJI2= O.693/ke, where the elimination rate constant, 
ke, is the slope of the terminal phase of the plasma-concentration time curve. Its 
calculation was based on at least three data points. CI is calculated as dose/ AUC and F 
is expressed as AUCp.o'/AUCi.v. corrected for the administered dose. Ratio AUC and 
Ratio Cmax were estimated as the ratio tissues/plasma for AUC and Cmax values, 
respectively. 
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3.6. IDN 5738 and IDN 5839 
3.6.1. Standard and QC solutions 
For standards, a stock solution for each analyte was prepared at the concentration of 
101.2 Jlg/mL for IDN 5738 and 102.4 Jlg/mL for IDN 5839. For QCs, a stock solution 
of each analyte was prepared at 100.0 Jlg/mL. The stock solution of the IS was prepared 
at 116.2 Jlg/mL. All stock solutions were prepared in methanol and stored at -20°C for 
six months before preparing fresh ones. 
Working solutions to obtain the standard points (O-B for IDN 5738 and O-A for ION 
5839) of the calibration curve and the working solutions to prepare the plasma QC 
samples, for both the analytes, were obtained by combining different amounts of the 
stock solutions and further dilution with methanol to obtain IDN 5738 and ION 5839 at 
the final concentrations reported here below: 
IDN 5738 IDN 5839 
Standard concentration concentration 
(JiglmL) (JiglmL) 
G 0.25 0.25 
F 0.50 0.50 
E 1.00 1.00 
D 5.00 5.00 
C 10.00 10.00 
B 15.00 20.00 
A 50.00 
Quality IDN 5738 IDN 5839 
control concentration concentration 
solution (JiglmL) (J1g/mL) 
sL 0.75 0.75 
sM 6.00 15.00 
sH \5.00 40.00 
The IS working solution was prepared at 10 Jlg/mL by diluting the stock solution with 
methanol. 
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3.6.2. Preparation of standard and QC samples 
Control mouse plasma aliquots (90 flL) were spiked with 10 flL of each working 
solution to obtain a final dilution of 1: 1 0, giving six calibration standards in the range 
0.025-1.500 flg/mL for IDN 5738 and seven in the range 0.025-5.000 flg/mL for IDN 
5839. 
To prepare QC samples, three fractions of mouse plasma were added with an 
appropriate amount of QC solutions (sL, sM and sH), obtaining QC plasma samples at 
the final concentrations of 0.075, 0.600 and 1.500 flg/mL for IDN 5738 and 0.075, 
1.500 and 4.000 flg/mL for IDN 5839. 
Several aliquots of the three fractions were stored at -20°C as controls for future assays 
and to check the short term stability under storage conditions. 
3.6.3. Processing standards and samples 
Mouse plasma samples (100 flL) were mixed with 10 flL of IS working solution (100 ng 
of IS) and 200 flL of 0.1 % HCOOH in CH3CN kept at 4°C. After vortexing for lOs, the 
mixture was centrifuged at 4°C for 10 min at 13000 rpm. The supernatant was 
recovered and 5 flL were injected into the LC-MSIMS system. 
3.6.4. Chromatographic conditions 
The HPLC system consisted of an Alliance separation module 2695 (Waters, Milford, 
MA, USA). 
For both methods, the samples were separated on a SunFire C 18 column (3.5 flm, 150 x 
2.1 mm) coupled with a C18 precolumn (4 x 3 mm) Waters (Milford, MA, USA), held 
at 30°C. The mobile phases for the chromatographic separation were composed of 0.1 0/0 
HCOOH in water (MPA) and 0.1 % HCOOH in acetonitrile (MPH). The IIPLC system 
was set up to operate at a flow rate of 0.2 mL/min at the following gmdient conditions: 
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step 1- from the initial condition of 50% MPB to 95% over 4 min; step 2- maintenance 
of 95% MPB over 2 min; step 3- from 95% MPB to 100% over 4 min~ step 4-
maintenance of 100% MPB over 1 min; step 5- from 100% MPB to the initial condition 
over 2 min; the initial condition was held for 7 min. The total run time was 20 min. 
Peaks were detected by SRM mode. 
At the end of the daily analyses, the HPLC column was washed with CH30H/H20 (I: 1 ) 
for 30 min at the flow rate of 0.2 mL/min. 
The temperature of the autosampler was 4°C. 
3.6.5. Mass spectrometric conditions 
The HPLC system was coupled with a Micromass Quattro Ultima Pt triple-quadrupole 
mass spectrometer (Waters, Milford, MA, USA). 
The mass spectrometer operated in negative ion mode and was used to obtain both the 
mass spectra (MS ') and the product ion spectra (MS2). The instrument was equipped 
with an electro spray ionization interface and used argon as the collision gas. The 
biological samples were analysed with the ion spray needle operating at -2500 V and 
the cone voltage at -70 V. The mass spectrometer was programmed to allow the 
[M+HCOOr of ION 5738, ION 5839 and ION 5127 at m/z 915, 912 and 932 
respectively, to pass through the first quadrupole into the collision cell. The 
characteristic product ions of these three compounds were monitored in the third 
quadrupole at m/z 583, 523 and 260 for ION 5738; 806, 623 and 563 for ION 5839 and 
at 826 and 583 for ION 5127 (IS). 
All mass parameters related to the two methods are schematized III the following 
paragraphs: 
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3.6.5.1. IDN 5738 
Source: ElectroSpray in negative ion mode and with heater gas at 300°C 
Capillary voltage (kV): -2.50 
Cone voltage (V): -70 
Collision cell gas: argon at a pressure of 3.54 e-3 
Collision energies (eV): 19.0 - 21.0 
Qualitative analyses, for the acquisition of MS and MSIMS spectra, were done by direct 
infusion of standard solutions (1 Jlg/mL) of ION 5738 and ION 5127. 
Quantitative analysis of the same substances in plasma was done by Selected Reaction 
Monitoring (SRM) mode, measuring the following fragmentation products of the 
[M+HCOOr: 
Compound [M+HCOOr (mlz) product ion (m/z) collision energy (eV) 
ION 5738 915.3 583 19.0 
ION 5738 915.3 523 21.0 
ION 5738 915.3 260 19.0 
ION 5127 932.0 583 20.0 
ION 5127 932.0 826 19.0 
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3.6.5.2. ION 5839 
Source: ElectroSpray in negative ion mode and with heater gas at 300°C 
Capillary voltage (kV): -2.50 
Cone voltage (V): -70 
Collision cell gas: argon at a pressure of3.74 e-3 
Collision energies (eV): 16.0 - 30.0 
Qualitative analyses, for the acquisition of MS and MSfMS spect~ were done by direct 
infusion of standard solutions (l Jlg/mL) of ION 5839 and ION 5127. 
Quantitative analysis of the same substances in plasma was done by SRM. measuring 
the following fragmentation products of the [M+HCOOr: 
Compound 
ION 5839 
ION 5839 
ION 5839 
ION 5127 
ION 5127 
[M+HCOOr (m/z) 
912.4 
912.4 
912.4 
932.0 
932.0 
product ion (m/z) 
563 
623 
806.4 
583 
826 
collision energy (eV) 
30.0 
17.0 
16.0 
20.0 
19.0 
The MS and MSfMS mass spectra of ION 5738 and ION 5839. with 
chemical structures and identification of the main fragment ions are reported in figure 
17. 
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Figure 17. MS and MSIMS mass spectra of ION 5738 and ION 5839, with 
chemical structures and identification of the main fragment ions [instrument used: 
LCQ Deca XP Plus ion trap mass spectrometer] 
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3.6.6. Validation study 
Two different validation studies were performed, one for each compound. The linearity 
of the calibration curves was validated over three days and calculated. as described in 
section 3.4, by the ratio of the HPLC-MSIMS peak areas for ION 5738/IS and IDN 
5839/IS to the nominal concentration of ION 5738 and ION 5839 in the standard 
sample. 
Precision and accuracy of the method were evaluated on three different days by 
determining the analytes in three replicates of three QC samples at the nominal 
concentrations of 0.075, 0.600 and 1.500 Jlg/mL for ION 5738 and 0.075, 1.500 and 
4.000 flg/mL for ION 5839. A standard calibration curve was prepared and processed 
each day to analyse the QC samples. 
To establish the LOQ an aliquot of 450 JlL of control plasma was spiked with 50 JlL of 
a 0.25 flg/mL solution of ION 5738 or ION 5839 to produce a nominal plasma 
concentration of 25 ng/mL of the analyte. Five replicates of the obtained LOQ samples 
were processed and analysed by HPLC-MSIMS according to the previously described 
procedure together with a freshly prepared standard curve with a blank control and a 
blank control added with IS. 
The percentage extraction recovery of the two analytes was calculated in triplicate at 
two plasma concentrations (0.100 and 1.000 flg/mL) for ION 5738 and at three plasma 
concentrations (0.100, 1.000 and 5.000 Jlg/mL) for ION 5839. Peak-area ratios of both 
analytes from extracted samples were compared to those from external standards 
prepared in methanol. The absence of the matrix effect that could influence the 
ionization of ION 5738 and ION 5839 was also assessed. The matrix effect. at each 
concentration level. was determined by comparing the mean area of the analytes 
prepared in solvent with the sanle quantity of the two taxane derivatives added to 
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biological matrix after the entire procedure of extraction. The absence of significant 
variations « 15%) for the areas of both the analytes was verified, so it was possible to 
exclude any matrix effect causing ion suppression or enhancement. 
The stability in the matrix of the two taxanes was evaluated analysing QC samples in 
triplicate at each QC concentration level, immediately after preparation and after 
approximately one month of storage at nominally -20°C. 
3.6.7. Application of the method: pharmacokinetics of ION 5738 and ION 
5839 in CDlmice 
Both compounds were dissolved in a vehicle containing tween 80 and absolute ethanol 
in the proportion 1: 1 and diluted (1 :5) with saline to the final concentration of 6 mg/mL. 
Each taxane derivative was administered orally by gavage or injected in the tail vein of 
the mice. The experiments were carried out in 8-10 weeks old female CO 1 mice (body 
weight 25±2 g). 
To determine the pharmacokinetic profile and the bioavailability of ION 5738 and ION 
5839 after single administration, mice were treated p.o. or i.v. with single dose of 60 
mg/kg. For ION 5738 study, blood samples were taken at the following time points: 5. 
15, 30 minutes and 1, 2, 4, 8, 16 and 24 hours after i.v. administration and at 15, 30, 45 
minutes and 1, 1.5, 2,4, 8, 16 and 24 hours after oral treatment, while for IDN 5839. the 
sampling was conducted at 5, 15, 30 minutes and 1, 2, 4, 8 and 10 hours after i.v. 
administration and at 15, 30, 45 minutes and I, 1.5, 2, 4 and 10 hours after oral 
treatment. Blood was obtained from the retro-orbital plexus under isoflorane anesthesia 
and collected in heparinized tubes. After centrifugation at 2500 rpm at 4°C for 10 
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minutes, plasma was separated and frozen stored at -20°C until analysis. Three mice 
were used for time point and animals were sacrificed by cervical dislocation. 
3.6.8. Identification of circulating metabolites 
Qualitative analyses of plasma samples, from mice treated with ION 5738 and ION 
5839, have been done with the following instruments and conditions for the 
identification of metabolites. The HPLC-MS system consisted of a Surveyor 
autosampler and Surveyor MS pump, combined with a LCQ Oeca XP Plus ion trap 
mass spectrometer Thermo Electron (Waltham, MA, USA). Separation was performed 
using an Ornnispher 3 C I8 column, 100 x 2.00 mm x Y4" at a flow rate of 0.2 mL/min. 
The elution solvents were: water with 0.1 % of formic acid (MPA) and acetonitrile 
(MPB); the elution gradient was from 20 to 1000/0 of MPB in 32 min, with a 6 min hold 
of 100% MPB and a final re-equilibrating step to 200/0 of MPB for 8 min. 
The LCQ ion trap was used in positive ion mode, with a standard electro spray source 
(ESI) directly coupled to the HPLC column. The spray capillary was kept at 5.0 kV, 
while the ion transfer capillary was kept at 1 OV, at a temperature of 225°C. Instrument 
data were recorded using data dependent acquisition (OOA), by programming the ion 
trap to perform an acquisition loop consisting of an initial full scan MS (600-1200 amu) 
and then by choosing, in real time, the 3 most abundant ions, to perform their MS/MS 
spectra (normalized collision energy of 30%). 
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3.7. IDN 6140 
3.7.1. Pharmacokinetic study in plasma samples 
3.7.1.1. Standard and QC solutions 
For standards, a stock solution of the analyte was prepared at the concentration of 100.6 
J.1g/mL. For QCs, a stock solution was prepared at 100.2 J.1g/mL. The stock solution of 
the IS, ION 5738, was prepared at 101.2 J.1g/mL. All stock solutions were prepared in 
methanol, stored at -20°C and brought to room temperature before use. 
Working solutions to obtain the plasma standard points (G-A) of the calibration curve 
and working solutions to prepare the plasma QC samples were obtained by combining 
different amounts of the stock solutions and further diluted with methanol to obtain ION 
6140 at the final concentrations reported below: 
IDN 6140 
Standard concentration 
(Jig/mL) 
G 0.10 
F 0.25 
E 0.50 
D 1.00 
C 5.00 
B 10.00 
A 20.00 
Quality IDN 6140 
control concentration 
solution (Jig/mL) 
sL 0.15 
sM 0.75 
sH 15.00 
The IS working solution was prepared at 5.06 J.1g/mL by diluting the stock solution with 
methanol. 
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3.7.1.2. Preparation of standard and QC samples 
Control mouse plasma aliquots (90 ~L) were added with 10 ~L of each ION 6140 
working solution to produce a final dilution of 1: 1 0, giving seven calibration standard 
points in the range 0.010-2.000 ~g/mL. 
To prepare QC samples, three fractions of control mouse plasma were spiked with an 
appropriate amount of QC solutions (sL, sM and sH), obtaining a final plasma 
concentration of 0.015 ~g/mL, 0.075 ~g/mL and 1.500 flg/mL, respectively. 
Several aliquots of 100 flL of the three fractions were stored at -20°C, as controls for 
future assays and to check the stability under storage conditions. 
3.7.1.3. Processing standards and samples 
Plasma samples (100 flL) were spiked with 10 flL of IDN 5738 (5.06 flg/mL in 
methanol) as IS and with 200 flL of 0.1 % HCOOH in CH3CN kept at 4°C. After vortex 
mixing for lOs, the samples were centrifuged at 4°C for 10 min at 13000 rpm. 
The supernatant was recovered and a volume of 10 flL was injected into the HPLC-
MSIMS system for quantitative analysis. 
3.7.1.4. Chromatographic conditions 
The HPLC system consisted of a Series 200 autosampler and mlcropump (Perkin 
Elmer). The samples were separated using a SunFire C 18 (3.5 flm, 150 x 2.1 mm) 
column coupled with a C18 precolumn (4 x 3 mm) and with the following gradient 
conditions: 
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Time (minutes) 0.1 % HCOOH in 0.1 % HCOOH in H20 (%) CH3CN (%) 
0 50 50 I 
4 5 95 i 
6 5 95 i I 
10 0 100 
-, 
13 0 100 
I 
14 50 50 I 
20 50 50 I 
The flow-rate was 0.2 mL/min and peaks were detected by SRM mode. At the end of 
the daily analyses, the HPLC column was washed with CH30HlH20 (1: 1) for 30 min at 
the flow rate of 0.2 mL/min. 
The temperature of the autosampler and the column was 4°C and 30°C, respectively. 
3.7.1.5. Mass spectrometric conditions 
The HPLC system was coupled with an API 4000 triple quadrupole mass-spectrometer 
(Applied Biosystems, Foster City, CA, USA). 
The mass spectrometer operated in negative ion mode and was used to obtain both the 
mass spectra (MS I) and the product ion spectra (MS2). The instrument was equipped 
with a Turbo V source. The biological samples were analysed with the ion spray needle 
operating at -4200 V. The mass spectrometer was programmed to allow the 
[M+HCOOr of ION 6140 and ION 5738 at m/z 942.4 and 915.5 respectively, to pass 
through the first quadrupole into the collision cell. The characteristic product ions of 
these two compounds were monitored in the third quadrupole at m/z 151.1, 593.2 and 
653.4 for ION 6140 and at 260.2 and 583.4 for ION 5738 (IS). 
All the mass parameters related to the method are here schematized: 
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Source: Turbo V in negative ion mode and with heater gas at 350°C 
Capillary voltage (kV): -4.2 
CAD: 4.00 
Curtain gas: 20.00 
Gas 1: 35.00 
Gas 2: 52.00 
Collision energies (e V): -21.0 -;- -62.0 
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Qualitative analyses, for the acquisition of MS and MSIMS spectra, were done by direct 
infusion and FIA (Flow Injection Analysis) of standard solutions (50 ng/mL) of ION 
6140 and IDN 5738. 
Quantitative analysis of the same substances in plasma was done by SRM mode, 
measuring the following fragmentation products of the [M+HCOOr: 
Compound Ql mass (amu) Q3 mass (amu) CE (V) CXP (V) EP (V) OP (V) 
IDN 6140 
IDN 6140 
IDN 6140 
942.4 
942.4 
942.4 
151.1 
593.2 
653.4 
-62.0 
-31.0 
-21.0 
-14.0 -11.0 -57.0 
-18.0 -11.0 -57.0 
-22.0 -11.0 -57.0 
Compound Ql mass (amu) Q3 mass (amu) CE (V) CXP (V) EP (V) OP(V) 
IDN 5738 
IDN 5738 
The MS 
915.5 
915.5 
and MSIMS 
260.2 
583.4 
mass 
-29.0 -13.0 -11.0 -72.0 
-24.0 -21.0 -11.0 -72.0 
spectra of IDN 6140, with 
chemical structure and identification of the main fragment ions arc reported in figure 18. 
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chemical structure and identification of the main fragment ions [instrument used: 
LCQ Deca XP Plus ion trap mass spectrometer] 
3.7.1.6. Validation study 
A validation study in plasma matrix was perfonned for ION 6140. The linearity of the 
calibration curves was validated over three days and calculated, as described in section 
3.4, by the ratio of the LC-MSIMS peak areas for ION 6140/lS to the nominal 
concentration of ION 6140 in the standard sample. 
Precision and accuracy of the method were evaluated on three different days by 
detennining the analyte in three replicates of three QC samples at the nominal 
concentrations of 0.015, 0.075 and 1.500 J.1g/mL. A standard calibration curve was 
prepared and processed each day to analyse the QC samples. 
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To establish the LOQ, an aliquot of 90 JlL of control plasma was spiked with 10 JlL of a 
0.10 Jlg/mL solution of ION 6140 to produce a nominal plasma concentration of 10 
ng/mL of the analyte. Five replicates of the obtained LOQ samples were processed and 
analysed by LC-MSIMS according to the previously described procedure, together with 
a freshly prepared standard curve with a blank control and a blank control spiked with 
IS. 
The percentage extraction recovery of ION 6140 was calculated in triplicate at three 
plasma concentrations (0.025, 0.1 00 and 2.000 Jlg/mL). Peak-area ratios of the 
analyte/IS from extracted samples were compared to those from external standards 
prepared in 0.1 % HCOOH in acetonitrile. It was also ensured the absence of the matrix 
effect that could influence the ionization of IDN 6140. The matrix effect, at each 
concentration level, was assessed by comparing the mean areas of the analyte obtained 
from samples prepared in solvent with those prepared adding the same quantity of ION 
6140 to biological matrix after the entire procedure of extraction. It was verified the 
absence of significant variations « 15%) for the area of the analyte and IS, so it was 
possible to exclude any matrix effect of ion suppression or enhancement. 
The stability of ION 6140 in the matrix was evaluated analysing QC samples in 
triplicate at each QC concentration level, immediately after preparation and after 
approximately one month of storage at nominally -20°C. 
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3.7.1.7. Application of the method 
3.7.1. 7.1. Pharmacokinetics of IDN 6140 in CDI mice 
ION 6140 was dissolved in a vehicle containing tween 80 and absolute ethanol in the 
proportion 1: 1 and diluted (1 :5) with saline to the final concentration of 0.54 mg/mL. 
The new taxane derivative was administered orally by gavage or injected in the tail vein 
of the mice. The experiments were carried out in 8-10 weeks old female eo 1 mIce 
(body weight 25±2 g). 
To determine the pharmacokinetic profile and the bioavailability of ION 6140 after 
single administration, mice were treated p.o. or i.v. with a single dose of 5.4 mglkg. 
At the following time points after i.v. (5, 15, 30, minutes and 1, 2, 4, 8, 16, 24, 48 
hours) or p.o. treatment (15, 30, 45 minutes and 1, 1.5, 2, 4, 8, 16, 24, 48 hours), blood 
samples were obtained from the retro-orbital plexus under isoflurane anaesthesia and 
collected in heparinized tubes. Four mice were used for each time point and the animals 
were sacrificed by cervical dislocation. After centrifugation at 2500 rpm at 4 De for 10 
minutes, plasma was separated and frozen stored at -20De until analysis. 
The tissue distribution of ION 6140 was studied in brain and liver. These organs were 
removed at several time points after i.v. and p.o. treatment (15 minutes and 1, 2, 4, 8 
and 24 hours), immediately frozen in dry ice and stored at -20De until analysis. 
Faeces and urine were collected from mice housed in metabolic cages, before dosing 
and 24 and 48 hours after the treatment. The fractions were immediately measured and 
frozen stored (-20De) until the determination of ION 6140 excretion. 
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3.7.1.7.2. Pharmacokinetics after oral repeated treatment 
To detennine whether repeated oral treatments with ION 6140 could cause liver 
metabolic induction, two groups of female mice were treated on day 10 with an oral 
dose of 5.4 mg/kg. The two groups had been previously treated p.o. once a day for 9 
consecutive days with 5.4 mg/kg of ION 6140 or with vehicle dissolved in 0.9% NaCI 
solution. 
Blood samples were collected at 30 and 45 min and 1, 2, 6 and 24 hours after the 
administration of ION 6140. Three mice were used per time point. Blood was obtained 
from the retro-orbital plexus under isoflurane anesthesia and collected in heparinized 
tubes. The animals were sacrificed by cervical dislocation. The plasma fraction was 
immediately separated by centrifugation (2500 rpm, 10 min, 4°C) and stored at -20°C 
until analysis. 
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3.7.2. Distribution study in brain tissue 
For the quantitation method of IDN 6140 - extracted from brain tissue - a validation 
study was not performed, but the matrix effect, the recovery and the intra-day precision 
and accuracy of the method were evaluated. 
3.7.2.1. Standard and QC solutions 
For standards, a stock solution of the analyte was prepared at the concentration of 99.8 
flg/mL. For QCs, a stock solution was prepared at 102.8 flg/mL. The stock solution of 
the IS, ION 5738, was prepared at 100.5 flg/mL. All stock solutions were prepared in 
methanol, stored at -20°C and brought to room temperature before use. 
Working solutions to obtain the standard points (O-A) of the calibration curve and 
working solutions to prepare the brain QC samples were obtained by combining 
different amounts of the stock solutions and further diluted with methanol to obtain ION 
6140 at the final concentrations previously described for its quantitation in plasma 
samples. The IS working solution was prepared at 5.06 flg/mL by diluting the stock 
solution with methanol. 
3.7.2.2. Preparation of brain standard and QC samples 
Brain tissue was homogenized in 6.8 parts (w/v) of CH3CN/CH30H 3:1. Homogenate 
was then added with 10 flL of appropriate ION 6140 working solutions to produce a 
final dilution 1: 1 0, giving seven calibration standards (0.010, 0.025. 0.050, 0.100, 
0.500, 1.000, 2.000 flg/mL). 
To prepare QC samples, control brain tissue - homogenized in 6.8 parts (w/v) of 
CH3CN/CH30H 3: 1 - was added with an appropriate amount of QC solutions (st, sM 
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and sH), obtaining a final brain concentration of 0.015 llg/mL. 0.075 llg/mL and 1.500 
llg/mL, respectively. 
3.7.2.3. Processing standards and samples 
Samples of brain tissue were homogenized in 6.8 parts (w/v) of CH3CN/CH30H 3: 1. 
Standard, QC and unknown samples were added with 50.6 ng of ION 5738 as IS, 
shaken for 30 minutes, centrifuged at 4000 rpm for 10 minutes and the obtained 
supernatant dried under nitrogen. The residue was then dissolved in 1 mL of MP AlMPB 
1: 1, vortexed and centrifuged at 13000 rpm for 10 minutes at 4°C. A volume of 10 ilL 
of the collected supernatant was injected into the HPLC system for quantitative 
analysis. 
3.7.2.4. Chromatographic and mass spectrometric conditions 
The chromatographic and MS conditions used, were the same reported for quantitation 
of ION 6140 in plasma samples. 
3.7.2.5. Matrix effect and recovery 
The absence of a matrix effect that could influence the ionization of ION 6140, was 
verified by injecting an extracted control brain sample into the LC-MS/MS system, 
during the post-column infusion of an ION 6140 solution at a concentration of 50 
ng/mL in 0.1 % HCOOH in IhO/CH3CN 1: 1. 
In addition, the mean area of the analyte prepared in solvent was compared with the one 
obtained for the same quantity of ION 6140 added to biological matrix after the entire 
procedure of extraction. 
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Percentage extraction recovery of ION 6140 at the concentration of 0.100 flg/mL in 
triplicate was determined by comparing peak-area ratios of analyte/IS for extracted 
samples with those obtained from external standards prepared in MP AlMPB 1: 1. 
3.7.2.6. Application of the method: pharmacokinetics of I ()N 6140 in 
normal and tumour brain tissue 
To define ION 6140 distribution in normal brain tissue, brains removed from the mice 
employed to assess the plasma pharmacokinetic profile were used, whereas to collect 
brain tumour sample, a new experiment was performed. For this purpose, U-87 MG 
human glioma cell line (5x lOs) was stereotactically injected into the brain of 
anesthetized CD 1 nude mice. A dose of 7 mg/kg of ION 6140 was administered to two 
mice as i.v. bolus four weeks after the tumour implant. Two hours after the treatment, 
the brain was removed, separated from the tumour and both of them immediately frozen 
in dry ice and stored at -20°C to be assayed for compound content. 
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3.7.3. Distribution study in liver tissue 
Even for this tissue, a validation study was not performed, but the matrix effect the 
recovery and the intra-day precision and accuracy of the method were evaluated. The 
development of the extraction method from liver samples was particularly difficult 
because of a very important matrix effect. Control liver tissue was homogenized in 
water in proportion 1: 1 (w/v). Then a volume of different organic solvents was added in 
proportion 1:4 with the volume of the homogenized tissue in order to obtain the 
extraction procedure from the tissue. CH3CN, CH30H, EtOH, CH30CH3, isopropanoL a 
solution of CH30HlEtOH in proportion 1: 1 and CH30HlCH3CNiisopropanol 1: 1 : 1 were 
tested. Each of the obtained solvent mixtures was then vortexed for lOs and centrifuged 
at 4°C for 10 min at 4000 rpm. The supernatant was recovered and 20 I-1L were injected 
into the LC-MS/MS system during the post-column infusion of an IDN 6140 solution at 
the concentration of 50 ng/mL in 0.1 % HCOOH in H20/CH3CN 1: 1. No one of the 
tested extraction solvents or mixture was appropriate to be used. As an example, figure 
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Figure 19. Chromatographic trace obtained infusing IDN 6140 at the concentration of 50 ng/mL 
during the chromatographic run of a sample of liver ti ue e traded with HJC 
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As it is possible to observe, close to IDN 6140 retention time (6.7 min, the trace \\ 
not steady. Many different strategies were tried to avoid the matrix effect of Ii er tis ue : 
changing of chromatographic conditions, changing of ion source (APel) and sample 
dilution. Taking the tested method modifications separately, the matrix effect was till 
very important and preventing any sort of quantitation. Finally, it was set up a method 
diluting the sample, changing the chromatographic conditions and the extraction solvent 
mixture obtaining almost the total reduction of the matrix effect during the post-column 
infusion (figure 20). The method is described in the following paragraphs. 
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Figure 20. Chromatographic trace obtained infusing IDN 6140 at the concentration of 50 nglmL 
during the chromatographic run of a sample of liver tissue extracted with 
CHJOH/O. l% HCOOH in CH3CN 1:1 [instrument used: API 4000 mass spectrometer] 
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3.7.3.1. Standard and QC solutions 
The IDN 6140 stock and working solutions for the preparation of standard and QC 
samples were the same used to assay the analyte from brain tissue. 
3.7.3.2. Preparation of liver standard and QC samples 
Liver tissue was homogenized in 5 parts (w/v) of CH30HlO.l % HCOOH in CH3CN I: I. 
Homogenate was then divided in aliquots of 900 ~L and each aliquot was spiked with 
1 00 ~L of appropriate ION 6140 working solutions to produce seven calibration 
standards (0.010, 0.025, 0.050, 0.100, 0.500, 1.000, 2.000 ~g/mL). Then the aliquots 
were shaken at room temperature for 30 min. 
To prepare QC samples, control liver tissue - homogenized in 5 parts (w/v) of 
CH30H/O.1 % HCOOH in CH3CN 1: 1 - was divided in aliquots of 900 ~L and each 
aliquot was added with 1 00 ~L of QC solutions (sL, sM and sH), obtaining final liver 
concentration of 0.015 ~g/mL, 0.075 ~g/mL and 1.500 ~g/mL, respectively. 
3.7.3.3. Processing standards and samples 
Liver tissue samples were weighed, homogenized in 5 parts (w/v) of CH30H/O.l 0/0 
HCOOH in CH3CN 1: 1 and shaken for 30 min at room temperature. One mL was then 
collected from each sample and used for the quantitation of ION 6140. 
Standard, QC and unknown samples were added with 506 ng of ION 5738 as IS. 
vortexed, centrifuged at 4000 rpm for 10 minutes at 4°C and the obtained supernatant 
was transferred and centrifuged again in the same conditions. The second supernatant 
was dried under nitrogen. The residue was then dissolved in a volume of 0.1 % HCOOH 
in IhO (MPA)/O.I % HCOOH in CH3CN (MPB) 9: L to obtain about a 16-fold dilution 
(w/v) of the tissue sample analysed. After prolonged shaking - necessary to assure the 
complete solubili/ation of the residue - samples and standards were centrifuged at 4000 
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rpm for 10 minutes at 4°C, and 200 JlL of the supernatant were transferred into vials for 
HPLC analysis. 
A volume of 10 JlL of the supernatant was injected into the HPLC system for 
quantitative analysis. 
3.7.3.4. Chromatographic conditions 
The HPLC system consisted of a Series 200 autosampler and mlcropump (Perkin 
Elmer). The samples were separated using a SunFire C18 (3.5 Jlm 150 x 2.1 mm) 
column coupled with a C 18 precolumn (4 x 3 mm) and with the following gradient: 
Time (minutes) 0.1 % HCOOH 0.1 % HCOOH Flow rate in H20 (%) in CH3CN (%) {J.1L/min) 
0 90 10 300 
12 90 10 300 
26 15 85 200 
32 15 85 200 
34 90 10 300 
41 90 10 300 
Peaks were detected by SRM mode. At the end of the daily analyses, the HPLC column 
was washed with CH30HlH20 (1:1) for 30 min at the flow rate of 0.2 mL/min. 
The temperature of the autosampler and the column was 4°C and 30°C, respectively. 
3.7.3.5. Mass spectrometric conditions 
The MS conditions were the same reported for quantitation of ION 6140 from plasma 
samples. 
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3.7.3.6. Matrix effect and recovery 
Besides the post-column infusion described above, the absence of the matrix effect was 
ensured by comparing the mean area of the analyte peaks obtained from external 
standards prepared in MPAlMPB 9:1 with those obtained adding the same quantity of 
the analyte to biological matrix after the entire procedure of extraction. 
There were no significant variations « 150/0) for the areas of IDN 6140 indicating the 
absence of any matrix effect of ion suppression or enhancement. 
Percentage extraction recovery of IDN 6140 at the concentration of 0.025 and 0.100 
flg/mL in triplicate was determined by comparing peak-area ratios of analyte and IS 
from extracted samples with those from external standards prepared in MPAlMPB 9: 1. 
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3.7.4. In vitro metabolism of IDN 6140 using S9 fraction 
IDN 6140 solution was prepared in acetonitrile at the concentration of 500 Jlg/mL 
(100X the plasma Cmax obtained after i.v. treatment) to study the in vitro metabolism 
with liver S9 fraction. 
Two mg of 7-ethoxycoumarin were dissolved in 1 mL of methanol and diluted to 2 mL 
with 100 mM Tris buffer pH 7.4. 1 mL of such solution was further diluted to 10 mL 
with the same buffer. 
Liver S9 requires exogenous cofactors for activity. The co factors used consist of an 
NADPH-regenerating system (phase I oxidation), uridine 5' -diphospho-a-O-glucuronic 
acid (UDPGA; phase II glucuronidation), and 3' -phosphoadenosine-5' -phosphosulphate 
(PAPS; phase II sulfation). Incubations were conducted in 100 mM Tris buffer pH 7.4. 
The NAOPH Regenerating System (NRS) was prepared following the procedure 
reported below: 
1.7 mg/mL NAOP (170 mg for 100 mL), 7.8 mg/mL glucose-6-phosphate (780 mg for 
100 mL) and 6 units/mL glucose-6-phosphate dehydrogenase (600 units for 100 mL) 
were added to a 2% NaHC03 solution. 
In order to study phase II conjugation, immediately before the incubation, 1.9 mg/mL 
UOPGA (190 mg for 100 mL) and 100 Jlg/mL PAPS (10 mg for 100 mL) were added to 
a portion ofNRS. 
Samples were prepared by adding 320 JlL of 100 mM Tris buffer pH 7.4, 125 JlL of 
NRS (with or without UOPGA and PAPS), 5 JlL of ION 6140 or 7-ethoxycoumarin 
standard solution. In the samples incubated either without S9 fraction or ION 6140, an 
equal volume of 100 mM Tris huffer pH 7.4 buffer was added. 
The reaction was started by adding 50 JlL of the liver S9 fraction to the samples. IDN 
6140 and 7-ethoxycoumarin samples were incubated at 37°C up to 120 minutes. 
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The sample scheme comprised a blank sample (without adding ION 6140), To and Tlh 
(stopped immediately or 2 hours after the adding of S9 fraction, respectively) samples 
in triplicate and a T2h sample obtained by the addition of boiled S9 fraction to evaluate 
ION 6140 stability. 
The same scheme was used for incubation of 7-ethoxycoumarin to evaluate the 
metabolic activity of the microsomes: 7-hydroxycoumarin was identified on the basis of 
the retention time in comparison with the standard and used as a marker of oxidative 
metabolism. 
The reaction was stopped at selected times by adding 1 mL of methanol. Samples were 
shaken, centrifuged at 13000 rpm for 10 minutes (4 DC) and the supernatants used for 
LC-MS/MS analysis. 
3.7.4.1. Samples analysis 
7-ethoxycoumarin and 7-hydroxycoumarin were analysed according to the HPLC 
method described in Appendix 1. Qualitative analyses of ION 6140 for the 
identification of metabolites were done with a HPLC-MS system consisting of a 
Surveyor autosampler and Surveyor MS pump (Thermo Finnigan) combined with a 
LCQ Oeca XP Plus ion trap mass spectrometer (Thermo Electron, Waltham, MA, 
USA). Separation was performed using a Zorbax SB-C18 column, 150 x 0.5 mm 10 
(Agilent, Santa Clara, CA, USA) at a flow rate of 10 J,1L/min. The elution solvents 
were: water with 0.1 % of formic acid (solvent A) and acetonitrile (solvent B); the 
elution gradient was from 50 to 100% of solvent B in 20 min, with a 6 min hold of 
1000/0 B and a final re-equilibrating step to 50% of B for 12 min. 
The LCQ ion trap was used in negative ion mode, with the same conditions used for the 
analyses of ION 5738 and ION 5839. 
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3.7.4.2. Results evaluation 
The chromatograms obtained were compared among the groups to detect the generated 
metabolites. 
3.7.5. IDN 6140 quantitation in faeces and urine 
IDN 6140 was assayed by LC-MS/MS in faeces and urine collected before dosing and 
24 and 48 hours after the administration of 5.4 mg/kg of the compound. 
The extraction method from urine samples was the same developed for ION 6140 
quantitation in plasma. The matrix effect was defined by the post-column infusion of an 
IDN 6140 solution at the concentration of 50 ng/mL in MP AlMPB 1: 1 whi Ie a blank 
extracted sample was injected on the chromatographic column. 
As regards faeces, firstly, recovery and matrix effect were evaluated. To assess them, I 
used control faeces from mice treated with only the vehicle used to dissolve ION 6140 
for animal treatment. A volume of 4% BSA solution in proportion 1:3 w/v and 
successively, a volume of bidistilled water in proportion 1:3 v/v were added to control 
faeces. Then, control faeces were homogenized and vortexed and finally, aliquots of 1 
mL were collected. The extracted sample was obtained adding 3 mL of 0.1 % HCOOH 
in CH3CN to the 1 mL aliquot. Then the mixture was vortexed and centrifuged for 10 
min at 4000 rpm and at 4°C. The obtained supernatant was dried under nitrogen and the 
residue was dissolved in 200 ~L of MP AlMPB 1: 1. The reconstituted sample was then 
vortexed. centrifuged at 13000 rpm for 10 min at 4°C and transferred to vials for the 
injection into the IIPLC system. The matrix effect was assessed by lIsing the post-
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column infusion method. A suppression contribution of the matrix on IDN 6140 signal 
was evaluated, but it was steady and not so important to prevent the quantitation. 
The recovery was evaluated at the concentration of 0.100 J.lglmL in triplicate and 
because of the matrix effect, the percentage extraction recovery was defined by 
comparing peak-area ratios of analyte/IS from extracted samples with those prepared 
adding the same quantity of the analyte to a faeces sample after the entire procedure of 
extraction. 
To prepare standards and quality control samples, control faeces were homogenized 
with a 4% BSA solution and water as previously described. Aliquots of 900 J.lL of the 
mixture obtained were spiked with 100 J.lL of standard solutions or quality control 
solutions and shaken. 
Faeces samples were weighed, added with a BSA solution in the proportion 1:3 (w/v) 
and homogenized by the means of an ultra turrax. 4 mL were then collected from the 
mixture and added with 12 mL of bidistilled water. After vigorously shaking of the 
samples, 1 mL was collected and used to dose IDN 6140. 506 ng of IS and 3 mL of 
0.1 % HCOOH in CH3CN were then added to samples, standards and quality controls. 
The supernatant extraction mixture was vortexed, centrifuged and dried under nitrogen. 
The residue was rinsed with 200 J.lL of MP AlMPB 1: 1, vortexed and centrifuged again 
for 10 min at 4000 rpm and 4°C. 
Ten J.lL were injected into the HPLC system. The chromatographic and mass 
spectrometric conditions were the same set up for plasma samples. 
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CHAPTER 4 
RESULTS 
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4.1. ION 5390 
When I started my research project with ION 5390, it had been previously reported that 
it has at least two mechanisms of action, one related to antimitotic effect causing direct 
cytotoxicity and the other one related to its antiangiogenic properties. This second one 
is probably particularly important when the compound is given continuously for a 
prolonged time. Experimental evidence suggested that ION 5390 given daily by oral 
route for a prolonged time had good antitumor activity with very limited toxicity. A 
pharmacokinetic study conducted in mice in our lab, showed that this compound is 
rapidly (T max = 0.25 h) absorbed after oral administration of a dose of 60 mg/kg and has 
a good oral bioavailability, of 43%. This finding could be explained by the fact that ION 
5390, unlike paclitaxel and docetaxel, is a poor substrate for the P-gp or other 
transporters that pump the drug out of the cells and that are particularly abundant in the 
gastrointestinal mucosa. The plasma AUe after three oral doses of 60, 90 and 120 
mg/kg indicated a dose-dependent increase of this pharmacokinetic parameter, being 
9.9, 19.8 and 35.1 ~g/mL *h respectively, but not in bioavailability - assessed by 
dividing the AUe after oral route by the Aue after i.v. route - which decreased from 
43% to 27% at the highest dose tested. The reason for this decrease appeared to be 
related to a dose-dependent kinetics after intravenous administration, the clearance 
being 2.6, 1.4 and 0.9 L/kg and the half-life 24, 36 and 54 min respectively. after the 
dose of 60, 90 and 120 mg/kg, respectively. This caused a much greater increase in 
AUe values after i.v. administration comparing to the oral one. At this point, it was 
very important to try to understand if the dose-dependent kinetics of ION 5390 was 
caused by the saturation of its elimination. 
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4.1.1. Faecal and urinary excretion 
4.1.1.1. Elimination of unchanged IDN 5390 
Firstly, I investigated the faecal and urinary excretion of IDN 5390 in CDFI female 
mice treated i. v. and orally with 60, 90 and 120 mg/kg. Excretion of the parent drug per 
se was low (Table 7). 
Dose/via Actual 0-24 h 24-48 h Total dose dose (% of dose) (% of dose) recovered (0/0) 
(mg/kg) (mg) feces unne feces unne feces unne 
60 p.o. 4.9 3.0 0.27 0.14 0.05 3.1 0.32 
60 i.v. 5.4 2.8 0.30 0.06 0.15 2.9 0.45 
90 p.o. 7.0 3.6 0.29 0.12 0.19 3.8 0.48 
90 i.v. 7.2 3.2 1.24 / 0.15 3.2 1.40 
120 p.o. 9.7 4.2 0.17 0.51 0.06 4.7 0.20 
120 i.v. 9.7 2.9 0.83 0.14 0.14 3.1 1.00 
Table 7. Faecal and urinary excretion of IDN 5390 in female CDn mice after different p.o. and i.v. 
doses 
The percentage of IDN 5390 eliminated in faeces after intravenous treatment did not 
appear to depend on the doses, being in the range of 2.9-3.20/0 of the dose. After oral 
treatment the range of excretion was slightly superior ranging between 3.1 and 4.70/0. 
The elimination of the compound in urine was much lower than in faeces, but was 
higher after i.v. (0.5-1.4%) than after oral doses (0.2-0.50/0). 
Since IDN 5390 was excreted to a similar extent at all three doses, it was possible to 
exclude saturation in the elimination process of the compound. 
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4.1.1.2. Elimination of metabolites 
In order to detect even those metabolites formed in a small amount, only samples of 
mice treated with the highest dose were analysed. Therefore, I performed HPLC-
MSIMS analysis in faeces and urine of mice treated with the dose of 120 mglkg. Figure 
21 shows the typical fragmentation pattern of IDN 5390 obtained by LC-MSIMS 
analysis. 
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Figure 21. Positive-ion ElectroSpray Ionization-MSIMS spectrum of IDN 5390 (panel A) and 
scheme of fragmentation pattern (panel B). Amu, atomic mass unit(s) [instrument 
used: API 4000 mass spectrometer] 
Faeces and urine of mice revealed that IDN 5390 was extensively metabolized and after 
both p.o. and i.v. single doses, several taxane-related structures were found. On the basis 
of the mlz ratio, I hypothesized the formation of metabolites mainly derived from 
reactions of oxidation, mono- and di-hydroxylation of IDN 5390 and conjugation with 
sulphate (figure 22). 
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~ [M+H'] Major fragrrent ions (m) 
788 rrl., 688,509,327 
804 748,704,327,178 
820 764,720,343,178 
868 812,768,389,162 
884 828,784,407,178 
H ~ 786 730, 686, 525, 403 
~ ~ 802 746,702,541,341 
~ ~ 818 762,718,341, 178 
H ~H 866 810,766,644,483 
H ~H 882 826, 782, 660, 483 
~ ~H 898 842,798,676,499 
Figure 22. LC-MS/MS fragmentations of ION 5390 and metabolites derived directly from the 
parent drug (series A) and from the retrograde cyclization product, 7,8 cyclized ION 
5390 (series B) 
On the basis of the fragmentation pattern obtained by the ion trap mass spectrometer, it 
was not possible to ascertain the exact identity of the products of metabolic 
modifications of taxane structure. In analogy with information on the murine 
metabolism of paclitaxel 36, 186. I considered position 6 as a possible target of 
hydroxylation reaction. 
According to figure 22. the hydroxyl function most likely to be conjugated with 
sulphate is in position 9 for the parent drug (A series) in view of its enolic nature and in 
7 for 7.8-cyc1ized ION 5390 derivatives (B series). Table 8 tentatively reports the 
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percentages of faecal and urinary excretion of the main hypothesized metabolites, 
assuming that the metabolites and the parent compound had similar responses in the 
mass spectrometer. 
Retention oral intravenous Compound MW time (min) 
urine(%) faeces (%) urine (%) faeces (%) 
IDN 5390 787 23.7 0.17 4.2 0.83 2.9 
Ml 803 19.9 0.13 9.1 0.94 5.8 
M2 803 22.2 0.16 / 0.44 / 
M3 819 19.1 0.11 / 0.30 0.5 
M4 867 21.5 / 15.0 / 10.8 
M5 883 16.5 / 7.9 / 4.4 
Cl 785 27.3 0.24 / 0.46 / 
C2 801 23.6 0.04 1.7 0.09 1.6 
C3 801 21.9 0.04 / 0.13 / 
C4 817 19.6 0.04 4.8 0.13 6.2 
C5 865 27.4 / 0.9 / 0.4 
C6 881 21.0 / 1.1 / 0.6 
C7 897 17.1 / 0.8 / / 
0.9 45.5 3.3 33.2 
Total excretion (%) 
46.4 36.5 
Table 8. Faecal and urinary excretion (percentage of the dose) of the main ION 5390 metabolites in 
CDFI female mice after intravenous or oral treatment with 120 mglkg of the compound 
After oral treatment, the most abundant metabolites in faeces, as a percentage of the 
dose, were M4 (15.0%), Ml (9.1%) and M5 (7.9'110). M4 and Ml are products of 
sulphate conjugation and hydroxylation of IDN 5390, respectively, while M5 is the 
sulphate of MI. Modification of ION 5390 structure involving fonnation of the typical 
taxane scaffold and di-hydroxylation gave C4, amounting to 4.8% of the dose. These 
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metabolites (M 1, M4, M5 and C4) were also the most abundant after intravenous 
treatment. As reported in table 8, several other metabolites were quantified in faeces 
after both treatments. The total amount of the dose recovered, as ION 5390 per se and 
metabolites, amounted to respectively 45.5 and 33.20/0 after oral and intravenous 
treatment. 
In urine, 3.30/0 of IDN 5390 and metabolites was recovered after intravenous treatment 
and 0.9% after oral administration. M2 and C3, two isomers of Ml and C2 with 
different retention times, were found in urine. M2 is probably an epimer of Ml and CJ 
could be an epimer or a structural isomer of C2. From the fragmentation pattern of these 
monohydroxylated derivatives (figure 22), it was not possible to establish which 
stereo genic centre was involved in the epimerization and which part of the ring system 
in the isomerism. As it is possible to notice in figure 23 (panel A), besides the 
stereogenic centres already present in IDN 5390 structure, with the cyclization of C 
ring, two new centres were formed in positions 7 and 8, generating theoretically 4 
different isomers as shown in panel B. 
A 
ox 
red 
1l 
Results 
B 
up - up down - down 
up - down down - up 
Figure 23. Mechanism of C ring cyclization (panel A) and 4 possible isomers consequent to the 
formation of the stereogenic centres in positions 7 and 8 (panel 8) 
The percentage of metabolites excreted was higher after oral (420/0) than i.v. treatment 
(33%), suggesting a relevant contribution of the intestinal metabolism and/or liver first-
pass effect. According to this observation, it is important to notice that all the sulphate 
conjugates (M4, M5, C5, C6, C7) were more abundant in faeces of mice treated orally 
(in the range of 1.4-2.3 fold higher) than intravenously and that these metabolites were 
not present in urine. 
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4.1.2. Identification of metabolites in plasma samples 
On the basis of the knowledge about the metabolites found in faeces and urine samples, 
it was decided to better define the metabolic pathway of ION 5390 searching for the 
same compounds in plasma. For analytical reasons, the study of metabolites was 
conducted in faeces and urine of mice treated with a dose of 120 mg/kg but, with 
plasma samples, the dose investigated was the one used in the optimal schedule for 
. .. 90 g/k 161 162 antItumour acttvIty: m g , . 
LC-MS/MS analysis showed that among the metabolites found in faeces and urine, the 
most abundant in plasma were C 1, M 1, C3 and M3. 
As shown in figure 24, reporting the plasma profile of formation and elimination of 
these metabolites in comparison with the one of the parent drug, they were found at 
levels 4-5 fold lower than ION 5390. 
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Figure 24. Plasma pharmacokinetic profile in CDFI mice of the main metabolites of ION 5390 and 
the parent drug after intravenous (panel A) and oral administration (panel B). (Plasma 
levels in logarithmic scale) 
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4.1.3. In vitro metabolic study 
In order to complete the information relative to the metabolism, it was decided to 
investigate an in vitro system using murine and human liver microsomes with the aim of 
determining the cytochrome P450-associated metabolic properties, establishing the 
extent to which in vitro IDN 5390 metabolism fitted the in vivo data in mice and 
comparing the results obtained in vitro using microsomes of the two species. 
First of all, the recovery and the stability percentage of ION 5390 were determined in 
the two microsomal systems using average values of the chromatographic peak area 
obtained by three different samples. The recovery of ION 5390 from murine and human 
micro somes was 111.2 and 106.4%, respectively. The stability of ION 5390 in the 
reaction conditions after 4 hours incubation was 83.1 and 85.80/0 with mouse and human 
microsomes, respectively. 
As reported in table 9, after 4 hours incubation, the formation of 13 and 5 metabolites 
was observed with mouse and human liver microsomes, respectively. Based on the 
retention time and the fragmentation pattern, the table reports the name of the detected 
metabolites only if they were already characterized in urine, faeces or plasma samples. 
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Compound MW Retention (relative percentage, %) time (min) 
munne human 
IDN 5390 787 23.7 44.0 0.8 
M1 803 19.9 20.1 56.6 
M3 819 19.1 l.8 10.1 
785 23.5 0.4 / 
785 25.2 l.1 / 
785 26.3 0.4 / 
Cl 785 27.3 0.2 0.3 
785 28.7 0.6 / 
785 29.6 0.9 / 
801 20.0 3.5 / 
C3 801 2l.9 4.6 / 
801 22.2 l.2 / 
C2 801 23.6 7.1 5.2 
C4 817 19.6 3.4 5.4 
Table 9. Relative percentage of ION 5390 and its metabolites formed in murine and human 
microsome systems 
Results 
IDN 5390 was extensively metabolized with human microsomes - the percentage of 
unchanged parent compound was only 0.8% in the end of the reaction - whereas less 
than 600/0 was modified with murine microsomal system. The most abundant metabolite 
in both the systems was the monohydroxylated derivative of ION 5390 (M 1). 
The data suggested that the reaction of retrograde C cyclization (figure 23, panel A) is 
more favoured in the murine system not only for the presence of six peaks with 
molecular weight of 785 in murine samples vs just one, C 1, in human microsomes - but 
also considering the second metabolite in terms of relative percentage of formation: in 
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the murine system, it was a derivative of series B (C2, figure 22) whereas with human 
microsomes, a derivative of series A (M3). 
As already mentioned and shown in figure 23, the other 5 metabolites with a molecular 
weight of 785 were probably isomers of C 1. The same explanation can be given to the 
presence of 4 mono-hydroxylated derivatives of C 1. Going on the analysis of the 
murine samples, I also found one di-hydroxylated metabolite of IDN 5390 and one of 
Cl amounting to 1.8 and 3.4%, respectively. 
No differences were detectable in the concentrations of IDN 5390 and metabolites from 
the samples incubated with and without VDPGA, indicating that UGTs do not play any 
role in the metabolism of IDN 5390. 
In our lab a decrease of IDN 5390 bioavailability was demonstrated after 1 or 2 weeks 
of single or double oral daily doses of 90 mg/kg of the compound; i.e. the AUC value 
after p.o. daily administration on day 14 was 2-fold lower than that on day 1. This 
phenomenon was not due to the vehicle, polysorbate 80, that was reported to potentially 
affect the absorption of several drugs, reducing their bioavailability. Mice received 
polysorbate 80 daily for 1 week, followed by a single dose of IDN 5390 at 90 mg/kg. 
The AVC in these mice was superimposable with that obtained after a single dose 
without polysorbate 80 pretreatment 187. 
In the light of the knowledge about IDN 5390 metabolism, to explain the decrease of 
IDN 5390 disposition, it was hypothesized a metabolic auto induction mechanism as 
already suggested for paclitaxel 188. An experiment was perfonned to detennine whether 
liver metabolic induction was responsible for the decrease in IDN 5390 AUC. The 
pharmacokinetics was studied following an i.v. dose of 90 mg/kg IDN 5390 given after 
a week of daily oral treatment with 90 mg/kg. IDN 5390 was quantified in these plasma 
samples and the pharmacokinetic parameters were elaborated: there was no reduction of 
plasma levels, and the AlIC after chronic treatment was 37.9 J..lg/mL *h, close to the 41.0 
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llg/mL *h found after a single dose. These data suggest a metabolic auto induction 
mechanism at the level of the intestinal metabolism of IDN 5390 following prolonged 
oral treatment. 
Among the different metabolites tentatively characterized, C 1 appeared to be the most 
interesting one because, thanks to the formation of the bond between the positions 7 and 
8, it showed the same tetracyclic core of paclitaxel. Although ION 5390 is an active 
compound, the opening of the convex taxane core has per se a detrimental effect on the 
.. f l' 1 159 189 190 M . Id h b 1 k' actIvIty 0 pac Itaxe ' , . oreover, It wou ave een re evant to now Its exact 
structure considering that it is the parent compound of series B metabolites (figure 22) 
and it is a circulating derivative. Indena S.p.A. synthesized and provided us two 
different products of the cyclization reaction of ION 5390. They were analysed by the 
mass spectrometer and one of them, named ION 5910 and having the structure shown in 
figure 25, corresponded to C 1. 
o 0 
o 
Figure 25. Chemical structure orCl (ION 5910) 
In summary, ION 5390 is able to affect endothelial cell motility 160, it has a favourable 
bioavailability, it is well tolerated without causing any apparent toxicity (i.e. no body 
weight loss at therapeutically active dose), even upon repeated oral treatment. and 
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shows significant antineoplastic activity on a panel of different tumour models. 
. I d' I' I . 161 162 Inc u lng some pac ltaxe -resIstant tumours ' . 
Despite the favourable properties described above, ION 5390 has a very high metabolic 
clearance with a short half-life: twelve metabolites were identified in faeces and urine. 
four of them were found in plasma at detectable levels and seven present the restored 
taxane scaffold. With human microsomes, the percentage of metabolized ION 5390 at 
the end of the incubation time was 99%. For all these reasons, ION 5390 is difficult to 
manage and its metabolic-pharmacokinetic profile has to be carefully evaluated - in 
terms of activity and toxicity of every metabolite - in case of further clinical 
development, particularly with a prolonged schedule of daily dose. 
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4.2. IDN 5614 
The results obtained, prompted Indena S.p.A. to synthesize an ION 5390 derivative 
(ION 5614, figure 26) having the two positions involved in the cyclization reaction 
protected by a methyl group in order to preserve the antiangiogenic properties of IDN 
5390 - emphasized by its low toxicity - and to diminish the metabolic clearance. 
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Figure 26. Chemical structure of IDN 5614 
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To verify the success of the introduced modifications that had led to ION 5614, it was 
decided to define first its metabolic profile in vitro, using mouse liver microsomes, 
before further characterizing the in vivo phannacokinetic profile of this new taxane 
derivative. IDN 5614 is structurally related to ION 5390. Therefore, in order to compare 
their metabolic pattern, the incubation of ION 5390 with mouse liver microsomes was 
repeated reproducing exactly the same experimental conditions for both taxanes, In 
particular as regards the chromatography. 
Figure 27 shows the Total Ion Chromatogram (TIC) acquired in MS scan of an ION 
5614 sample with incubation time equal to 0, To, (panel A) and after 4 hours 
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microsomal reaction, T4h (panel B). Obviously, by displaying data as a TIC, the mass 
spectrometer is used as a general detector; there is no selectivity in the data, but it is 
useful in understanding the overall chromatography and hunting for new peaks. 
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Figure 27. TIC of the incubation sample of IDN 5614 at To (panel A) and after 4 hours of 
microsomal reaction, T 4h (panel B) [instrument used: LCQ Oeca XP Plus ion trap mass 
spectrometer] 
Basing on TIC data, in T 4h sample IDN 5614 presents, at about 32 minutes, a peak 
height almost halved in comparison with To sample and the formation of several 
metabolites. Table 10 reports the quantitative evaluation of the obtained results: more 
than 500/0 of IDN 5614 was metabolized within 4 hours (table 10). 
ION 5614 parameter 
metabolization without 
addition of UDPGA 
stability in the incubation 
medium 
recovery from microsomes 
Amount 
(%) 
51.2 
87.5 
87.9 
Table 10. Quantitative evaluation of the results obtained incubating IDN 5614 with mouse 
microsomes for 240 minutes 
Results 
The percentages reported in table 10 were obtained using the average values of ION 
5614 chromatographic peak area, obtained in three different samples. In this 
experiment, the stability of IDN 5614 in the reaction conditions after 4 hours incubation 
and its recovery with the extraction followed procedure, were both found to be around 
90%. 
To make a quantitative estimation of the reaction products, it was assumed that the 
metabolites and IDN 5614 had similar response in the mass spectrometer. On the basis 
of the HPLC-MSIMS analysis, IDN 5390 was found among the metabolites of ION 
5614. 
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Figure 28. ION 5614 disappearance and ION 5390 formation kinetics after microsomal incubation 
of ION 5614 
As shown in figure 28, after 1 h incubation, the percentage of IDN 5614 decreased from 
100% to 70% and IDN 5390 was 6.8% of the total amount of the parent compound. 
Afterwards, even the percentage of ION 5390 decreased to 2.40/0 at 4 h, probably as a 
consequence of its metabolism. 
Having found ION 5390, as a product of di-demethylation of ION 5614 in position 7 
and 9, it was searched for a metabolite with mlz ratio of 802, that is the product of 
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mono-demethylation. Three peaks, characterized by m/z ratio of 802 were identified, 
but on the basis of their MS2 obtained with the ion trap mass spectrometer, it was not 
possible to understand if they were metabolites of IDN 5614 (mono-demethylated 
derivatives) or of IDN 5390 (monohydroxy-7,8-cyclized IDN 5390 derivatives). 
However, it is worth noting that the chromatographic trace related to metabolites with 
mlz ratio of 802 generated by microsomal reaction of IDN 5614 (figure 29, panel A) is 
different from the one of IDN 5390 (figure 29, panel B). Therefore, they may be mono-
demethylated derivatives ofIDN 5614. 
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Figure 29. Chromatographic traces of metabolites with mlz ratio of 802 obtained after microsomal 
reaction of IDN 5614 (panel A) and of IDN 5390 (panel B) [instrument used: L Q 
Deca XP Plus ion trap mass spectrometer] 
Among the metabolites found in the incubation sample of ION 5614, two with m/z rati 
of 786 and 800 were probably characterized by the fonnation of the typical -ring of 
14 
Results 
taxanes. In fact, to obtain the closing of C-ring it is sufficient to have demethylation in 
position 9 (figure 23, panel A). 
All the metabolites described after microsomal reaction with IDN 5390 were found also 
after IDN 5614 incubation, rendering very difficult to understand if they were direct 
products ofIDN 5614 or originated by IDN 5390. For this reason, it was decided not to 
further characterize IDN 5614 metabolic profile. No differences were observed in the 
chromatograms obtained from the samples incubated with and without UDPGA, 
indicating that the UGTs have not a significant role in the metabolism of IDN 5614 and 
its metabolites. 
To conclude, my results showed that the methylations, in positions 7 and 9, introduced 
in IDN 5390 structure were not useful to minimize its high metabolic clearance. 
Therefore, the pharmacokinetic properties of IDN 5614 were not further investigated. In 
fact, with drugs extensively metabolized, there are two main problems besides the 
limited plasma disposition and the diminished pharmacological activity: 
1- it is necessary to characterize the structure and the biological activity of each 
metabolite; 
2- the individual genetic variation (polymorphism) leads to a wide variability of 
metabolism across individuals. 
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ION 5738, ION 5839 and ION 6140 
The other three taxane derivatives, provided by Indena S.p.A., were ION 5738, ION 
5839 and ION 6140 (see structures in figure 30 and 43). All of them were obtained by 
modifying the ortataxel structure. The first two compounds were obtained at the same 
moment whereas IDN 6140 was received successively. For this reason, the studies on 
IDN 5738 and IDN 5839 were conducted in parallel and therefore, the work done on 
these two taxane derivatives, is reported comparing each other. 
The metabolism of ortataxel was previously investigated both in vitro and in vivo. In the 
literature, it was reported that the metabolic pathways - characterized in rats and dogs in 
vivo and in rat, dog and human liver microsomes - mainly involve the formation of 
products of phase I biotransformation reactions. In particular, they are a monohydroxy 
derivative, the metabolite lacking the side chain in position 13 and the epimers of them 
and of the parent compound 191,192. 
Accordingly, it was expected ortataxel derivatives would have not presented the 
problem of an extensive metabolism, therefore it was decided to begin the study of these 
new taxanes, defining their pharmacokinetic profile in mice. 
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4.3. IDN 5738 and IDN 5839 
4.3.1. Method development 
ION 5738 and ION 5839 differ from each other in the groups bound to the positions 1 
and 14 (figure 30). 
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Figure 30. Chemical structure of ION 5738 and ION 5839 
4.3.1.1. HPLC-MSIMS 
In figures 31 and 32 (panel C), are reported the typical SRM chromatograms for IDN 
5738 and ION 5839 respectively, showing the quantifier transition of ION 5738 and 
ION 5839 for an extracted mouse plasma standard sample at LOQ, containing the 
compounds at the concentration of 25 ng/mL and IS (ION 5127) at 1 Jlg/mL in 
comparison with a chromatogram of a blank plasma sample (panel A) and a blank 
plasma sample with IS added (panel 8). 
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Figure 31. (A) SRM chromatograms of a mouse blank plasma sample; (8) SRM chromatogram of 
a mouse blank plasma with IS added; (C) Signal-to-noise ratio of ION 5738 at LOQ 
concentration (25 ng/mL); (0) SRM chromatograms of an extracted plasma sample 
of a treated mouse showing IDN 5738 and IS. The measured concentration was 70.7 
"g/mL [instrument used: API 4000 mass spectrometer] 
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Figure 32. (A) SRM chromatograms of a mouse blank plasma sample; (B) SRM chromatograms of 
a mouse blank plasma with IS added; (C) Signal-to-noise ratio of IDN 5839 at LOQ 
concentration (25 ng/mL); (D) SRM chromatograms of an extracted plasma sample 
of a treated mouse showing IDN 5839 and IS. The measured concentration was 57.8 
p.g/mL [instrument used: API 4000 mass spectrometer] 
The elution of the analytes was selective with a good separation of peaks in about 11 
minutes (IDN 5738 at 10.6 min, IDN 5839 at 10.9 and IS at 11.2 min). No interfering 
peaks were present at these retention times and the peaks of all compound wer 
completely resolved from the plasma matrix. 
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The [M+HCOOr of each analyte was selected as the precursor ion and the collision 
energy was optimized to obtain the respective product ions with a high signal. For each 
analyte, three SRM transitions were selected and IDN 5738, IDN 5839 and IS were 
quantified using the transition m/z 915 > 260, mlz 912 > 623 and m/z 932 > 583, 
respectively. 
As final example, panel D of figure 31 and 32 shows the SRM chromatograms of two 
mouse plasma samples taken 5 minutes after the intravenous treatment with ION 5738 
or IDN 5839. They correspond to a concentration of 70.7 ~g/mL of ION 5738 and 57.8 
~g/mL ofIDN 5839. 
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4.3.2. Validation study 
4.3.2.1. Matrix effect and recovery 
According to the method described in section 3.6.6., it was possible to exclude the 
presence of any matrix effect of ion suppression or enhancement. The recovery was 
evaluated in triplicate at 2 or 3 different concentrations of ION 5738 and ION 5839, 
respectively. As shown in table 11, the mean extraction recovery for ION 5738 at 0.l00 
and 1.000 f.lg/mL was >96%, with good reproducibility indicated by the CV < 30/0. The 
recovery of ION 5839 at 0.100, 1.000 and 4.000 f.lg/mL was higher than 900/0, with 
reproducibility expressed as CV < 14%. 
Concentration 
J.1g/mL 
ION 5738 
0.100 
1.000 
ION 5839 
0.100 
1.000 
4.000 
Recovery 
ratio (%) 
96.4 
99.6 
90.1 
98.4 
109.5 
CV%, 
2.5 
0.8 
14.0 
13.8 
4.8 
Table 11. Recovery of ION 5738 and ION 5839 from mouse plasma (N=3) 
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4.3.2.2. Calibration curves 
Table ] 2 reports the accuracy and precision for each analyte detennined at every day of 
the two validation studies. 
Concentration JlglmL 
Spiked 
IDN 5738 
0.025 
0.050 
0.100 
0.500 
1.000 
1.500 
IDN 5839 
0.025 
0.050 
0.100 
0.500 
1.000 
2.000 
5.000 
Found 
(mean ± SO, 
3 days) 
0.021 ± 0.002 
0.050 ± 0.002 
O. 112 ± 0.00 1 
0.540 ± 0.023 
1.006 ± 0.032 
1.450 ± 0.023 
0.020 ± 0.000 
0.052 ± 0.005 
0.111 ± 0.003 
0.532 ± 0.018 
1.025 ± 0.070 
2.045 ± 0.087 
4.904 ± 0.147 
Calibration curve parameters 
R2 
X-coefficient 
Y -intercept 
Precision (%) 
between runs 
7.2 
3.0 
1.3 
3.1 
3.2 
1.6 
0.0 
9.0 
2.5 
3.5 
6.8 
4.3 
3.0 
IDN 5738 
0.997 ± 0.001 
0.811 ± 0.052 
0.007 ± 0.004 
Accuracy (%) 
85.3 
100.7 
112.0 
107.9 
100.6 
96.6 
80.0 
104.7 
111.0 
106.4 
102.5 
102.2 
98.1 
IDN 5839 
0.998 ± 0.001 
0.347 ± 0.035 
0.005 ± 0.000 
Table 12. Accuracy and precision data for calibration curves of ION 5738 and ION 5839 
The peak area ratios of analytelIS versus the nominal concentrations were plotted and a 
least-squares linear regression, weighted by the reciprocal of the concentration, was 
applied to generate the calibration curves. The calibration curves. prepared on three 
different days. showed good linearity (figures 33 and 34) and acceptable data over a 
wide range of concentrations (0.025-1.500 J.1g/mL for IDN 5738 and 0.025-5.000 
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/lg/rnL for ION 5839), With the coeffiCients of detennination, R2, equal to or better than 0.996. 
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Results 
4.3.2.3. Precision, accuracy and LOQ 
The precision and accuracy of the two methods were evaluated analyzing three 
replicates of the QC samples at 0.075, 0.600 and 1.500 J.1g!mL for ION 5738 and 0.075, 
1.500 and 4.000 J.1g!mL for IDN 5839, within a single-run analysis for intra-day study, 
and over three consecutive runs for inter-day study. The accuracy and precision (CV%) 
for the two analytes are shown in table 13. 
IDN 5738 theoretical IDN 5839 theoretical 
concentration (p..tglmL) concentration (p..tg/mL) 
0.075 0.600 1.500 0.075 1.500 4.000 
Intra-day 
DAYl 
Mean (N=3) 0.076 0.553 1.117 0.068 1.528 3.505 
CV% 5.7 2.3 1.0 3.7 4.0 2.5 
Accuracy% 101.3 92.2 93.1 91.1 101.9 87.6 
DAY 2 
Mean (N=3) 0.085 0.582 1.183 0.076 1.586 3.527 
CV% 2.0 1.8 11.2 3.3 4.6 2.9 
Accuracy% 113.3 97.1 98.6 100.9 105.7 88.2 
DAY 3 
Mean (N=3) 0.084 0.552 1.252 0.074 1.429 3.436 
CV% 2.2 8.2 2.8 3.4 1.8 2.0 
Accuracy% 112.0 92.0 104.3 99.1 95.2 85.9 
Inter-day 
Mean (N=9) 0.082 0.562 1.184 0.073 1.514 3.489 
CV% 5.8 5.5 7.4 5.5 5.6 2.4 
Accuracy% 109.2 93.6 99.2 97.0 100.9 87.2 
Table 13. Intra- and inter-day validation of the method for quantitative determination of ION 5738 
and ION 5839 
The methods were precise and accurate, with intra- and inter-day CV :s 120/0 and 
accuracy in the range of92.0-113.3% for IDN 5738 and 85.9-105.7% for ION 5839. 
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The LOQ was defined as the lowest concentration that could be measured with a 
precision within 20% and accuracy between 80 and 1200/0. Consistent with our aims, the 
LOQ was set at 25.0 ng/mL for both the analytes and validated through five replicates. 
At the LOQ, the intra-day CV% and accuracy were respectively 7.90/0 and 96.80/0 for 
ION 5738 and 9.60/0 and 103.2% for ION 5839. It is important to note that, as shown in 
panel C of figures 31 and 32, because of the high signal-to-noise ratio (> 500 for ION 
5738 and> 300 for ION 5839), a lower LOQ could have been set for both the analytes. 
being LOOs of 0.14 and 0.25 ng/mL for ION 5738 and ION 5839, respectively. 
4.3.2.4. Stability in frozen matrix 
The stability of the two taxane derivatives was assessed by analyzing QC samples at 
concentrations of 0.075, 0.600 and 1.500 J.1g/mL for ION 5738 and 0.075, 1.500 and 
4.000 J.1g/mL for ION 5839. The results obtained for the short term stability of the two 
new taxane derivatives in frozen matrix showed that they are stable over about one 
month in mice plasma at -20°C. For ION 5738, the accuracy was in the range 99.1-
109.40/0 and the CV% between 6.1 and 12.2% while for IDN 5839, the accuracy and the 
CV% were in the range 85.1-100.9% and 0.0-12.80/0, respectively. 
In summary, the present methods revealed high selectivity, precision and accuracy and 
they are sensitive enough to allow the determination of the plasma concentrations of the 
two compounds in mice. 
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4.3.3. Pharmacokinetic results 
The two developed assays for the determination of IDN 5738 and IDN 5839 were 
employed to measure plasma concentrations of the two compounds in mice and applied 
to study the preclinical pharmacokinetics of the two taxane derivatives. Figures 35 and 
36 report the concentration-time profiles of IDN 5738 and IDN 5839 in plasma of CDl 
female mice after i.v. and p.o. administration of 60 mg/kg of the two novel taxanes (the 
concentration-time data are listed in appendices 3 and 4). 
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Figure 35. ION 5738 plasma decay curves after an intravenous or p.o. administration of a dose of 60 
mg/kg in COl female mice 
Plasma samples taken at the first time points after the treatment were diluted with an 
appropriate quantity of control mouse plasma determined on the basis of ortataxel 
phannacokinetics 168. In spite of that, plasma samples from 5 minutes to 1 hour after the 
intravenous treatment with IDN 5738 and at 5 minutes after the i.v. admini tration of 
IDN 5839, showed concentrations superior to the highest standard point of the 
calibration curve, therefore they were suitably diluted with control mouse plasma and 
re-analysed aller having as es ed the independence of analysis from the dilution. It was 
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evaluated by adding control mouse plasma to a standard at a ten-fold ULOQ 
concentration in order to have 1: 1 0 and 1: 1 00 ratios. 
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Figure 36. IDN 5839 plasma decay curves after an intravenous or p.o. administration of a dose of 60 
mg/kg in COl female mice 
Table 14 reports the main pharmacokinetic parameters obtained from the concentration-
time data. 
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Compound Treatment (l1~i;;'i) Tmax TUl AUC AUCinf (l1g/mL*b) CI (Lib/kg) Vbd F (b) (b) (l1g/mL*b) (L/kg) (°,10) 
ION 
5738 
ION 
5839 
1.v. 
p.o. 
1.v. 
p.o. 
71.2 
13.7 
55.2 
7.1 
0.08 2.2 
0.75 2.3 
0.08 2.4 
1.00 2.8 
92.5 93.0 0.6 2.1 
49.1 49.4 / / 
40.0 40.9 1.5 5.0 
22.1 23.6 / / 
Table 14. Main pharmacokinetic parameters of ION 5738 and ION 5839 after i.v. and oral 
administration ofa dose of60 mglkg in female COl mice 
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Following the intravenous bolus of IDN 5738, a Cmax of 71.2 Jlg/mL was achieved and 
after a rapid distribution phase the compound was eliminated with a tenninal half-life 
(T 1;'2) of 2.2 hours and a clearance (CI) 0.6 L/hJkg. After the oral treatment, the 
compound was rapidly absorbed achieving at 45 min a Cmax of 13.7 Jlg/mL and 
eliminated with the same half-life observed after the intravenous treatment. A 
comparison between the experimental AVCs obtained after oral and intravenous 
treatment, revealed that this compound has good absorption after oral administration, 
the bioavailability being 53.1 %. Similar results were obtained for IDN 5839, that after 
intravenous bolus achieved a Cmax of 55.2 Jlg/mL and it was eliminated with a TY2 of 2.4 
h and CI of 1.5 L/hJkg. After oral administration, the compound achieved within 1 hour 
a Cmax of 7.1 Jlg/mL, then plasma concentration declined with a half-life of 2.8 h; the 
bioavailability was 56.10/0. The high bioavailability of the two taxanes under 
examination supports the fact that they are not pumped out of the cells by P-gp and this 
evidence is in line with the cytotoxic data obtained on two human breast cancer cell 
lines, sensitive (LCC6 and MCF7) and resistant (LCC6-R and MCF7-R) to paclitaxcl 
144. That is why, on LCC6-R cell line, characterized by the overexpression of P-gp, IDN 
5738 and IDN 5839 were more toxic than paclitaxel and docetaxel with lower resistance 
index of 8 and 6, respectively in comparison with those of the two parent drugs of 111 
and 92. The better cytotoxicity of these new derivatives in comparison with paclitaxel 
and docetaxel is shown even on MCF7-R cell line with IDN 5738 and IDN 5839 having 
a resistance index of 8 and 43, respectively compared to 253 and 460 of paclitaxel and 
docetaxel, respectively. 
ION 5738 and ION 5839 showed plasma concentrations consistent with those indicated 
to be cytotoxic against the aforementioned cell lines both sensitive and resistant ones. 
These concentrations were maintained in plasma of mice up to at least 16 and 10 hours 
after the administrations of ION 5738 and ION 5839, respectively. 
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4.3.4. Circulating metabolites of IDN 5738 and IDN 5839 
The expected lack of extensive metabolism of IDN 5738 and IDN 5839 had to be 
assessed in vivo, thus it was decided to search for metabolites in the same pta rna 
samples analysed for defining the pharmacokinetics of the two new taxanes. 
It was not expected to defme the metabolic pathway of the two compounds under study, 
but only to verify or deny the hypothesis made on the basis of structural evaluations. A 
regards the circulating metabolites, no sulfate or glucuronide derivatives were found in 
plasma of mice treated with IDN 5738 or IDN 5839. 
Among IDN 5738 metabolites, 4 monohydroxylated derivatives (MI-M4) were found. 
As shown in figure 37, the retention time of these metabolites were 18.49, 18.80,19.46 
and 20.60 minutes against 26.69 of the parent compound (the mass spectra 
fragmentation patterns and chromatograms to back up identification of IDN 5738 
metabolites are listed in appendix 5). 
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Figure 37. Chromatographic trace relative to monohydroxylated derivatives of (ON 5738 
[instrument used: LCQ Deca XP Plus ion trap mass spectrometer] 
The first three peaks were referable to derivatives (MI-M3) characterized by the 
hydroxylation on the benzoyl group in position 2 (figure 38). 
Result 
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HO 
Figure 38. Hypothesized structure for mODohydroxylated metabolites of IDN 5738 (MI-M3) 
The structure of monohydroxylated derivatives was hypothesized and designed with the 
hydroxyl group in meta position according to paclitaxel metabolic pattern, but on the 
basis of the ion trap mass spectrometer spectra, it was not possible to draw definitive 
conclusions on the structure of these metabolites. 
As already mentioned, ortataxel incurs the epimerization in position 7, but in this case, 
three peaks with the same mlz ratio and fragmentation pattern were found, suggesting 
they are isomers. It is not possible to define them epimers because epimers are 
diastereoisomers that differ in configuration of only one stereogenic centre therefore, 
generating just two compounds. 
The fourth peak, at retention time of 20.60 min, is believed to be the metabolite (M4) 
with the hydroxyl group on the t-butyl group of the side chain in position 13 (figure 39). 
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Figure 39. Structure of a monohydroxylated metabolite of IDN 5738 (M4) 
No dihydroxylated metabolites either related to 14 substituted baccatin III were present 
in the analysed samples. The metabolites were present in detectable quantities up to the 
plasma sample taken after 8 hours since both the oral and intravenous treatments. 
As regards IDN 5839 metabolites, only two monohydroxylated derivatives (m1 and m2) 
were found at the retention time of 20.40 and 21.66 minutes (figure 40) against 27.73 of 
the parent compound (the mass spectra fragmentation patterns and chromatograms to 
back up identification of IDN 5839 metabolites are listed in appendix 6). 
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Figure 40. Chromatographic trace relative to monohydroxylated derivatives of ION 5839 (m t and 
m2) [in trurnent u ed: LCQ Deca XP Plu ion trap rna 
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The metabolite (mt) eluted at 20.40 min presented the modification on the carbonyl of 
the benzoyl group (figure 4t). 
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Figure 41. Structure ora mODohydroxylated metabolite ofIDN 5839 (ml) 
The derivative (m2) having retention time of 21.66 min is characterized by the presence 
of the hydroxyl group on the t-butyl group of the side chain in position 13 (figure 42). 
"-
HO 
Figure 42. Structure of a mODohydroxylated metabolite of ION 5839 (m2) 
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At the retention time of 18.40 min, it was found a peak corresponding to a metabolite 
(m3) characterized by the mlz ratio of 824, that is lacking of 44 Oa in comparison with 
the parent compound. This metabolite was probably the product of a decarboxylation 
reaction involving the ring comprised between the positions 1 and 14. Finally. at 16.36 
min, there was a peak related to a metabolite (m4) characterized by the loss of side 
chain in position 13, giving the 1,14 substituted baccatin III. 
Even in the case of ION 5839, no dihydroxylated metabolites were present In the 
analysed samples. The metabolites were present in detectable quantities up to the 
plasma sample taken after 4 hours since the oral treatment. 
In summary, my data defined for these compounds an interesting pharmacokinetic 
profile, nevertheless superimposable with that of ortataxel against a halved half life and 
a comparable cytotoxic activity on the sensitive and resistant LCC6 and MCF-7 cell 
lines. 
In the meantime, Indena S.p.A. went on with the synthesis and screening of new taxane 
derivatives structurally optimized on the basis of the findings related to ION 5738 and 
ION 5839. A new ortataxel derivative, ION 6140, showed a very good cytotoxic 
activity, not only in comparison with ortataxel, but even to ION 5738 and ION 5839. 
On the basis of these preliminary results in vitro, it was decided to draw attention to 
ION 6140. 
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4.4. IDN 6140 
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Figure 43. Chemical structure of ION 6140 
4.4.1. Method development 
Results 
In figure 44 (panel C), it is reported the SRM chromatogram for ION 6140, showing the 
quantifier transition for an extracted mouse plasma standard sample at LOQ, containing 
the compound at the concentration of 10 ng/mL and IS at 0.5 J.1g/mL in comparison with 
a chromatogram of a blank plasma sample (panel A) and a blank plasma sample with IS 
added (panel B). 
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Figure 44. (A) SRM chromatograms of a mouse blank plasma sample; (8) SRM chromatogram of 
a mouse blank plasma with IS added; (C) Signal-to-noise ratio (377.7) of IDN 6140 at 
LOQ concentration (10 nglmL); (D) RM chromatograms of an e traded mou e pia. ma 
ample 2 hours after i.v. treatment. The mea ured concentration wa 0.225 J,lg/mL 
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The elution of IDN 6140 and IDN 5738, used as Internal Standard (IS) was selective 
and at 6.7 and 6.4 minutes, respectively. As shown in figure 44 panel A. no interfering 
peaks were present at these retention times and the peaks of the analyte and IS were 
completely resolved from the plasma matrix. The formate adduct [M+HCOOr of ION 
6140 and IS were selected as precursor ions and the collision energy was optimized to 
obtain the respective product ions with a high signal. IDN 6140 and IS were quanti tied 
using the transition mlz 942> 653 and m/z 915> 260, respectively. 
As the final example, panel D of figure 44 shows the SRM chromatograms of a mouse 
plasma sample taken 2 hours after the intravenous treatment with ION 6140. It 
corresponds to a concentration of 0.225 Jlg/mL of the analyte. 
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4.4.2. Validation study 
4.4.2.1. Matrix effect and recovery 
The matrix effect was assessed by infusing post-column a solution of ION 6140 at the 
concentration of 50 ng/mL during the chromatographic run of an extracted plasma 
matrix sample. 
Close to IDN 6140 retention time, there were no variations into the chromatographic 
profile indicating the absence of any enhancement or suppression effect, thus indicating 
absence of matrix effect. 
Recovery experiments were performed in triplicate at 3 representative concentrations 
over the calibration range: 0.025, 0.100 and 2.000 ~g/mL. As shown in table 15, the 
mean extraction recovery for IDN 6140 was higher than 85% with a reproducibility 
expressed as CV < 5%. 
Concentration 
f.1g1mL 
0.025 
0.100 
2.000 
Recovery 
ratio (0/0) 
85.5 
114.0 
112.7 
5.0 
3.5 
4.1 
Table 15. Recovery of IDN 6140 from mouse plasma (N=3) 
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4.4.2.2. Calibration curves 
Extracted standard curves prepared in the concentration range of 0.010-2.000 Jlg/mL 
showed a good linearity, with the coefficient of detennination, R2, always greater than 
0.998 (table 16). 
Calibration curve accuracy (%) 
Days 0.010 0.025 0.050 0.100 0.500 1.000 2.000 Rl slope 
1 110.0 96.0 100.0 96.0 101.0 103.7 98.2 0.9993\ 4.07 
2 100.0 108.0 88.0 101.0 100.8 103.8 98.\ 0.999\\ 3.98 
3 90.0 88.0 114.0 111.0 93.4 100.4 100.7 0.99854 3.34 
Mean 100.0 97.3 100.7 102.7 98.4 102.6 99.0 0.99899 3.80 
SD 10.0 10.1 13.0 7.6 4.3 1.9 1.5 0.0004 0.40 
Cv% 10.0 1 0.3 12.9 7.4 4.4 1.9 1.5 10.5 
Table 16. Precision, accuracy and linearity of the calibration curves 
The table also reports the results of the accuracy of the calibration curve during the 
three days of the validation study. Mean accuracy values were between 97.3 and 
102.7% and the precision, expressed as CV%, was in the range: 1.5-12.90/0. 
4.4.2.3. Precision, accuracy and LOQ 
The LOO was defined as the concentration at which the signal-to-noise ratio was 3. The 
calculated LOO was 0.079 ng/mL. 
Consistent with the prearranged aims, the LOQ of ION 6140 was set at 10.0 ng/mL and 
validated through five replicates. As shown in table 17, the intra-day CV% and accuracy 
were respectively 4.90/0 and 92.0%. 
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Nominal conc. 
ng/mL 
10.0 
Mean observed 
conc. (ng/mL) 
9.2 
N 
5 
CV 
(0/0) 
4.9 
Results 
92.0 
Table 17. Limit of quantitation of ION 6140 in mouse plasma 
The reproducibility of the method was evaluated analyzing three replicates of three QC 
samples containing IDN 6140 at the nominal concentrations of 0.015 (QCL). 0.075 
(QCM) and 1.500 f.1g/mL (QCH) in three different days using, each day. extracted 
standard curves made in the range 0.010-2.000 f.1g/mL. The intra- and inter-day 
precision and accuracy are reported in table 18. 
Mean 
QCs concentration 
observed Day 
(JJglmL) 
L 0.014 
M 0.078 
H 1.455 
L 0.014 
Intra-day 2 M 0.083 
H 1.440 
L 0.016 
3 M 0.068 
H 1.352 
L 0.015 
Inter-day overall M 0.077 
H 1.415 
CVO/o 
% 
Accuracy 
7.1 93.3 
9.1 104.0 
6.8 97.0 
4.1 93.3 
1.2 
3.4 
110.7 
96.0 
6.2 106.7 
4.5 
3.5 
8.1 
9.9 
90.7 
90.1 
98.5 
102.1 
5.4 94.4 
Table 18. Summary of intra- and inter-assay precision and accuracy of the quantitation method of 
ION 6140 
The method was found to be precise and accurate, being CV~ 9.9% and accuracy in the 
range of90.1-11 0.7% for each tested concentration. 
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4.4.2.4. Stability 
4.4.2.4.1. In frozen matrix 
The stability of ION 6140 was assessed by analyzing QC samples of frozen plasma at 
concentrations of 0.015, 0.075 and 1.500 ~g/mL. The results obtained for the short term 
stability of the new taxane derivative, in frozen matrix, showed that it is stable over 
about one month in mice plasma at -20°C, the accuracy being in the range: 89.5-100.0% 
and the CV% between 0.6 and 12.3%. 
4.4.2.4.2. Freeze/thaw stability 
The freeze/thaw stability was defined by processing and analyzing in triplicate a 
standard sample - at the concentration of 0.1 00 ~g/mL - fresh, and after the first, the 
second and the third freeze/thaw cycle. ION 6140 was stable in mouse plasma over 
three freeze/thaw cycles as demonstrated by a CV% and the accuracy of 4.4 and 97.2 
after the first, 3.5 and 100.3 after the second and 0.9% and 98.0% after the third cycle, 
respectively. 
Considering the satisfactory results obtained during the validation, it was possible to 
conclude that the developed method for the quantitation of ION 6140 was suitable to 
measure plasma concentrations of the new taxane. Therefore it was applied to study the 
preclinical pharmacokinetics of the compound in examination in mice. 
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4.4.3. Pharmacokinetic results: definition of the intravenous and oral 
pharmacokinetics of IDN 6140 and assessment of its bioavailability in 
CD1 mice 
Figure 45 shows the pharmacokinetic profiles of IDN 6140 in plasma of CDI female 
mice after i.v. or p.o. administration of 5.4 mg/kg of the taxane derivative (the 
concentration-time data are listed in appendix 7). 
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Figure 45. ION 6140 plasma decay curves after an intravenous or p.o. administration of a dose of 
5.4 mg/kg in COl female mice 
Following the intravenous bolus, IDN 6140 disappeared from plasma according to a two 
compartment open model with a long terminal half-life of 21.8 h and a clearance of 0.8 
L/h/kg (see table 19). 
TIn AUC 
(h) (Jig/mL*h) T 
Cmu 
reatment (Jig/mL) 
Tmu 
(b) 
l.V. 4.7 0.08 21.8 5.6 
p.O. 0.4 0.75 26.0 1.7 
AUCiof 
(JiglmL*h) 
6.5 
2.1 
CI 
(Llhlkg) 
0.8 
I 
Vbd F 
(L/kg) (%) 
26.1 
/ 33 
Table 19. Main pharmacokinetic parameters of ION 6140 after i.v. and oral administration of a 
dose of 5.4 mg/kg in female COl mice 
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Results 
After oral administration, the drug achieved a Cmax of 0.38 Jlg/mL within 1 hour and 
then the plasma concentration declined with an elimination half-life of 26.0 h. The 
bioavailability (F) of the oral administration was 33%. ION 6140 was still detectable up 
to 48 h at a concentration of 13.4 nM, 20-fold higher than that necessary to exert 
cytotoxic activity on human lung tumour cell line H460 (IC50=0.49±0.03 nM, 
determined after 72 hours exposure). 
It is particularly important to notice the value of the volume of distribution (V bd): this 
parameter is a direct measure of the extent of the compound distribution into the body. 
The bigger it is, the higher is the distribution into the body, either by binding to 
components in or by partitioning extensively into tissues. Comparing the V bd of the 14-
functionalized taxanes considered in this project, ION 6140 showed the biggest value, 
being 26.1 L/kg after the administration of a dose of 5.4 mg/kg, against 5.9 of ortataxel, 
5.0 of ION 5839 and 2.1 of ION 5738, after a dose of 60 mg/kg for every of these three 
derivatives. This finding prompted me to investigate the distribution of ION 6140 into 
tissues, also considering the good partition of ortataxel into organs 191. 
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4.4.4. IDN 6140 distribution into tissues 
4.4.4.1. Brain 
4.4.4.1.1. Method development 
Results 
In figures 46 (panel C), the SRM chromatogram for IDN 6140 obtained in brain tissue 
was reported, showing the quantifier transition for an extracted mouse standard sample 
at LOQ, containing the compound at the concentration of 10 ng/mL and IS at 0.5 Jlg/mL 
in comparison with a chromatogram of a blank sample (panel A) and a blank sample 
with IS added (panel B). 
Even from brain tissue, the elution of IDN 6140 and IDN 5738 (IS) was selective and at 
6.8 and 6.6 minutes, respectively. As shown in panel A of the same figure, no 
interfering peaks were present at these retention times and the peaks of the analyte and 
IS were completely resolved from the brain matrix. With regard to mass spectrometer 
conditions, the same ones optimized for analysing IDN 6140 in plasma samples were 
used. 
As a final example, panel D shows the SRM chromatograms of a mouse brain sample 
taken 2 hours after the intravenous treatment with IDN 6140. It corresponds to a 
concentration of 0.634 Jlg/sample of the analyte. 
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Figure 46. (A) SRM chromatograms of a mouse blank brain sample; (8) SRM chromatogram of a 
mouse blank sample with IS added; (C) Signal-to-noise ratio (70.4) of IDN 6140 at LOQ 
concentration (10 nglmL); (0) SRM chromatograms of an extracted ample of a trea ted 
mouse. The mea ured concentration was 0.634 Jig! ample 
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4.4.4.1.2. Recovery 
F or extraction methods from tissues, a whole procedure of validation is not necessary. 
but it is important to define the percentage of recovery and, because of the use of the 
mass spectrometer, to verify the absence of any matrix effect of ion suppression or 
enhancement. 
First of all, the absence of any matrix effect that could influence the ionization of ION 
6140 was ensured using the method of post-column infusion. 
Percentage extraction recovery of IDN 6140 was evaluated at the concentration of 0.1 00 
flg/mL in triplicate. As shown in table 20, the mean extraction recovery of ION 6140 
from brain was good, being approximately 80% with a reproducibility, expressed as 
CV%,of5.2. 
Concentration 
(J1g1mL) 
0.100 
Recovery CV%, 
. . 
ratIO (%) 
79.9 5.2 
'Each value is the mean of three determinations 
Table 20. Recovery of ION 6140 from mouse brain tissue 
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4.4.4.1.3. Distribution of IDN 6140 in mouse brain tissue 
Figure 47 shows the distribution of IDN 6140 in brain tissue of CD 1 female mice after 
i.v. and p.o. administration of 5.4 mglkg of the compound (the concentration-time data 
are listed in appendix 8). 
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Figure 47. Brain concentration-time curves of IDN 6140 in mice after oral and i.v. administration of 
5.4 mg/kg of the compound. Each poiDt represents the mean obtained from four mice 
Main pharmacokinetic parameters of IDN 6140 in brain tissue are shown in table 21. 
After oral and i.v. administration, IDN 6140 was rapidly, the T max being < 2 h, and well 
distributed in the brains of mice achieving a Cmax of 0.14 and 4.00 ~g/mL, respectively. 
emu Treatment (flg/mL) 
I.v. 4.00 
p.o. 0.14 
*brain/plasma 
Tmu 
(h) 
2 
Tll2 
(h) 
30.3 
36.3 
Aue 
(Jlg/mL'h) 
20.5 
1.9 
*Ratio *Ratio 
AVe emax 
3.7 0.8 
1.1 0.4 
Table 21. Main pharmacokinetic parameters of ION 6140 in brain ti sue, after i.v. and oral 
administration of a dose of 5.4 mg/kg to female COl mice 
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The compound disappeared from brain with half-lives higher than those determined in 
the plasma compartment, 30.3 hours after i.v. and 36.3 hours after p.o. against 21.8 
hours (after i.v) and 26 hours (after p.o.), indicating accumulation in brain tissue. 
The ratio brain AVC/plasma AVC for IDN 6140 was 1.1 after oral and 3.7 after i. 
administration (table 21). This indicates a high distribution of the compound in this 
tissue in comparison with the plasma compartment (figure 48) reflecting the high 
ability ofIDN 6140 of crossing the blood brain barrier. 
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Figure 48. Plasma and brain concentration-time curves of IDN 6140 in mice after i.v. administration 
of 5.4 mg/kg of the compound. Each point represents the mean obtained from four mice 
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4.4.4.1.4. Tumour 
Considering the encouraging results obtained on normal brain tissue, it was decided to 
verify the distribution of IDN 6140 in brain tumour tissue. CD 1 xenografted nude mice 
were obtained, by a colleague of mine, inoculating intracranially U-87 MG human 
glioma cell line. The first step, to ensure a correct quantitation of IDN 6140, was to 
verify the complete healing up of the blood brain barrier (BBB) consequent to the 
injection of cells. Therefore, IDN 6140 concentrations were measured in plasma and 
brain samples of two groups of mice, with and without the tumour implant, treated 2 
days after the implant with an intravenous dose of 5.4 mg/kg. The samples were taken 2 
hours after the i.v. administration of IDN 6140. As shown in table 22, ION 6140 
concentrations determined in the two conditions were superimposable, both in plasma 
and in brain samples, demonstrating the integrity of the BBB two days after the tumour 
implant. 
Two days after the tumour implant 
Tumour Plasma Brain 
implant (,...glmL) mean sd (,...glg) mean sd 
0.095 1.128 
yes 0.069 0.076 0.017 0.860 0.995 0.l34 
0.063 0.997 
0.080 1.172 
no 0.077 0.072 0.011 1.146 1.117 0.074 
0.059 1.032 
Table 22. Plasma and brain levels of ION 6140 in COl nude mice, with or without brain tumour 
implant, after single i.v. bolus of 5.4 mglkg 
To determine ION 6140 distribution in tumour, two xenografted mice were treated 
intravenously with a dose of 7.0 mg/kg, 4 weeks after the tumour implant. The tumour 
was collected 2 hours after the treatment and ION 6140 was measured both in tumour 
and in the remainder of the brain tissue. In one sample a concentration of 2.194 ~g/g 
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was achieved in normal tissue against 24.583 in tumour and in the other one 1.510 Ilg/g 
in normal brain tissue against 96.000 in tumour. Even though this experiment was 
conducted just in two mice, there are no doubts about IDN 6140 ability of distributing 
in tumour achieving a concentration 10-40 fold higher than in the normal brain tissue. It 
is very important to note that this concentration is 2-9 fold higher than the one necessary 
to exert cytotoxic activity on U-87 MG in vitro (12 nM). 
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4.4.4.2. Liver 
4.4.4.2.1. Method development 
In order to understand if the high distribution of IDN 6140 was not limited to brain but 
also to other tissues, the relative distribution of this taxane derivative was evaluated in 
liver. The optimization of the extraction procedure from liver tissue was really time 
consuming because of a very important matrix effect during the MSIMS analysis: an 
almost complete suppression of IDN 6140 and IS signals was observed. Many organic 
solvents were tested and a method was developed characterized by the use of 
methanol/O.l % formic acid in acetonitrile 1: 1 as extraction solvent and by a very long 
chromatographic run (41 minutes). As shown in figure 49, the matrix effect was 
completely knocked down: no interfering peaks were present on the chromatographic 
trace of blank sample (panel A) and the signal-to-noise ratio at the concentration of 10 
ng/mL (LOQ) was 188.3 (C). 
As final example, in panel D is reported the SRM chromatograms of a mouse liver 
sample taken 2 hours after the intravenous treatment with ION 6140. It corresponds to a 
concentration of 1.124 Jlg/mL of the analyte. 
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Figure 49. (A) SRM chromatograms of a mouse blank liver sample; (8) RM chromatogram of a 
mouse blank sample with IS added; (C) Signal-to-noi e ratio (188.3) of ION 6140 at 
LOQ concentration (10 nglmL); (0) SRM chromatograms of an e tracted ample of 
a treated mouse showing ION 6140 and I . The measured concentration wa 1.124 
",glmL I instrument u ed: API 4000 mass spectrometer] 
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4.4.4.2.2. Recovery 
The recovery of IDN 6140 was defined in triplicate at the concentrations of 25.0 and 
1000.0 ng/mL. As shown in table 23, the mean extraction recovery for ION 6140 
resulted to be more than 80% with acceptable reproducibility, being <15.00/0. 
Concentration 
("glmL) 
0.025 
1.000 
Recovery 
• * 
ratio (0/0) 
103.2 
82.9 
CV%, 
14.9 
4.1 
'Each value is the mean of three detenninations 
Table 23. Recovery of ION 6140 from mouse liver tissue 
Re ult 
4.4.4.2.3. Distribution of IDN 6140 in mouse liver tissue 
Figure 50 shows the distribution of IDN 6140 in liver tissue of CDt female mice after 
i.v. and p.o. administration of 5.4 mglkg of the compound (the concentration-time data 
are listed in appendix 9). 
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Figure 50. Liver concentration-time curves of IDN 6140 in mice after oral and i.v. administration of 
5.4 mg/kg of the compound. Each pOint represents the mean obtained from four mice 
As shown in table 24, after oral and i.v. administration, IDN 6140 was rapidly, the Tmax 
being :s 1 h, and extensively distributed in the liver of mice achieving a Cmax of 6.15 and 
9.76 Jlg/mL, respectively. It is worth noticing that differently from plasma compartment 
and brain, in liver tissue the half life after oral treatment not only is shorter than the one 
after i.v. administration but it resulted to be halved. This may be due to the first pas 
effect through the liver. 
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Treatment ijJ.g/mL) 
l.v. 9.76 
p.o. 6.15 
*liver/plasma 
Tmas 
(hr) 
0.25 
1 
Re ul' 
Tlfl AUe *Ratio *Ratio 
(hr) ijJ.g/mL·h) AVe Cnux 
16.0 89.0 15.9 2.1 
8.0 61.5 36.2 15.4 
Table 24. Main pharmacokinetic parameters of ION 6140, concerning liver tissue, after i.v. and oral 
administration of a dose of 5.4 mg/kg in female CDI mice 
The ratio liver AUC/plasma AUC for IDN 6140 is 36.2 after oral and 15.9 (figure 51) 
after i.v. administration, indicating high distribution of the compound in this tissue. 
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Figure 51. Plasma and liver concentration-time curves of IDN 6140 in mice after i.v. administration 
of 5.4 mg/kg of the compound. Each point represents the mean obtained from four mice 
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4.4.5. Pharmacokinetics of IDN 6140 after Oral Repeated Treatment 
On the basis of the good distribution of IDN 6140 in brain tissue, obtained after both i. \'. 
and p.o. administrations, it has been decided to define its activity in U-87 MG glioma 
tumour model. 
A colleague of mine performed an intravenous treatment with a dose of 7 mglkg 
administered once a week for three consecutive weeks. A significant reduction of the 
tumour mass was achieved increasing the life span of mice. Nevertheless, this schedule 
was associated with a high degree of toxicity (only three administrations were given 
instead of four because of the body weight loss of 200/0). It was reasoned that the good 
bioavailability (more than 30%) of IDN 6140 could make it feasible to test repeated low 
daily dose that might be equally effective but less toxic. 
In principle a single daily dose was expected be ideal to maintain therapeutically 
effective IDN 6140 levels, as the half-life of the drug was approximately equivalent to 
the interval between doses (t1l2=26 h). Nevertheless, the continuous daily treatment may 
have relevant pharmacokinetic drawbacks: it is known that paclitaxel (PTX) and ION 
5390 show a decrease in drug availability after repeated administrations. Repeated i. v. 
administrations of PTX caused modifications of its pharmacokinetics, diminishing its 
plasma levels up to 96 hours after the last administration 188. As regards ION 5390. after 
prolonged daily oral doses given for two weeks, a decrease in drug bioavailability was 
found 187. These literature data, reported for other taxanes, prompted an evaluation of 
whether prolonged oral daily treatment with ION 6140 did not induce relevant 
phannacokinetic changes. Mice were treated p.o. with a daily dose of 5.4 mglkg for 10 
days and on day 10, another group of mice was treated with a single oral dose of 5.4 
mg/kg in order to compare the concentration plasma level after chronic and acute 
treatment. For both treatments, plasma was collected at 30 and 45 minutes and at I, 2, 6 
186 
Results 
and 24 hours after the administration of ION 6140 and this taxane deri vative was 
determined by LC-MS/MS. 
ION 6140 Cmax at 45 minutes was 91.3 nglmL after a 10 days chronic treatment 
compared to 602.8 nglmL after the acute one. The AVC value after the chronic 
treatment, 420.4 nglmL *hr, was much lower than that found following the single dose 
administration, 1318.1 nglmL *hr. These results clearly indicated that IDN 6140 
exposure was decreased after repeated administrations. We can make two hypotheses to 
explain these findings after repeated oral treatment: 
1- there could be a reduction of absorption of IDN 6140 or 
2- an induction of ION 6140 metabolism 
In any case, the relevant observed pharmacokinetic changes prevented undertaking an 
evaluation of the antitumour activity of ION 6140 given orally for a prolonged time. 
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4.4.6. Metabolism 
4.4.6.1. In vitro metabolic profile 
The in vitro metabolism of IDN 6140 was assessed using liver S9 fraction. Liver S9 
fractions are subcellular fractions that contain drug-metabolizing enzymes including the 
cytochromes P450 and flavin monooxygenases. With this system, it is possible to 
evaluate even two phase II reactions, the conjugation with glucuronic acid and the 
sulfation. 
After 2 hours incubation, only 100/0 of IDN 6140 was metabolized with the formation of 
6 detectable metabolites (MI-M6). Two of them (Ml and M2), probably epimers, were 
related to the loss of the side chain in position 13, giving a derivative of baccatin III 
(figure 52) and four (M3-M6) were products of mono-hydroxylation reaction. 
o 
II 
o 
H3CAo 
o 
Figure 52. Hypothesized structure of ION 6140 metabolites showing baccatin III related scaffold 
(Ml and M2) 
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Among the mono-hydroxylated metabolites, three (M3-M5) showed the modification in 
the side chain in position 13 and one (M6) on the benzoyl group in position 2. he 
hypothesized structure ofM6 is reported in figure 53. 
, 
" HO 
'I 
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H3C 
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I 
CH3 
Figure 53. Hypothesized structure for the mono-hydroxylated metabolite of IDN 6140 (M6) on the 
benzoyl group in position 2 
It was not provided the structure of M6 with the hydroxyl group in a specific position 
on the benzoyl group because, on the basis of ion trap mass spectrometer spectra it was 
not possible to affirm it for a certainty and it was difficult to speculate on the favoured 
reaction site. 
As regards the mono-hydroxylated derivatives on the side chain in position 13 (M3-
M5), one of them (M3) may present the modification on the t-butyl group (figure 54, 
panel A) and the others (M4 and M5) on the isopropyl group (figure 54. panel 8). Even 
in this case, probably the two peaks, characterized by the same mlz ratio and 
fragmentation pattern. are related to two epimers. 
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Figure 54. Hypothesized structure for monohydroxylated metabolites of ION 6140 (M3-M5) on the 
side chain in position 13: M3 is shown in panel A and M4 and M5 in panel B 
No dihydroxylated metabolites were present in the analysed sample. No differences 
were detectable in the concentration of IDN 6140 and metabolite from the 'amples 
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incubated with and without UOPGA and PAPS, indicating that UGTs and sulfation do 
not play any role in the biotransformation and inactivation of the compound. 
4.4.7. Excretion ofIDN 6140 
4.4.7.1. Urine samples 
To determine ION 6140 in urine samples, it was first defined the effect of this matrix on 
ION 6140 signal at mass spectrometer using the same chromatographic conditions 
optimized for the quantitation of the compound from plasma samples. At the retention 
time of ION 6140, an important reduction of the signal was observed, but the effect of 
urine matrix was steady, along the chromatographic trace, from 6.3 minutes up to the 
end of the run. It was verified not only the effect of a blank sample, but even of urine 
collected by mice treated just with the vehicle used to administer ION 6140, that is a 
solution of tween 80 and absolute ethanol in the proportion 1: 1 further diluted with 
saline. The SIN ratio at LOQ concentration (10 nglmL) was 92.8. 
The urinary excretion of the compound was investigated in CD 1 female mice treated 
intravenously or orally with a dose of 5.4 mg/kg. After both treatments, ION 6140 was 
detectable just in the fraction 0-24 hours and in a very small amount, corresponding to 
0.009% and 0.006% of the administered dose, after i.v. or oral treatment, respectively. 
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4.4.7.2. Faeces samples 
Even with this matrix, it was firstly defined its effect on IDN 6140 signal for the mass 
spectrometer using the same chromatographic conditions optimized for the quantitation 
of the compound in plasma samples. At the retention time of ION 6140, a strong 
suppression of the signal was observed, but the effect of faeces matrix was constant. 
along the chromatographic trace, from 5 up to 7 minutes. It was verified the effect of 
faeces collected up to 24 hours, from mice treated just with the vehicle used to 
administer IDN 6140. The SIN ratio at LOQ concentration (10 ng/mL) was 10.1. 
Because of the matrix effect, the recovery of ION 6140 was defined comparing the peak 
area ratio of analyte/IS obtained from extracted faeces samples and faeces in which the 
same quantity of ION 6140 was added after the entire procedure of extraction. The 
percentage extraction recovery of ION 6140 was evaluated at the concentration of 0.100 
Jlg/mL in triplicate. As shown in table 25, the mean recovery of ION 6140 from faeces 
was good, being approximately 900/0 with a reproducibility, expressed as CV%, of2.1. 
Concentration 
(llglmL) 
0.100 
Recovery 
ratio· (%,) 
90.6 
CV% 
2.1 
'Each value is the mean of three detenninations 
Table 25. Recovery of ION 6140 from mouse faeces 
The faecal excretion of the compound was investigated in CO 1 female mice treated 
intravenously or orally with a dose of 5.4 mg/kg. After both treatments, ION 6140 was 
detectable both in the fractions 0-24 and 24-48 hours. As shown in table 26. the 
percentage excretion of ION 6140 was very different between the two routes of 
administration, being 6.4 and 70.80/0 of the administered dose, after i.v. or oral 
treatment, respectively. 
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I 
Oose/via Actual dose 0-24 h 24-48 h Total dose 
(mg/kg) (mg) (% of dose) (% of dose) recovered (0/0) 
I 
5.4 i.v. 0.523 4.14 2.23 6.37 1 
5.4 p.o. 0.518 68.96 l.87 70.83 
I 
Table 26. Faecal excretion of ION 6140 in female COl mice after i.v. and p.o. administration of a 
dose of 5.4 mg/kg 
The very large excretion after oral treatment could be explained considering the 
bioavailability of ION 6140, amounting to 330/0. As ION 6140 does not incur an 
extensive metabolism, it is possible to hypothesize that the amount not absorbed after 
oral administration, may be excreted in faeces as ION 6140 per se. 
The low excretion percentage obtained after the intravenous treatment, together with the 
high volume of body distribution determined (26.1 L/kg) and the long half-life, clearly 
suggests a wide partition of ION 6140 into tissues in agreement with what observed in 
brain and liver. 
Discussion 
CHAPTERS 
DISCUSSION 
194 
Discussion 
Taxol went into Phase I clinical trials in 1984 and already in 1982, Kingston's group 
had started to try to modify paclitaxel functional groups one at a time, to see whether 
they were individually necessary for the in vitro activity of the compound 193. Many 
different changes have been made on taxane structure in order to try to improve 
cytotoxicity and chemical properties of paclitaxel. Kingston et al. summarized only 
some of chemical modifications introduced on paclitaxel structure (figure 55). 
Acetyl or acetoxy 
group may be 
removed without 
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N-acyl group required; of activity; some 
some acyl analogs acyl analogs 
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increase activity 
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alkenyl and substituted aromatic 
groups give improved activity 
Figure 55. Structure-activity relationships of paclitaxel(Kingston 2007) 
Among all the investigated changes, two of them - the C-ring opening through the 
cleavage of bond 7-8 and the introduction of a functional group in position 14 - led to 
the compounds studied in this thesis: IDN 5390, IDN 5614, IDN 5738, IDN 5839 and 
IDN 6140. The opening of C-ring led to C-seco paclitaxel analogues, IDN 5390 and 
IDN 5614, while IDN 5738, IDN 5839 and IDN 6140 have an introduction of a 
functional group in position 14. 
As regards the considered C-seco derivatives, I demonstrated that both of them were 
characterized by extensive metabolism. Data collected after the reaction of ION 5390 
with human and murine microsomes suggested that there is a variation, both 
195 
Discussion 
quantitative and qualitative, in the metabolic profile across the two studied species. In 
the Safety Testing of Drug Metabolites issued in February 2008, FDA suggests the 
identification of differences in drug metabolism, between animals used in nonclinical safety 
assessments and humans, as early as possible, during the drug development process. 
because the discovery of disproportionate drug metabolites late in drug development can 
potentially cause development and marketing delays. In fact generally, metabolites 
identified only in human plasma or metabolites present at disproportionately higher levels 
in humans than in any of the animal test species should be considered for safety assessment. 
FDA recommends a safety concern for human metabolites, that are formed at greater than 
10 percent of parent drug systemic exposure at steady state, because of the metabolites 
themselves may be toxic or pharmacologically active. In the case of ION 5390 in vitro 
metabolism with human microsomes, it was found a monohydroxylated derivative of 
the compound amounted to 57% while it was only 20% after reaction with murine 
microsomes. Even if the system used did not refer to the steady state, it clearly indicated 
that ION 5390 metabolic profile had to be carefully evaluated in case of further clinical 
development. 
In order to evaluate metabolites safety, two approaches could be followed: 
1- To identify an animal species that fonns the metabolite at adequate exposure 
levels (equivalent or greater than the human exposure) and then investigate the 
drug toxicity in that species or 
2- To synthesize the drug metabolite and directly administer it to the animal for 
further safety evaluation. 
To assess the safety of the disproportionate drug metabolite, the studies that may need 
to be performed comprise: general toxicity studies - in which the toxicity of the drug 
metabolite should be investigated at multiples of the human exposure or at least at 
levels comparable to those measured in humans -; genoloxidly sludies, emhryo-felal 
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development toxicity studies (when a drug is intended for use in a population that 
includes women of childbearing potential) and carcinogenicity studies (for drugs that 
are administered continuously for at least 6 months, or that are used intermittently in the 
treatment of chronic or recurrent conditions). 
As concerned the toxicities possibly correlated to the administration of ION 5390. 
besides the very important differences both qualitative and quantitative between the 
metabolic pattern obtained after human or mouse microsomes reaction, another point 
deserves to be considered. In vivo data concerning the fecal excretion of ION 5390 in 
mouse showed that three metabolites amounted each to 8-15% of the total dose 
administered due to the biliary elimination as the predominant route of excretion. as 
already known for taxanes. Further characterization of these metabolites should be done 
because they may reflect potential localized bile duct toxicity and gastro-intestinal 
mucositis. 
Besides the limited plasma disposition and the diminished pharmacological activity, 
another problem correlated to the extensive metabolism of this compound is referable to 
the individual genetic variation (polymorphism) that leads to a wide variability of 
b 1· . d··d I 73 97 meta 0 Ism across III IVI ua s ' . 
For all the reasons listed before, a careful characterization of the mam ION 5390 
metabolites in terms of in vitro biological activity and toxicity would be advisable. 
Considering the large extent of IDN 5390 metabolites and the difficulties m 
synthesizing them due to the presence of some stereo genic centres on the parent 
compound, the introduction of some modifications on IDN 5390 structure, in order to 
obtain a new derivative potentially less subject to the metabolism, seemed to be the hest 
way to follow. Considering that many IDN 5390 metabolites were derived from the 
retro-cyclization reaction, forming C-ring, the protection of the involved positions. 7 
and 9, seemed to he sufficient to assure the decrease of the metabolism. Following this 
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address, ION 5614 was synthesized by the methylation of positions 7 and 9 of IDN 
5390 structure. The followed line seemed to lead to a compound that potentially showed 
two advantages: the decrease of metabolic clearance and the preservation of the 
antioangiogenic properties of ION 5390. 
All taxanes show antiangiogenic properties through their ability in inhibiting of 
endothelial cell motility. In fact, the motility of endothelial cells is a crucial event in the 
process of angiogenesis, the complex formation of a new, functional vascular network, 
necessary for tumour and metastasis growth 194. In this view, ION 5390 appeared to be a 
particular taxane because of its antiangiogenic properties compared to a weak 
cytotoxicity, rendering this taxane a cytostatic compound rather than a cytotoxic one 195. 
Comparing ION 5390 structure to that of paclitaxel and docetaxel, the main difference 
is in the C-ring and for this reason, it may be that the integrity of C-ring is fundamental 
to maximize the cytotoxic activity but not to exert the antiangiogenic one. 
In fact, it is already known that the ability of paclitaxel to inhibit cell motility occurs at 
low concentrations and is unrelated to its anti-proliferative activity 196. This is consistent 
with an antiangiogenic activity of taxanes at subcytotoxic concentrations. 
Unfortunately, the in vitro definition of ION 5614 metabolism, showed that the 
chemical modifications introduced on ION 5390 structure were not able to prevent the 
formation of the C-ring - having found ION 5390 as an ION 5614 metabolite -
convincing me of not studying further the pharmacokinetic profile of ION 5614. 
Consequently on my results, it was decided to tentatively define the cytotoxicity of IDN 
5390 metabolites formed after the incubation with liver microsomes. Therefore. a 
colleague of mine compared the cytotoxicity of ION 5390, before and after incubation 
with mouse microsomes, on human ovarian cancer cell line (A2780) 187. Many different 
ION 5390 concentrations, in the range 0 to 800 nM, were incubated with microsomes 
and, after 4 hours, a small amount of the incubation mixtures was added to the cells 
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obtaining final theoretical IDN 5390 concentrations in the range 0 to 80 nM. After 72 
hours of exposure, the cytotoxicity of the incubation mixture was approximately 10-fo ld 
higher than IDN 5390 per se demonstrating the high activity of the metabolites fonned 
during the reaction with mouse liver microsomes. 
Among the different metabolites tentatively characterized, the one obtained just from 
the formation of the bond between the positions 7 and 8 appeared to be the most 
interesting one, as a cytotoxic agent, because it showed the same tetracyclic core of 
paclitaxel. Indena S.p.A. synthesized this metabolite, obtaining ION 5910. They 
successively compared the cytotoxicity of this new derivative to ION 5390 one on a 
human mammary carcinoma, sensitive and resistant cell line (MCF-7 and MCF-7/R) 
and on a human lung tumour cell line (H460) (table 27). 
compound 
ION 5390 
ION 59\0 
cell line 
MCF-7 MCF-71R 
ICso 
(nM ± SE) 
11.2 ± 0.8 1044±93 
1.1 ± 0.1 97 ± II 
RI 
93 
88 
"460 
ICso 
(nM ± SE) 
29 ± 7 
1.7 ± 0.5 
Cell lines: MCF-7/R, subline with acquired resistance to doxorubicin and collateral 
resistance to paclitaxel and docetaxel 
RI: ICso resistant celllioe/lCso sensitive lioe 
Table 27. Cytotoxic potency of IDN 5910 compared to IDN 5390 
After 72 hours of exposure, IDN 5910 cytotoxicity was at least 10-fold higher than IDN 
5390 one on all the tested cell lines. These results confinned once more the connection 
between the integrity of C-ring and the cytotoxic activity of taxane derivatives. 
The importance of this metabolite is highlighted by the fact that I found it as one of the 
major circulating metabolites in plasma of mice treated with ION 5390. In fact, it was 
demonstrated by LC-MSIMS analysis, that the metabolite obtained by the rctro-
cyclization of C-ring and formed in vitro showed the same structure of that one found in 
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vivo. Therefore, it probably plays an important role in the pharmacological effect of 
ION 5390. 
With regard to the 14-functionalized derivatives, three different compounds - ION 5738. 
ION 5839 and ION 6140 - were considered. The last one was obtained by a further 
structural modification on ION 5839 structure. 
I firstly characterized the pharmacokinetic profile of ION 5738 and ION 5839. On the 
basis of both in vitro and in vivo experiments, even though the considered compounds 
were only two, some structural-activity considerations could be tentatively drawn. The 
high bioavailability of the two taxanes supports the fact that they are not pumped out of 
the cells by P-gp and this evidence is in line with the cytotoxic data obtained on human 
breast tumour cell lines sensitive (LCC6) and resistant cell sub-lines (LCC6-MOR) 178. 
In fact, on LCC6-MOR lines, characterized by the overexpression of P-gp, ION 5738 
and ION 5839 were more toxic than paclitaxel and docetaxel with lower resistance 
index of 8 and 6 respectively, in comparison with those of the two parent drugs of 111 
and 92, confirming the ability of the 14-modified taxanes to overcome multi-drug 
resistance effect, as was demonstrated for ortataxel 180 . However, aI, 14 carbonyl bridge 
may be essential for a good cytotoxicity against multi-drug resistant cell lines as 
ortataxel and ION 5839 are more cytotoxic than ION 5738 that lacks this group 179. The 
replacement of 14-oxygen with a methylidene group seems to be not significant for the 
cytotoxicity and the oral absorption being 48.00/0 and 56.1 %, the bioavailability of 
ortataxel and ION 5839, respectively. In contrast, as seen for IDN 5738, the 
introduction of an azido group in 14 seems to negatively modulate the potency of the 
product, whilst acquiring a very interesting resistance index and maintaining a very 
good oral absorption (F = 53%). 
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These findings suggested that the further modification in the positions 1.14 of the 
baccatin ring gave rise to a series of new compounds which maintain the relevant 
features of the parent compound: ortataxel. 
Taking the pharmacokinetic profile of these new derivatives into consideration, it is 
possible to observe that they were rapidly absorbed (within 1 h) with bioavailability 
higher than 500/0 and plasma concentrations that are consistent with those shown to be 
active in cytotoxic studies on two human breast cancer cell lines sensitive (MCF7 and 
LCC6) and resistant (cell sub-lines: MCF7-R and LCC6-MDR) to paclitaxel. These 
concentrations were maintained in plasma of mice up to at least 16 and 10 hours after 
the administrations of IDN 5738 and IDN 5839, respectively. 
In summary, my data defined for these compounds a favourable pharmacokinetic 
profile, nevertheless superimposable with that of ortataxel against a halved half-life and 
a comparable cytotoxic activity on the sensitive and resistant LCC6 and MCF-7 cell 
lines, rendering IDN 5738 and IDN 5839 little interesting for further development. 
Successively, Indena S.p.A. went on with the synthesis and screening of new taxane 
derivatives structurally optimized on the basis of the findings related to IDN 5738 and 
IDN 5839 and they succeeded in getting IDN 6140. This new taxane derivative was 
obtained by the introduction of a methoxy meta-substituent on the 2-benzoate of taxane 
scaffold of IDN 5839 structure. The interest for IDN 6140 was based on a well known 
and reported characteristic of paclitaxel chemistry. The meta derivatives, and in 
particular methoxy derivatives, were much more cytotoxic than paclitaxel, thanks to thc 
"meta-effect" that is the enhanced interaction between the C -2 ring and asp224 in the ~-
I· b' d' k 181 182 tubu In In mg poc et ' . 
This new ortataxel derivative showed a very good cytotoxic activity on a human lung 
cancer cell line (H460), superior not only to paclitaxel and ortataxeL but even to IDN 
5738 and IDN 5839. 
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The defined phannacokinetic profile of ION 6140 was very different from that of the 
other derivatives. In fact it showed, besides a sufficiently good bioavailability (330/0), at 
48 hours after the administration, concentrations 20-fold higher than the ICso 
detennined on H460 cell line as the outcome of a very long elimination half-life (22 and 
26 hours after i.v. and p.o. treatment, respectively). Nevertheless, the most interesting 
feature of this new derivative consisted in its large volume of distribution. This 
parameter is a direct measure of the extent of drug distribution into the body and being 
at least 4-fold higher for ION 6140 than one of the other 14-functionalized derivatives, 
it was decided to investigate the distribution of ION 6140 into tissues. Knowing the 
feature of ortataxel to cross the Blood Brain Barrier (BBB) 174, ION 6140 distribution 
was defined in brain tissue. Table 28 summarizes the pharmacokinetic parameters 
related to the brain distribution of ION 6140 in comparison with the ones of paclitaxel 
and ortataxel 174. The ratio between brain and plasma AUC of ION 6140 was 20 and 
292-fold higher than ortataxel and paclitaxel one respectively, indicating the very good 
ability of ION 6140 to cross the BBB. 
Parameter paclitaxel ortataxel ION 6140 
i.v. dose (mg/kg) 54 90 5.4 
Plasma Aue 0-6 hours (llg/mL * h) 116.6 36 *3.2 
Brain Aue 0-6 hours (llg/mL * h) 1.4 6.3 * 11.2 
R 0.012 0.175 3.5 
T/2 (l (min) 35 8 5 
T/2 ~ (hr) 1.0 2.1 21.8 
- ----
*AUC 0-8 hours 
R: ratio between brain and plasma AUC 
1'12 a: plasma distribution half-life 
TI2 p: plasma elimination half-life 
Table 28. Comparison between the brain distribution of paclitaxel, ortataxel and ION 6140 
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At Mario Negri Institute and at National Tumor Institute the cytotoxicity of IDN 6140 
on two human glioma cell lines, U-87 MG and GBM (data not shown) was tested. On 
both the cell lines, ION 6140 was as potent as ortataxel and slightly more potent than 
paclitaxel against both the cell lines 174. 
As already mentioned, it may be inferred from the presence of P-gp in brain capillaries 
that this drug efflux pump is a factor in limiting the penetration of certain agents into 
brain tumours. However, by contrast with normal brain capillaries which constitute the 
BBB, brain tumour capillaries are compromised or "leaky", and the extent to which P-
gp expression in brain tumours neovasculature retains its capacity to limit drug 
penetration had seemed to be reduced. Gallo et al. demonstrated that even in the 
neovasculature of brain tumours, P-gp has the facility to limit paclitaxel penetration, 
although somewhat less so than in normal brain 137. That renders particularly important 
the distribution of ION 6140 in normal brain tissue but even more in tumour brain 
tissue. The tumour brain distribution of ION 6140 was defined in CD 1 xenografted 
nude mice - obtained inoculating intracranially U-87 MG cell line - treated 
intravenously with the taxane derivative. Even though this experiment was conducted 
just in two mice, there are no doubts about the ability of distributing in tumour and the 
potentially activity of ION 6140. In fact, in comparison with its concentration in normal 
brain tissue, it achieved a concentration 10-40 fold higher in tumour and this 
concentration was 2-9 fold higher than the one necessary to exert cytotoxic activity on 
U-87 MG in vitro (12 nM). 
In parallel, ION 6140 concentrations were determined also in a glioblastoma cell line 
(GBM), in order to define the uptake in this cells showing an ICso around 17 nM. 
Knowing that a mean diameter of a GBM cell is around 24 Jlm, we found an IDN 6140 
intracellular concentration of 1.2 mM after one hour treatment with a 10 JlM solution of 
the compound. This information suggests that there is a high cellular uptake of I DN 
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6140. Taking all these results together, they prompted us to define IDN 6140 in vivo 
activity to verify if its ability to cross the BBB could be translated into efficacy against 
brain tumours. A colleague of mine perfonned an evaluation of IDN 6140 anti tumour 
activity against two orthotopically growing human glioma, U-87 MG and GBM, in nude 
mice. On U-87 MG tumour model, paclitaxel (PTX), used as reference drug, was given 
intravenously at the dose of 54 mg/kg four times every fourth day and IDN 6140 was 
administered i.v. according to two different schedules: 5.4 mg/kg four times every 
fourth day and 7 mg/kg four times every seven days 197. To define the ability of IDN 
6140 to affect the growth of intracranial tumours, the following parameters were 
considered: the efficacy expressed as increment of life span (ILS%) - calculated as: (T-
C)/C where T and C were the median survival time of treated and control groups, 
respectively -, the tumour growth monitored by Magnetic Resonance Imaging and the 
mouse body weight recorded to evaluate the compound toxicity. The schedule of 
treatment with the dose of 7 mg/kg was interrupted (three administrations were given 
instead of four) due to the observed toxicity in mice (body weight loss of 200/0). As 
shown in figure 56, even if IDN 6140 was effective in increasing the survival of mice (P 
< 0.015 and 0.0001) bearing U-87 MG tumour, the ILS (350/0) did not reach the 
conventional limit defining the anti tumour activity (40%). 
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Figure 56. Survival curves obtained testing different schedules in mice transplanted with U-87 MG 
tumour cells 
In figure 57, images obtained by magnetic resonance are reported and they clearly 
indicate a significant reduction of the tumour mass in mice treated with ION 6140. 
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Di ClJ sian 
Different coronal RARE Tlw images after Gd-DTPA contrast agent i.p. injection; bright 
areas show the tumor region. The three different panels refer respectively to a control 
mouse, PTX treated mouse and ION 6140 treated mouse. Images have been acquired by a 
7T Bruker Biospec 70/30 with the following parameters: repetition time, 700 m ; echo 
time, 9.2 ms; FOV 2x2 cm2; slice thickness, I mm; 256x256 data matrix. 
Figure 57. Magnetic resonance images of brain of human glioma (U-87 MG) bearing mice 
untreated (panel A), treated with paclitaxel (panel B) and with ION 6140 (panel ) 
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A similar experiment was performed in human glioma tumour (GBM) bearing mice 
treated with IDN 6140 at the dose of 4 mg/kg given every week for six times. This 
different schedule was chosen in order to diminish the dose of administration. avoiding 
toxicities, and to treat the animals for a longer period. In this experiment, the chosen 
reference was ortataxel. Even in this orthotopic tumour model, characterized hy a 
slower rate of growth, the increment of survival time (ILS=30%) was not sufficient to 
gain antitumour activity of IDN 6140 (figure 58), but the reduction of tumour volume 
was appreciable 69 days post inoculum (figure 59). 
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Figure 58. Survival curves obtained testing different schedules in mice transplanted with GBM 
tumour cells 
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Oi fferent coronal RARE T I w images after Gd-OTPA contrast agent i. v. injection; bright 
areas show the tumor region. The three different panels refer respectively to a control 
mouse, ortataxel treated mouse and IDN 6140 treated mouse. [mages have been acquired 
by a 7T Bruker Biospec 70/30 with the following parameters: repetition lime, 700 ms; 
echo time, 9.2 ms; FOV 2x2 cm2; slice thickness, 1 mm; 256x256 data matrix. 
Figure 59. Magnetic resonance images of brain of buman glioma (GUM) bearing mice untr sted 
(panel A), treated with ortataul (panel 8) and with ION 6140 (panel C) 
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Summarizing all the data concerning IDN 6140, it was found: 
kinetics characterized by a very long half-life; 
good distribution both in nonnal and tumour brain tissue; 
good cytotoxic activity on human glioma cell lines, U-87 MG and GBM; 
considerable reduction in tumour volume; 
increasing in life span of treated mice not too far from the limit established 
for defining antitumour activity; 
toxicity observed in mice with all the doses and schedules tested. even if 
with lower doses it was possible to treat the animals for a longer period; 
it is possible to conclude that probably the tested schedules were not optimal for this 
compound. The good reduction in tumour volume is not in accordance with the 
marginal anti tumour activity observed, probably due to the restarting of cancer growth 
at the end of the treatment. For this reason, considering the different growth rate of the 
two tumour models, the optimal schedule, on the slower one (GBM), for a compound 
with such a long half-life and associated to toxicity when administered more frequently 
than once a week, may be made up in repeated cycles. For example, cycles of four 
weekly administrations could be suspended with a break to allow the animal recovery 
from toxicity and then re-started obtaining in this way, the extension of the treatment. 
Translating the half-life obtained in mice to humans, it may be of some days and taking 
together with the quite good bioavailability of IDN 6140 and the related toxicity. this 
compound might be administered to patients weekly by oral route. This would be in line 
with what has been highlighted for docetaxel and paclitaxel: the adoption of weekly 
schedule seems well tolerated and more effective than 3-weekly regimen 56. The 
potential efficacy of IDN 6140 could be employed for the therapy of Central Nervous 
System (eNS) tumours and metastasis - the latter originated from advanced breast 
cancer - according to the known in vitro activity of taxanes on human glioblastoma and 
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breast cancer cells and taking into consideration that about 30% of advanced breast 
cancer patients shows relapses on eNS. 
As final consideration of this thesis work, I would like to highlight the importance of 
phannacokinetic studies during preclinical evaluations of new compounds. The 
preclinical development of new anticancer agents towards initial phases of clinical 
investigation IS very expensive and time-consuming. In many cases, the 
phannacokinetics of new anticancer agents IS investigated when the toxicological 
evaluations are perfonned. 
The data shown in the present thesis indicate that it is important to undertake 
pharmacokinetic and metabolism studies early on during the initial process of 
preclinical development. Knowledge of metabolism and pharmacokinetics can in fact 
help to take rational go/no-go decisions, providing indications on structural changes 
required to improve the pharmacological properties and thus the effectiveness of the 
new molecule. 
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CHAPTER 7 
APPENDIX 
AppendiT 
Appendix 1. Analytical method for 7-ethoxycoumarin and its metabolite 
Analytical standards 
7 -ethoxycoumarin 
7 -hydroxycoumarin 
Preparation of mobile phase solution 
0.5 % (v/v) acetic acid 
batch 054K3687 
batch 1123370 
Sigma 
Fluka 
5 mL of acetic acid were diluted to 1000 mL with deionized water 
HPLC conditions 
HPLC Alliance senes 2695 HPLC system (Waters Associates, 
Milford, MA, USA) 
Detector 
Column 
Mobile phase A: 
Mobile phase B: 
Injection volume 
Flow rate 
Run time: 
W2487 at variable-wavelenght UV NIS (Waters 
Associates)~ A 320 nm 
Symmetry CI8, 150 x 4.60 mm, 5 J.1m; with Symmetry 
C 18 precolumn (Waters Associates) 
0.5 % acetic acid (v/v) 
acetoni tril e 
10 J.1L 
0.8 mL/min 
25 minutes 
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Gradient elution program: 
Time (min.) %A %8 
0 93 7 I 
5 80 20 I 
13 40 60 
18 40 60 
19 93 7 
24 93 7 
7 -ethoxycoumarin retention time: 16 minutes 
7 -hydroxycoumarin retention time: 10.8 minutes 
Acquisition system: Empower Software Chromatography Manager (Waters 
Associates) 
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Appendix 2. Analytical method for IDN 5614 and its metabolites 
Analytical standards 
ION 5614 lot # PGB646 Indena S.p.A. 
Preparation of mobile phase solution 
- 0.1 % (v/v) formic acid in water 
1 mL of formic acid was diluted to 1000 mL with deionized water 
- 0.1 % (v/v) formic acid in acetonitrile 
1 mL of formic acid was diluted to 1000 mL with acetonitrile 
HPLC-MS/MS conditions 
HPLC-MS/MS system consisting of a Surveyor autosampler and Surveyor MS pump 
were obtained from Thermo Finnigan, combined with LCQ Deca XP Plus ion trap mass 
spectrometer (Thermo Electron, Waltham, MA, USA). The analysis was perfonned in 
positive ion mode. 
Column 
Mobile phase A: 
Mobile phase B: 
Injection volume 
Flow rate 
Run time: 
Omnispher 3 C18, 100 x 2 mm, 3 ~m; (Varian) 
0.1 % formic acid (v/v) in water 
0.1 % formic acid (v/v) in acetonitrile 
10 ~L 
0.2 mL/min 
46 minutes 
Appendix 
Gradient elution program: 
Time (min.) %A %8 
0 60 40 
24 0 100 
36 0 100 
38 60 40 
46 60 40 
IDN 5614 retention time: about 32 minutes 
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Appendix 3. Raw data of IDN 5738 plasma concentrations in mice 
IDN 5738 plasma concentrations in mice after oral or i.v. administration of 60 
mglKg of the drug 
Schedule Mouse N° TJmepoints (h) conc.(lJ9Iml) mean standard deviation 
1 9.56 
2 0.25 7.53 9.48 1.91 
3 11.34 
4 13.93 
5 0.5 12.91 11.14 3.99 
6 6.57 
7 12.79 
8 0.75 15.62 13.67 1.69 
9 12.60 
10 12.64 
11 1 8.58 10.91 2.10 
12 11.51 
13 13.38 
14 1.5 8.12 11.23 2.76 
0 15 12.19 
a.. 16 10.76 
17 2 7.20 7.65 2.91 
18 4.99 
19 5.26 
20 4 3.02 4.28 1.15 
21 4.55 
22 1.12 
23 8 1.18 1.33 0.33 
24 1.71 
25 0.17 
26 16 0.04 0.10 0.10 
27 blQ 
28 blQ 
29 24 blQ I I 
30 0.03 
31 67.92 
32 0.08 74.82 71.16 3.47 
33 70.74 
34 40.68 
35 0.25 42.28 40.73 1.52 
36 39.24 
37 31.80 
38 0.5 31.66 32.74 1.75 
39 34.76 
40 14.43 
41 1 17.54 18.12 4.02 
42 22.40 
43 13.51 
:> 44 2 9.81 11.12 2.07 
- 45 10.04 
46 2.56 
47 4 6.59 4.25 2.09 
48 3.61 
49 4.12 
50 8 1.20 2.59 1.46 
51 2.44 
52 0.14 0.00 53 16 0.14 0.14 
54 0.05 
55 blQ I 56 24 blQ I 
57 0.02 
Ioq = 0.0251J91m1 
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Appendix 4. Raw data of IDN 5839 plasma concentrations in mice 
ION 5839 plasma concentrations in mice after oral or i.v. administration of 
60 mg/Kg of the drug 
Schedule Mouse N° Timepoints (h) conc.(~gJml) mean standard deviation 
1 5.24 
2 0.25 5.10 4.57 1.05 
3 3.36 
4 7.30 
5 0.5 6.70 6.65 0.68 
6 5.94 
7 6.90 
8 0.75 6.62 6.93 0.33 
9 7.28 
P.O. 10 6.86 11 1 4.42 7.13 2.85 
12 10.10 
13 4.62 
14 1.5 8.72 6.96 2.11 
15 7.54 
16 3.21 
17 2 3.41 3.21 0.21 
18 3.00 
19 1.54 
20 4 0.69 1.52 0.82 
21 2.33 
22 0.52 
23 10.2 0.33 0.38 0.13 
24 0.28 
31 57.82 
32 0.08 54.26 55.15 2.35 
33 53.38 
34 28.20 
35 0.25 27.86 28.03 0.24 
36 I 
37 18.94 
38 0.5 16.34 13.80 6.77 
39 6.13 
40 6.26 IV. 41 1 9.90 8.64 2.06 
42 9.75 
43 3.32 
44 2 3.38 3.20 0.26 
45 2.91 
46 2.11 
47 4 1.40 1.67 0.38 
48 1.50 
49 0.21 
50 10.2 0.36 0.28 0.08 
51 0.28 
loq = 0.025 ~g/ml 
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Appendix 5. Mass spectra fragmentation patterns and chromatograms to back up 
identification of IDN 5738 metabolites 
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Appendix 6. Mass spectra fragmentation patterns and chromatograms to back up 
identification of IDN 5839 metabolites 
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Appendix 7. Raw data of IDN 6140 plasma concentrations in mice after oral (panel 
A) and i.v. treatment (B) 
A Time (h) J,lg/mL Mean I sd CV% 
0.171 I 
0.25 0.151 0.156 0.012 7.6 0.157 
0.143 
0.186 
0.5 0.268 0.237 0.040 16.7 0.226 
0.269 
0.374 
0.75 0.350 0.347 0.383 0.054 14.1 
0.462 
0.192 
1 0.161 0.220 0.055 24.9 0.286 
0.239 
0.253 
1.5 0.179 0.207 0.040 19.5 0.188 
I 
0.135 
2 0.099 0.097 0.032 33.4 0.097 
0.056 
0.089 
0.100 0.076 0.023 30.1 4 0.064 
0.050 
0.041 
0.039 0.037 8 0.036 
0.004 10.6 
0.032 
0.028 
0.024 0.028 0.003 10.5 16 0.029 
0.031 
0.029 
0.016 0.023 0.007 30.9 24 0.028 
0.017 
0.011 
0.012 0.012 0.002 15.5 48 0.015 
0.011 
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B Time (h) JI9ImL Mean sd CV% 
4.264 
0.083 4.456 4.681 0.487 10.4 4.628 
5.376 
1.802 
0.25 1.942 1.484 1.758 0.194 11.0 
1.802 
0.757 
0.5 0.840 0.849 0.074 8.8 0.938 
0.860 
0.532 
1 0.579 0.552 0.022 3.9 0.538 
0.560 
0.260 
2 0.274 0.261 0.030 11.5 0.262 
0.246 
0.197 
4 0.192 0.180 0.021 11.7 0.180 
0.150 
0.096 
8 0.130 0.116 0.018 15.8 0.105 
0.133 
0.094 
16 0.093 0.082 0.014 17.4 0.064 
0.077 
0.046 
24 0.056 0.059 0.065 0.011 17.8 
0.070 
0.026 
48 0.027 0.029 0.003 10.2 0.031 
0.032 
lSI 
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Appendix 8. Raw data of IDN 6140 concentrations in mice brain tissue after oral 
(A) or intravenous (B) administration of the compound 
A ION 6140 
brain weight concentration concentration 
s.d. s.d-lOO/ 'ngJsam~lel '~e) mean time mean 1 0.42 16.8 
2 0.4 17.5 43 .8 
3 0.44 18.6 42.3 420 15 15 min 3.7 
4 0.42 17.6 41.9 
13 0.42 45.5 108.3 
14 0.4 33.7 84.3 
118.8 29.0 Ih 24.4 15 0.37 56.0 151.4 
16 0.35 46.0 131.4 
21 0.42 101.7 242.1 
.... 22 0.41 43.7 106 .6 66.6 2h 46 .8 c 142.4 QJ 23 0.43 49.7 115.6 E 24 0.42 44.3 la:i5 .... 
ro 
0.4 47.9 119.8 QJ 25 ... 
.... 26 0.49 82.1 167 .6 ro 112.5 45.1 4h 40.1 ... 27 0.36 37.6 104.4 a 
28 0.43 25.0 58 .1 
29 0.39 44.0 112.8 
30 0.43 20.1 46 .7 75.6 33.8 8h 447 31 0.4 26.9 67 .3 
32 0.41 5 .4 132 
37 0.42 39.3 93.6 
38 0 .37 9.8 26.5 56.1 35.3 24 h 63.0 39 0.3 23.7 79.0 
40 0.35 8.9 25 .4 
-value outside of the considered range 
B ION 6140 
brain weight concentration concentration s.d. time 
s.d -100/ 
mean 
(ng/sample) (ng/g) mean 
45 0.37 343 .8 929.2 
46 0.41 1147.4 27985 2785.1 1322.4 15 min 47 .5 
47 0.34 1182.4 3477 .6 
48 0.41 1613.3 3934.9 
53 0.43 2484 .2 5777 .2 
54 0.45 1876.8 4170.7 3988.9 1331.9 Ih 334 
55 0.37 1010.0 2729 .7 
56 0.4 1311.2 3278.0 
57 0.41 413.0 10C)7 3 
58 033 6315 1913.6 1878.2 841.1 2h 44 .8 ..... c 59 0.4 633 .6 1584.0 QJ 
E 60 0.28 842.2 3007.9 
.... 
58.2 142.0 ro 61 0.41 QJ 
... 
62 0.44 92.2 2095 747.7 716.S 4h 958 ..... 
::> 63 0.38 372.8 981.1 
64 0 .45 746.2 1658.2 
65 0.41 3105 7573 
66 0.44 59.2 1345 650.9 347.6 8h 53 .4 
67 0.41 3443 839.8 
68 0.43 374.9 871.9 
73 0.45 270.0 600.0 
74 0.43 190.7 4435 466.3 123.8 24h 266 
75 0.4 142.2 3555 
76 0 .42 252 600 
-valu ,lot ulc1uded In the mean calculation 
_ value outside of the considered range 
A 
.... 
c 
~ 
.... 
m 
.... 
.... 
ro 
.... 
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Appendix 9. Raw data of IDN 6140 concentrations in mice liver tissue after oral 
(A) or intravenous (B) administration of the compound 
ION 6140 
liver time weight vol 
total 
vol concentration concentration concentration 
number (hr) (g) (mL) (mL) (ng/ 1 mL) (ng/tot mL) (ng/g) 
1 1.42 7.10 8.52 156.3 1331.4 937.6 
2 1.54 7.70 9.24 295.3 2728.3 1771.6 
3 0.25 1.32 6.60 7.92 533.5 4225.6 3201.2 
4 1.18 5.90 7.08 563.8 3991.5 3382.6 
13 1.05 5.25 6.3 1125.0 7087.5 6750.0 
14 1.11 5.55 6.66 922.6 6144.5 5535.6 
15 1 0.85 4.25 5.1 1194.5 7167.0 6092.0 
16 1.12 5.60 6.72 861.0 5785.9 5166.0 
21 1.22 6.10 7.32 960.5 7030.9 5763.0 
22 1.39 6.95 8.34 787.2 6565.2 4723.2 
23 2 1.16 5.80 6.96 794.2 5527.6 4765.2 
24 1.39 6.95 8.34 768.6 6410.1 461l.6 
25 0.97 4.85 5.82 834.8 4858.5 5008.8 
26 1.37 6.85 8.22 676.4 5560.0 4058.4 
27 4 1.13 5.65 6.78 775.6 5258.6 4653.6 
28 1.19 5.95 7.14 722.5 5158.7 4335.0 
29 1.04 5.20 6.24 550.0 3432.0 3300.0 
30 1.13 5.65 6.78 180.1 122l.1 1080.6 
31 8 1.14 5.70 6.84 618.1 4227.8 3708.6 
32 1.08 5.40 6.48 515.3 3339.1 309l.8 
37 1.14 5.70 6.84 190.2 1301.0 1141.2 
38 1.33 6.65 7.98 78.8 628.8 472.8 24 1.42 7.10 8.52 154.8 1318.9 928.8 39 
40 0.99 4.95 5.94 80.6 478.8 483.6 
ION 6140 
total 
concentration concentration concentration liver time weight vol vol 
number (hr) (g) (mL) (mL) (ng/ 1 mL) (ng/tot mL) 
(ng/g) 
45 1.39 6.95 8.34 1795.3 14972.8 
10771.8 
46 1.23 6.15 7.38 1588.5 11723.1 
9531.0 
47 0.25 1.19 5.95 7.14 1659.8 11851.0 
9958.8 
48 1.17 5.85 7.02 1461.5 10259.7 
8769.0 
5533.2 
53 1.00 5.00 6.00 922.2 5533.2 
54 1.25 6.25 7.50 583.0 4372.5 
3498.0 
55 1 1.27 6.35 7.62 1250.0 9525.0 
7500.0 
56 1.15 5.75 6.90 942.2 6501.2 
5653.2 
5679.6 
57 1.51 7.55 9.06 946.6 8576.2 
58 1.27 6.35 7.62 1104.3 8414.8 
6625.8 
59 2 1.27 6.35 7.62 1124.1 8565.6 
6744.6 
1.27 6.35 7.62 1027.2 7827.3 6163.2 60 
61 1.14 5.70 6.84 846.1 5787.3 
5076.6 
62 1.13 5.65 6.78 895.9 6074.2 
5375.4 
4 1.01 5.05 6.06 861.2 5218.9 5167.2 63 
64 0.97 4.85 5.82 610.2 3551.4 
3661.2 
65 0.94 4.70 5.64 580.5 3274.0 
3483.0 
66 1.00 5.00 6.00 541.8 3250.8 
3250.8 
8 1.21 6.05 7.26 866.6 6291.5 5199.6 67 
1.00 5.00 6.00 628.2 3769.2 3769.2 68 
1.19 5.95 7.14 305.4 2180.6 1832.4 73 
74 1.25 6.25 7.50 269.0 2017.5 
1614.0 
24 1.18 5.90 7.08 370.6 2623.8 2223.6 75 
0.97 4.85 5.82 393.4 2289.6 2360.4 76 
mean 
(ng/g) 
2323.3 
6154.7 
4965.8 
4514.0 
2795.3 
756.6 
mean 
(ng/g) 
9757.7 
,. 
5546.1 
6303.3 
4820.1 
3925.7 
2007.6 
set 
(ng/g) 
1171.5 
955.7 
535.4 
409.8 
1171.5 
333.0 
sd 
(ng/g) 
836.2 
1635.4 
485.6 
782.7 
875.4 
344.8 
"'-3 .... ) 
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7.1. List of abbreviations 
amu 
APCI 
CE 
CXP 
DA 
DC 
DDA 
DP 
EP 
ESI 
HPLC 
HPLC-UVNIS 
IS 
LC-MS 
LC-MS/MS 
MP 
MS 
MW 
RF 
rpm 
SRM 
TIC 
atomic mass unit 
Atmospheric Pressure Chemical Ionization 
Collision Energy 
Collision cell exit potential 
Dalton 
Direct Current 
Data Dependent Acquisition 
Declustering Potential 
Entrance Potential 
Electro Spray Ionization 
High Performance Liquid Chromatography 
High Performance Liquid Chromatography-UltraViolet 
Visible Spectroscopy 
Internal Standard 
Liquid Chromatography-Mass Spectrometry 
Liquid Chromatography Tandem Mass Spectrometry 
Mobile Phase 
Mass Spectrometry 
Molecular Weight 
Radio Frequency 
rotation per minute 
Selected Reaction Monitoring 
Total Ion Chromatogram 
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CV Coefficient of Variation 
LOQ Limit of Quantification 
LOD Limit of Detection 
QC Quality Control 
SD Standard Deviation 
SE Standard Error 
ULOQ Upper Limit of Quantification 
AUC Area Under the Curve 
AUCinf Area Under the Curve extrapolated to infinite 
CI plasma clearance 
Cmax maximum plasma concentration 
E extraction ratio 
F bioavailability 
. intraperitoneal l.p. 
I.V. intravenous 
Ke costant of elimination 
Ml metabolite 1 
p.o. per os 
Rc~ accumulation factor for Cmax values 
R...uc accumulation factor for AUC values 
s.c. subcutaneous 
T .... maximum time 
Till half-life 
Vw volume of distribution 
2SS 
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ABCBI ATP-Binding Cassette Sub-Family B Member I 
BBB Blood Brain Barrier 
Bcl-2 B-cell leukemia 2 
BSA Bovine Serum Albumin 
CNS Central Nervous System 
Cyp Cytocrome P 
DCC Dicyclohexylcarbodiimide 
DMAP Dimethylaminopyridine 
DMPU Dimethy lpropy leneurea 
DMSO Dimethyl sulfoxide 
FDA Food and Drug Administration 
GLP Good Laboratory Practice 
GDP Guanosyl diphosphate 
GTP Guanosyl triphosphate 
HSRs Hyper Sensitivity Reactions 
IC50 Inhibitory concentration 50% 
MBT Metastatic Breast Cancer 
MDR Multi Drug Resistance 
MTD Maximum Tolerated Dose 
NCI National Cancer Institute 
NCCN National Comprehensive Cancer Network 
NSCLC Non Small Cell Lung Cancer 
PAPS Phosphoadenylphosphosulfate 
P-gp P -gl ycoprotein 
R.I. Resistant Index 
THF TetraHydroFuran 
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UOTs 
UDPOA 
ULN 
U ridinediphosphogl ucuronosyltransferases 
Uridinediphosphateglucuronic Acid 
Upper Limit of Normal 
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